{"PMC7454374": [["Testing for Viral Pathogens ::: QUESTION 1: TO TEST OR NOT TO TEST?", [["TEST", "TEST", 62, 66]]], ["THAT IS THE FIRST QUESTIONIn the first vignette (Box 1), which predates the novel coronavirus pandemic, an otherwise healthy child presenting with an upper respiratory infection during a period of low influenza activity does not necessarily need influenza-specific testing.", [["respiratory", "ANATOMY", 156, 167], ["coronavirus pandemic", "DISEASE", 82, 102], ["respiratory infection", "DISEASE", 156, 177], ["coronavirus", "ORGANISM", 82, 93], ["child", "ORGANISM", 125, 130], ["child", "SPECIES", 125, 130], ["an upper respiratory infection", "PROBLEM", 147, 177], ["low influenza activity", "PROBLEM", 197, 219], ["influenza-specific testing", "TEST", 246, 272], ["upper", "ANATOMY_MODIFIER", 150, 155], ["respiratory", "ANATOMY", 156, 167], ["infection", "OBSERVATION", 168, 177]]], ["Figure 2 illustrates the impact of influenza prevalence on the predictive value of NAAT.", [["influenza", "DISEASE", 35, 44], ["NAAT", "PROTEIN", 83, 87], ["influenza prevalence", "PROBLEM", 35, 55], ["influenza", "OBSERVATION", 35, 44]]], ["During periods of low prevalence, positive results have a high likelihood of being falsely positive.", [["low prevalence", "PROBLEM", 18, 32], ["falsely positive", "PROBLEM", 83, 99], ["low prevalence", "OBSERVATION_MODIFIER", 18, 32], ["positive", "OBSERVATION", 91, 99]]], ["Furthermore, since this patient has no strong indication for anti-influenza therapy [16], influenza-specific testing is unlikely to affect the decision to prescribe antiviral therapy.", [["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31], ["anti-influenza therapy", "TREATMENT", 61, 83], ["influenza", "PROBLEM", 90, 99], ["specific testing", "TEST", 100, 116], ["antiviral therapy", "TREATMENT", 165, 182]]], ["Alternatively, if the patient were significantly immunocompromised, had a severe influenza-like illness, or if the detection of another respiratory virus would influence the decision to prescribe an antiviral or withhold antibiotics, then syndromic testing for multiple viruses would be indicated.Testing for Viral Pathogens ::: QUESTION 1: TO TEST OR NOT TO TEST?", [["influenza-like illness", "DISEASE", 81, 103], ["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["significantly immunocompromised", "PROBLEM", 35, 66], ["a severe influenza-like illness", "PROBLEM", 72, 103], ["another respiratory virus", "PROBLEM", 128, 153], ["an antiviral", "TREATMENT", 196, 208], ["antibiotics", "TREATMENT", 221, 232], ["syndromic testing", "TEST", 239, 256], ["multiple viruses", "PROBLEM", 261, 277], ["TEST", "TEST", 359, 363], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["influenza", "OBSERVATION", 81, 90]]], ["THAT IS THE FIRST QUESTIONThe IDSA and Centers for Disease Control and Prevention (CDC) have published influenza testing algorithms for adults and children [16\u201318].", [["children", "ORGANISM", 147, 155], ["children", "SPECIES", 147, 155], ["Disease Control", "TREATMENT", 51, 66]]], ["Although relatively few studies have assessed the cost-effectiveness of molecular testing, modeling suggests that an approach of testing and then treating is generally preferred to empiric anti-influenza treatment during periods of moderate disease prevalence or when risk for severe disease is moderate to high [19, 20].", [["molecular testing", "TEST", 72, 89], ["an approach of testing", "TEST", 114, 136], ["empiric anti-influenza treatment", "TREATMENT", 181, 213], ["moderate disease prevalence", "PROBLEM", 232, 259], ["severe disease", "PROBLEM", 277, 291], ["moderate", "OBSERVATION_MODIFIER", 232, 240], ["disease", "OBSERVATION", 241, 248], ["severe", "OBSERVATION_MODIFIER", 277, 283], ["disease", "OBSERVATION", 284, 291], ["moderate", "OBSERVATION_MODIFIER", 295, 303]]], ["To be most useful in the outpatient setting, influenza results should be available during the patient visit.", [["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["influenza", "PROBLEM", 45, 54]]], ["In the ED, the greatest impact is observed when results are issued in under 2 hours [21, 22].Testing for Viral Pathogens ::: QUESTION 1: TO TEST OR NOT TO TEST?", [["TEST", "TEST", 155, 159]]], ["THAT IS THE FIRST QUESTIONBest practices for the diagnosis of coronavirus disease 2019 (COVID-19) are rapidly evolving.", [["coronavirus disease", "DISEASE", 62, 81], ["coronavirus", "ORGANISM", 62, 73], ["coronavirus disease", "PROBLEM", 62, 81], ["COVID", "TEST", 88, 93], ["coronavirus disease", "OBSERVATION", 62, 81]]], ["In the setting of ongoing community transmission, testing all symptomatic individuals is optimal for informing isolation practices, contact tracing, and evaluating the changing epidemiology.", [["testing", "TEST", 50, 57], ["contact tracing", "TEST", 132, 147]]], ["However, collection device and nucleic acid extraction reagent shortages have affected the availability of testing in some areas of the United States.", [["nucleic acid", "CHEMICAL", 31, 43], ["nucleic acid", "SIMPLE_CHEMICAL", 31, 43], ["collection device", "TREATMENT", 9, 26], ["nucleic acid extraction", "TREATMENT", 31, 54], ["testing", "TEST", 107, 114]]], ["In response, the IDSA [23] and others have developed expert recommendations for prioritized testing when resources are limited.Testing for Viral Pathogens ::: QUESTION 1: TO TEST OR NOT TO TEST?", [["prioritized testing", "TEST", 80, 99], ["TEST", "TEST", 189, 193]]], ["THAT IS THE FIRST QUESTIONSimilar guidance for other non\u2013influenza viruses exists only in selected immunocompromised host guidelines [24\u201327], where initial testing for multiple viruses in addition to influenza is endorsed, and in the American Academy of Pediatrics recommendation against routine viral testing for children with bronchiolitis [28].", [["influenza", "DISEASE", 200, 209], ["bronchiolitis", "DISEASE", 328, 341], ["children", "ORGANISM", 314, 322], ["children", "SPECIES", 314, 322], ["other non\u2013influenza viruses", "PROBLEM", 47, 74], ["initial testing", "TEST", 148, 163], ["multiple viruses", "PROBLEM", 168, 184], ["influenza", "PROBLEM", 200, 209], ["routine viral testing", "TEST", 288, 309], ["bronchiolitis", "PROBLEM", 328, 341], ["viruses", "OBSERVATION", 177, 184], ["influenza", "OBSERVATION", 200, 209], ["bronchiolitis", "OBSERVATION", 328, 341]]], ["In a general adult population, non\u2013influenza virus detections may not have the same influence on antibiotic prescribing and/or lengths of stay as do influenza results [2, 3, 29, 30].", [["non\u2013influenza virus", "ORGANISM", 31, 50], ["non\u2013influenza virus", "SPECIES", 31, 50], ["non\u2013influenza virus detections", "PROBLEM", 31, 61], ["antibiotic prescribing", "TREATMENT", 97, 119]]], ["Limited sample sizes, however, preclude drawing firm conclusions here and few studies have specifically assessed impact on the management of immunocompromised hosts [31].", [["Limited sample sizes", "TEST", 0, 20], ["drawing firm conclusions", "TEST", 40, 64], ["few studies", "TEST", 74, 85], ["immunocompromised hosts", "PROBLEM", 141, 164], ["sizes", "OBSERVATION_MODIFIER", 15, 20]]], ["Future studies need to be powered to measure the clinical impact of non\u2013influenza virus detections, especially for those being evaluated in the ED or on admission to the hospital.Testing for Bacterial Pathogens ::: QUESTION 1: TO TEST OR NOT TO TEST?", [["non\u2013influenza virus", "ORGANISM", 68, 87], ["non\u2013influenza virus", "SPECIES", 68, 87], ["Future studies", "TEST", 0, 14], ["non\u2013influenza virus detections", "PROBLEM", 68, 98], ["TEST", "TEST", 245, 249]]], ["THAT IS THE FIRST QUESTIONUntil recently, commercially available NAATs were limited to viral pathogens plus a few \u201catypical\u201d bacteria including Mycoplasma pneumoniae, Chlamydia pneumoniae, and Bordetella species.", [["Mycoplasma pneumoniae", "DISEASE", 144, 165], ["Chlamydia pneumoniae", "DISEASE", 167, 187], ["Mycoplasma pneumoniae", "ORGANISM", 144, 165], ["Chlamydia pneumoniae", "ORGANISM", 167, 187], ["Bordetella species", "ORGANISM", 193, 211], ["Mycoplasma pneumoniae", "SPECIES", 144, 165], ["Chlamydia pneumoniae", "SPECIES", 167, 187], ["Mycoplasma pneumoniae", "SPECIES", 144, 165], ["Chlamydia pneumoniae", "SPECIES", 167, 187], ["viral pathogens", "PROBLEM", 87, 102], ["a few \u201catypical\u201d bacteria", "PROBLEM", 108, 133], ["Mycoplasma pneumoniae", "PROBLEM", 144, 165], ["Chlamydia pneumoniae", "PROBLEM", 167, 187], ["Bordetella species", "PROBLEM", 193, 211], ["Mycoplasma pneumoniae", "OBSERVATION", 144, 165], ["Chlamydia pneumoniae", "OBSERVATION", 167, 187], ["Bordetella species", "OBSERVATION", 193, 211]]], ["It is clear that the presence of new or worsening infiltrates on chest X-ray is an independent predictor of antibiotic use irrespective of respiratory virus detection [29].", [["new or worsening infiltrates", "PROBLEM", 33, 61], ["chest X-ray", "TEST", 65, 76], ["antibiotic use", "TREATMENT", 108, 122], ["respiratory virus detection", "TEST", 139, 166], ["clear", "OBSERVATION", 6, 11], ["new", "OBSERVATION_MODIFIER", 33, 36], ["worsening", "OBSERVATION_MODIFIER", 40, 49], ["infiltrates", "OBSERVATION", 50, 61], ["chest", "ANATOMY", 65, 70], ["respiratory virus", "OBSERVATION", 139, 156]]], ["Thus, confidently excluding bacterial coinfection in patients with a suspected viral infection may help reduce unnecessary antibiotic use.", [["bacterial coinfection", "DISEASE", 28, 49], ["viral infection", "DISEASE", 79, 94], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["bacterial coinfection", "PROBLEM", 28, 49], ["a suspected viral infection", "PROBLEM", 67, 94], ["unnecessary antibiotic use", "TREATMENT", 111, 137], ["bacterial", "OBSERVATION_MODIFIER", 28, 37], ["coinfection", "OBSERVATION", 38, 49], ["viral", "OBSERVATION_MODIFIER", 79, 84], ["infection", "OBSERVATION", 85, 94]]], ["In addition, rapid tests that accurately rule in or out additional bacterial pathogens such as Pseudomonas, methicillin-resistant Staphylococcus aureus (MRSA), Legionella, or multidrug-resistant gram-negative organisms should have value for initial management decisions as long as they can reliably discriminate between infection and respiratory tract colonization.Testing for Bacterial Pathogens ::: QUESTION 1: TO TEST OR NOT TO TEST?", [["respiratory tract", "ANATOMY", 334, 351], ["methicillin", "CHEMICAL", 108, 119], ["Staphylococcus aureus", "DISEASE", 130, 151], ["infection", "DISEASE", 320, 329], ["respiratory tract colonization", "DISEASE", 334, 364], ["methicillin", "CHEMICAL", 108, 119], ["Pseudomonas", "ORGANISM", 95, 106], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 108, 151], ["MRSA", "ORGANISM", 153, 157], ["tract", "ORGANISM_SUBDIVISION", 346, 351], ["Staphylococcus aureus", "SPECIES", 130, 151], ["MRSA", "SPECIES", 153, 157], ["Staphylococcus aureus", "SPECIES", 130, 151], ["MRSA", "SPECIES", 153, 157], ["rapid tests", "TEST", 13, 24], ["additional bacterial pathogens", "PROBLEM", 56, 86], ["Pseudomonas", "PROBLEM", 95, 106], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 108, 151], ["MRSA", "PROBLEM", 153, 157], ["Legionella", "PROBLEM", 160, 170], ["multidrug-resistant gram-negative organisms", "PROBLEM", 175, 218], ["initial management", "TREATMENT", 241, 259], ["infection", "PROBLEM", 320, 329], ["respiratory tract colonization", "PROBLEM", 334, 364], ["TEST", "TEST", 431, 435], ["Staphylococcus aureus", "OBSERVATION", 130, 151], ["infection", "OBSERVATION", 320, 329], ["respiratory tract colonization", "OBSERVATION", 334, 364]]], ["THAT IS THE FIRST QUESTIONCurrent community-acquired pneumonia (CAP) [32] and hospital- or ventilator-associated pneumonia (HAP and VAP) guidelines [33] do not address molecular testing for bacterial pathogens other than a recommendation for nasal MRSA screening in patients with HAP/VAP.", [["nasal", "ANATOMY", 242, 247], ["pneumonia", "DISEASE", 53, 62], ["CAP", "DISEASE", 64, 67], ["pneumonia", "DISEASE", 113, 122], ["HAP", "DISEASE", 124, 127], ["VAP", "DISEASE", 132, 135], ["HAP", "DISEASE", 280, 283], ["VAP", "DISEASE", 284, 287], ["patients", "ORGANISM", 266, 274], ["MRSA", "SPECIES", 248, 252], ["patients", "SPECIES", 266, 274], ["MRSA", "SPECIES", 248, 252], ["acquired pneumonia (CAP)", "PROBLEM", 44, 68], ["ventilator", "TREATMENT", 91, 101], ["pneumonia", "PROBLEM", 113, 122], ["molecular testing", "TEST", 168, 185], ["bacterial pathogens", "PROBLEM", 190, 209], ["nasal MRSA screening", "TEST", 242, 262], ["HAP", "PROBLEM", 280, 283], ["VAP", "PROBLEM", 284, 287], ["pneumonia", "OBSERVATION", 53, 62], ["pneumonia", "OBSERVATION", 113, 122], ["VAP", "OBSERVATION", 284, 287]]], ["Since multiplex bacterial pneumonia panels are so new, their test performance and potential impact on clinical decision making are not yet established.", [["pneumonia", "DISEASE", 26, 35], ["multiplex bacterial pneumonia panels", "PROBLEM", 6, 42], ["their test performance", "TEST", 55, 77], ["bacterial", "OBSERVATION_MODIFIER", 16, 25], ["pneumonia", "OBSERVATION", 26, 35]]], ["In the absence of high-quality data, bacterial NAAT may prove most useful in situations where patients have new or worsening lung infiltrates, are moderately to severely ill, have received empiric antibiotics before obtaining cultures, and/or there is concern for multidrug-resistant bacteria or a polymicrobial infection.", [["lung", "ANATOMY", 125, 129], ["infection", "DISEASE", 312, 321], ["NAAT", "SIMPLE_CHEMICAL", 47, 51], ["patients", "ORGANISM", 94, 102], ["lung", "ORGAN", 125, 129], ["patients", "SPECIES", 94, 102], ["bacterial NAAT", "PROBLEM", 37, 51], ["new or worsening lung infiltrates", "PROBLEM", 108, 141], ["severely ill", "PROBLEM", 161, 173], ["empiric antibiotics", "TREATMENT", 189, 208], ["cultures", "TEST", 226, 234], ["multidrug-resistant bacteria", "PROBLEM", 264, 292], ["a polymicrobial infection", "PROBLEM", 296, 321], ["new", "OBSERVATION_MODIFIER", 108, 111], ["worsening", "OBSERVATION_MODIFIER", 115, 124], ["lung", "ANATOMY", 125, 129], ["infiltrates", "OBSERVATION", 130, 141], ["moderately", "OBSERVATION_MODIFIER", 147, 157], ["concern for", "UNCERTAINTY", 252, 263], ["resistant", "OBSERVATION_MODIFIER", 274, 283], ["bacteria", "OBSERVATION", 284, 292], ["polymicrobial", "OBSERVATION_MODIFIER", 298, 311], ["infection", "OBSERVATION", 312, 321]]], ["A recent meeting abstract highlights the importance of combined viral and bacterial testing, where clinician-directed testing would have missed potentially important viruses [34].Testing for Bacterial Pathogens ::: QUESTION 1: TO TEST OR NOT TO TEST?", [["bacterial testing", "TEST", 74, 91], ["TEST", "TEST", 245, 249]]], ["THAT IS THE FIRST QUESTIONThe second vignette (Box 2) is an example of the type of patient most likely to benefit from broad syndromic testing for viruses and bacteria at the same time.", [["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 83, 90], ["broad syndromic testing", "TEST", 119, 142], ["viruses", "PROBLEM", 147, 154], ["bacteria", "PROBLEM", 159, 167], ["most likely", "UNCERTAINTY", 91, 102]]], ["Molecular detection of high quantities of MRSA supports continuation of vancomycin in this case despite negative culture results.", [["MRSA", "DISEASE", 42, 46], ["vancomycin", "CHEMICAL", 72, 82], ["vancomycin", "CHEMICAL", 72, 82], ["vancomycin", "SIMPLE_CHEMICAL", 72, 82], ["MRSA", "SPECIES", 42, 46], ["MRSA", "SPECIES", 42, 46], ["Molecular detection", "TEST", 0, 19], ["high quantities", "PROBLEM", 23, 38], ["MRSA", "PROBLEM", 42, 46], ["vancomycin", "TREATMENT", 72, 82], ["high quantities", "OBSERVATION_MODIFIER", 23, 38], ["MRSA", "OBSERVATION", 42, 46]]], ["In addition, negative influenza results combined with detection of Haemophilus influenzae allow consideration of more-targeted gram-negative coverage along with cessation of antiviral therapy.", [["Haemophilus influenzae", "DISEASE", 67, 89], ["Haemophilus influenzae", "ORGANISM", 67, 89], ["Haemophilus influenzae", "SPECIES", 67, 89], ["Haemophilus influenzae", "SPECIES", 67, 89], ["negative influenza results", "PROBLEM", 13, 39], ["Haemophilus influenzae", "PROBLEM", 67, 89], ["antiviral therapy", "TREATMENT", 174, 191], ["influenza", "OBSERVATION", 22, 31], ["antiviral therapy", "OBSERVATION", 174, 191]]], ["Uncertainties associated with the interpretation of bacterial NAAT from lower respiratory tract (LRT) are discussed further under Question 3.Testing for Influenza ::: QUESTION 2: IF I DECIDE TO TEST, WHICH APPROACH IS BEST?Simple sample-to-answer molecular platforms and point-of-care devices enable high-performance influenza testing with a rapid turnaround time.", [["lower respiratory tract", "ANATOMY", 72, 95], ["Influenza", "DISEASE", 153, 162], ["NAAT", "GENE_OR_GENE_PRODUCT", 62, 66], ["lower", "ORGANISM_SUBDIVISION", 72, 77], ["respiratory tract", "ORGANISM_SUBDIVISION", 78, 95], ["bacterial NAAT", "PROTEIN", 52, 66], ["bacterial NAAT from lower respiratory tract", "PROBLEM", 52, 95], ["Influenza", "PROBLEM", 153, 162], ["Simple sample", "TEST", 223, 236], ["care devices", "TREATMENT", 280, 292], ["influenza testing", "TEST", 317, 334], ["lower", "ANATOMY_MODIFIER", 72, 77], ["respiratory tract", "ANATOMY", 78, 95]]], ["In a recent meta-analysis, the pooled sensitivity and specificity of rapid viral NAAT were 90.9% and 96.1%, respectively [35].", [["the pooled sensitivity", "TEST", 27, 49], ["rapid viral NAAT", "TEST", 69, 85]]], ["The CDC and IDSA influenza guidelines both favor molecular detection of influenza, as opposed to antigen testing, in the outpatient and hospital setting [16\u201318].", [["influenza", "DISEASE", 72, 81], ["The CDC", "TEST", 0, 7], ["IDSA influenza guidelines", "TREATMENT", 12, 37], ["influenza", "PROBLEM", 72, 81], ["antigen testing", "TEST", 97, 112]]], ["Whether molecular influenza testing for all patients is the most cost-effective approach remains uncertain.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["molecular influenza testing", "TEST", 8, 35], ["influenza", "OBSERVATION", 18, 27]]], ["For example, initial testing with a less expensive digital influenza immunoassay followed by molecular confirmation of negative results for high-risk or hospitalized patients is an alternative strategy that warrants additional study.Testing for SARS-CoV-2 ::: QUESTION 2: IF I DECIDE TO TEST, WHICH APPROACH IS BEST?The World Health Organization declared a public health emergency of international concern on 30 January 2020.", [["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["SARS-CoV", "SPECIES", 245, 253], ["initial testing", "TEST", 13, 28], ["a less expensive digital influenza immunoassay", "PROBLEM", 34, 80], ["molecular confirmation", "TEST", 93, 115], ["additional study", "TEST", 216, 232]]], ["Shortly thereafter, the US Secretary of Health and Human Services announced that circumstances existed justifying authorization of the emergency use of SARS-CoV-2 diagnostics.", [["SARS", "DISEASE", 152, 156], ["Human", "ORGANISM", 51, 56], ["Human", "SPECIES", 51, 56]]], ["Known concentrations of inactivated virus were used to determine the analytical characteristics of these tests.", [["Known concentrations of inactivated virus", "PROBLEM", 0, 41], ["these tests", "TEST", 99, 110], ["concentrations", "OBSERVATION_MODIFIER", 6, 20]]], ["In contrast, clinical test performance (ie, sensitivity and specificity) has yet to established.Testing for SARS-CoV-2 ::: QUESTION 2: IF I DECIDE TO TEST, WHICH APPROACH IS BEST?Available evidence suggests that SARS-CoV-2 is detectable in nasopharyngeal (NP) and oropharyngeal (OP) specimens, with peak levels typically measurable during the first week of symptoms [36\u201338].", [["nasopharyngeal", "ANATOMY", 240, 254], ["NP", "ANATOMY", 256, 258], ["oropharyngeal (OP) specimens", "ANATOMY", 264, 292], ["SARS", "DISEASE", 212, 216], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 212, 222], ["nasopharyngeal", "CANCER", 240, 254], ["oropharyngeal (OP) specimens", "CANCER", 264, 292], ["SARS-CoV", "SPECIES", 108, 116], ["SARS-CoV", "SPECIES", 212, 220], ["clinical test performance", "TEST", 13, 38], ["specificity", "TEST", 60, 71], ["SARS-CoV", "TEST", 212, 220], ["nasopharyngeal (NP) and oropharyngeal (OP) specimens", "TEST", 240, 292], ["peak levels", "TEST", 299, 310], ["symptoms", "PROBLEM", 357, 365], ["nasopharyngeal", "ANATOMY", 240, 254], ["oropharyngeal", "ANATOMY", 264, 277]]], ["The NP samples may be more sensitive than OP samples [36, 39], but detection rates appear to vary from patient to patient and change over the course of illness [37, 39].", [["NP samples", "ANATOMY", 4, 14], ["OP samples", "ANATOMY", 42, 52], ["illness", "DISEASE", 152, 159], ["NP samples", "CANCER", 4, 14], ["patient", "ORGANISM", 103, 110], ["patient", "ORGANISM", 114, 121], ["patient", "SPECIES", 103, 110], ["patient", "SPECIES", 114, 121], ["The NP samples", "TEST", 0, 14], ["OP samples", "TEST", 42, 52], ["detection rates", "TEST", 67, 82]]], ["Some patients with pneumonia, for example, have negative NP/OP samples but positive lower airway samples [40, 41].", [["samples", "ANATOMY", 63, 70], ["lower airway samples", "ANATOMY", 84, 104], ["pneumonia", "DISEASE", 19, 28], ["patients", "ORGANISM", 5, 13], ["airway samples", "MULTI-TISSUE_STRUCTURE", 90, 104], ["patients", "SPECIES", 5, 13], ["pneumonia", "PROBLEM", 19, 28], ["NP/OP samples", "TEST", 57, 70], ["positive lower airway samples", "PROBLEM", 75, 104], ["pneumonia", "OBSERVATION", 19, 28], ["lower", "ANATOMY_MODIFIER", 84, 89], ["airway", "ANATOMY", 90, 96]]], ["Like other viral diseases, shedding of viral RNA in respiratory secretions may persist beyond resolution of symptoms and seroconversion [37].", [["respiratory secretions", "ANATOMY", 52, 74], ["viral diseases", "DISEASE", 11, 25], ["viral RNA", "RNA", 39, 48], ["other viral diseases", "PROBLEM", 5, 25], ["viral RNA in respiratory secretions", "PROBLEM", 39, 74], ["symptoms", "PROBLEM", 108, 116], ["seroconversion", "PROBLEM", 121, 135], ["viral diseases", "OBSERVATION", 11, 25], ["viral RNA", "OBSERVATION", 39, 48], ["respiratory secretions", "OBSERVATION", 52, 74]]], ["Whether these patients remain infectious to others is uncertain.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["infectious", "PROBLEM", 30, 40], ["infectious", "OBSERVATION", 30, 40]]], ["Much work remains to define the optimal approach to COVID-19 diagnosis, and comparisons across assays and specimen types are important unmet needs.Testing for a Broad Range of Respiratory Pathogens Simultaneously ::: QUESTION 2: IF I DECIDE TO TEST, WHICH APPROACH IS BEST?Upfront multiplex testing for multiple viruses may be most cost-effective in pediatric patients, where it can reduce unnecessary antibiotics as well as chest radiographs [42].", [["specimen", "ANATOMY", 106, 114], ["chest", "ANATOMY", 425, 430], ["patients", "ORGANISM", 360, 368], ["patients", "SPECIES", 360, 368], ["COVID", "TEST", 52, 57], ["comparisons across assays", "TEST", 76, 101], ["Testing", "TEST", 147, 154], ["Upfront multiplex testing", "TEST", 273, 298], ["multiple viruses", "PROBLEM", 303, 319], ["unnecessary antibiotics", "TREATMENT", 390, 413], ["chest radiographs", "TEST", 425, 442], ["Respiratory Pathogens", "OBSERVATION", 176, 197], ["viruses", "OBSERVATION", 312, 319], ["chest", "ANATOMY", 425, 430]]], ["In contrast, a Veterans Affairs study evaluating a multiplex NAAT assay in adult outpatients during influenza season suggested that testing for influenza alone may be more cost-effective than a syndromic approach in this patient population [30].", [["influenza", "DISEASE", 144, 153], ["outpatients", "ORGANISM", 81, 92], ["patient", "ORGANISM", 221, 228], ["outpatients", "SPECIES", 81, 92], ["patient", "SPECIES", 221, 228], ["a multiplex NAAT assay", "TEST", 49, 71], ["influenza", "PROBLEM", 100, 109], ["influenza", "PROBLEM", 144, 153], ["a syndromic approach", "TREATMENT", 192, 212]]], ["Multiplex viral NAAT (potentially combined with bacterial NAAT) also makes clinical sense for immunocompromised and critically ill patients with pneumonia as well as for those with exacerbations of airway disease [43].", [["airway", "ANATOMY", 198, 204], ["NAAT", "CHEMICAL", 16, 20], ["critically ill", "DISEASE", 116, 130], ["pneumonia", "DISEASE", 145, 154], ["airway disease", "DISEASE", 198, 212], ["patients", "ORGANISM", 131, 139], ["airway", "MULTI-TISSUE_STRUCTURE", 198, 204], ["patients", "SPECIES", 131, 139], ["Multiplex viral NAAT", "PROBLEM", 0, 20], ["bacterial NAAT)", "PROBLEM", 48, 63], ["immunocompromised", "PROBLEM", 94, 111], ["pneumonia", "PROBLEM", 145, 154], ["airway disease", "PROBLEM", 198, 212], ["viral NAAT", "OBSERVATION", 10, 20], ["pneumonia", "OBSERVATION", 145, 154], ["airway", "ANATOMY", 198, 204]]], ["These are situations where treatment of non\u2013influenza viruses such as respiratory syncytial virus (RSV) or adenovirus may be considered (eg, in a stem-cell-transplant patient) and rapid test results are most likely to influence subsequent modifications of empiric broad-spectrum antibiotics.Testing for a Broad Range of Respiratory Pathogens Simultaneously ::: QUESTION 2: IF I DECIDE TO TEST, WHICH APPROACH IS BEST?While the analytic sensitivity of multiplex NAAT decreases the likelihood that an important pathogen will be missed, enhanced detection also complicates interpretation.", [["stem-cell", "ANATOMY", 146, 155], ["respiratory syncytial virus", "DISEASE", 70, 97], ["RSV", "DISEASE", 99, 102], ["NAAT", "CHEMICAL", 461, 465], ["non\u2013influenza viruses", "ORGANISM", 40, 61], ["respiratory syncytial virus", "ORGANISM", 70, 97], ["RSV", "ORGANISM", 99, 102], ["adenovirus", "ORGANISM", 107, 117], ["stem-cell", "CELL", 146, 155], ["patient", "ORGANISM", 167, 174], ["multiplex NAAT", "PROTEIN", 451, 465], ["respiratory syncytial virus", "SPECIES", 70, 97], ["patient", "SPECIES", 167, 174], ["respiratory syncytial virus", "SPECIES", 70, 97], ["RSV", "SPECIES", 99, 102], ["adenovirus", "SPECIES", 107, 117], ["non\u2013influenza viruses", "PROBLEM", 40, 61], ["respiratory syncytial virus (RSV)", "PROBLEM", 70, 103], ["adenovirus", "PROBLEM", 107, 117], ["rapid test", "TEST", 180, 190], ["empiric broad-spectrum antibiotics", "TREATMENT", 256, 290], ["Testing", "TEST", 291, 298], ["the analytic sensitivity", "TEST", 423, 447], ["multiplex NAAT", "TEST", 451, 465], ["an important pathogen", "PROBLEM", 496, 517], ["enhanced detection", "TEST", 534, 552], ["syncytial virus", "OBSERVATION", 82, 97], ["most likely", "UNCERTAINTY", 203, 214], ["Respiratory Pathogens", "OBSERVATION", 320, 341]]], ["Prolonged virus shedding detectable by NAAT, but not culture, is described in immunocompromised individuals [44], and children often asymptomatically shed respiratory viruses [45].", [["respiratory viruses", "DISEASE", 155, 174], ["children", "ORGANISM", 118, 126], ["NAAT", "PROTEIN", 39, 43], ["children", "SPECIES", 118, 126], ["Prolonged virus shedding", "PROBLEM", 0, 24], ["NAAT", "TEST", 39, 43], ["culture", "TEST", 53, 60], ["asymptomatically shed respiratory viruses", "PROBLEM", 133, 174], ["virus", "OBSERVATION", 10, 15], ["respiratory viruses", "OBSERVATION", 155, 174]]], ["In addition, nonviable bacteria may be detected by NAAT.", [["NAAT", "SIMPLE_CHEMICAL", 51, 55], ["NAAT", "PROTEIN", 51, 55], ["nonviable bacteria", "PROBLEM", 13, 31], ["nonviable", "OBSERVATION_MODIFIER", 13, 22], ["bacteria", "OBSERVATION", 23, 31], ["may be", "UNCERTAINTY", 32, 38]]], ["These phenomena have important implications for hospital infection control and treatment decisions.", [["infection", "DISEASE", 57, 66], ["These phenomena", "PROBLEM", 0, 15], ["hospital infection control", "TREATMENT", 48, 74], ["treatment decisions", "TREATMENT", 79, 98]]], ["Co-detection of multiple bacteria, viruses, or bacteria plus viruses is also common using NAAT, occurring in up to 30\u201340% of cases [46, 47].", [["multiple bacteria", "PROBLEM", 16, 33], ["viruses", "PROBLEM", 35, 42], ["bacteria plus viruses", "PROBLEM", 47, 68], ["NAAT", "TEST", 90, 94], ["multiple", "OBSERVATION_MODIFIER", 16, 24], ["bacteria", "OBSERVATION", 25, 33], ["viruses", "OBSERVATION", 35, 42]]], ["Available studies on the medical significance of mixed infections have reported variable results.", [["infections", "DISEASE", 55, 65], ["Available studies", "TEST", 0, 17], ["mixed infections", "PROBLEM", 49, 65], ["infections", "OBSERVATION", 55, 65]]], ["Additional studies are needed to understand whether coinfections portend poorer prognosis.Testing for a Broad Range of Respiratory Pathogens Simultaneously ::: QUESTION 2: IF I DECIDE TO TEST, WHICH APPROACH IS BEST?High analytic sensitivity also translates to high negative-predictive values (ie, generally >97%, depending on prevalence), but there may be important differences among individual panel targets or across manufacturers.", [["Additional studies", "TEST", 0, 18], ["Testing", "TEST", 90, 97], ["High analytic sensitivity", "TEST", 216, 241], ["Respiratory Pathogens", "OBSERVATION", 119, 140]]], ["It is incumbent on clinicians and laboratorians to understand the test characteristics of each individual panel target, especially if the results inform antibiotic de-escalation in high-acuity settings.", [["antibiotic de-escalation", "TREATMENT", 153, 177]]], ["Even the largest multiplex panels do not detect all potential pathogens, and the optimal multiplex panel design remains a matter of debate.", [["the largest multiplex panels", "TEST", 5, 33], ["all potential pathogens", "PROBLEM", 48, 71], ["the optimal multiplex panel", "TEST", 77, 104], ["largest", "OBSERVATION_MODIFIER", 9, 16], ["potential", "OBSERVATION_MODIFIER", 52, 61], ["pathogens", "OBSERVATION", 62, 71]]], ["As a result, current tests are not yet a replacement for bacterial and fungal culture with antimicrobial susceptibility testing.", [["current tests", "TEST", 13, 26], ["a replacement", "TREATMENT", 39, 52], ["bacterial and fungal culture", "TEST", 57, 85], ["antimicrobial susceptibility testing", "TEST", 91, 127]]], ["Culture also remains essential for epidemiologic studies, vaccine-related decisions, and local antibiograms.Testing for a Broad Range of Respiratory Pathogens Simultaneously ::: QUESTION 2: IF I DECIDE TO TEST, WHICH APPROACH IS BEST?Current bacterial pneumonia panels are intended for use with LRT samples, but FDA approval for specific specimen types (eg, sputum, endotracheal, and/or bronchial) varies by assay.", [["LRT samples", "ANATOMY", 295, 306], ["specimen", "ANATOMY", 338, 346], ["sputum", "ANATOMY", 358, 364], ["endotracheal", "ANATOMY", 366, 378], ["bronchial", "ANATOMY", 387, 396], ["pneumonia", "DISEASE", 252, 261], ["bronchial", "ORGAN", 387, 396], ["Culture", "TEST", 0, 7], ["epidemiologic studies", "TEST", 35, 56], ["vaccine", "TREATMENT", 58, 65], ["local antibiograms", "TEST", 89, 107], ["Testing", "TEST", 108, 115], ["Current bacterial pneumonia panels", "PROBLEM", 234, 268], ["LRT samples", "TEST", 295, 306], ["specific specimen types", "TEST", 329, 352], ["sputum", "TEST", 358, 364], ["endotracheal", "TEST", 366, 378], ["Respiratory Pathogens", "OBSERVATION", 137, 158], ["bacterial", "OBSERVATION_MODIFIER", 242, 251], ["pneumonia", "OBSERVATION", 252, 261], ["endotracheal", "ANATOMY", 366, 378], ["bronchial", "ANATOMY", 387, 396]]], ["Studies comparing diagnostic yield using different sample types collected concurrently from the same patient are currently underway.", [["sample", "ANATOMY", 51, 57], ["patient", "ORGANISM", 101, 108], ["patient", "SPECIES", 101, 108], ["different sample types", "TREATMENT", 41, 63]]], ["Factors to consider here include the higher likelihood of sputum samples to contain upper airway commensals and the theoretic benefit of site-directed bronchoalveolar lavage (BAL) over blind endotracheal suctioning in mechanically ventilated patients.", [["sputum samples", "ANATOMY", 58, 72], ["upper airway", "ANATOMY", 84, 96], ["bronchoalveolar lavage", "ANATOMY", 151, 173], ["BAL", "ANATOMY", 175, 178], ["endotracheal", "ANATOMY", 191, 203], ["upper airway", "ORGANISM_SUBDIVISION", 84, 96], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 151, 173], ["BAL", "MULTI-TISSUE_STRUCTURE", 175, 178], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 242, 250], ["sputum samples", "TEST", 58, 72], ["upper airway commensals", "PROBLEM", 84, 107], ["directed bronchoalveolar lavage", "TREATMENT", 142, 173], ["blind endotracheal suctioning", "TREATMENT", 185, 214], ["mechanically ventilated", "TREATMENT", 218, 241], ["upper", "ANATOMY_MODIFIER", 84, 89], ["airway", "ANATOMY", 90, 96], ["bronchoalveolar lavage", "OBSERVATION", 151, 173], ["endotracheal suctioning", "OBSERVATION", 191, 214]]], ["In addition, negative upper respiratory tract (URT) testing for viruses and atypical bacteria is not sufficient to rule out LRT infection.", [["upper respiratory tract", "ANATOMY", 22, 45], ["infection", "DISEASE", 128, 137], ["upper respiratory", "ORGANISM_SUBDIVISION", 22, 39], ["tract", "ORGANISM_SUBDIVISION", 40, 45], ["negative upper respiratory tract", "PROBLEM", 13, 45], ["URT) testing", "TEST", 47, 59], ["viruses", "PROBLEM", 64, 71], ["atypical bacteria", "PROBLEM", 76, 93], ["LRT infection", "PROBLEM", 124, 137], ["upper", "ANATOMY_MODIFIER", 22, 27], ["respiratory tract", "ANATOMY", 28, 45], ["infection", "OBSERVATION", 128, 137]]], ["In severe influenza, for example, viral shedding lasts a median of 6 days in URT as compared with a median of 11 days in LRT specimens [48] and certain strains of influenza including H1N1 and H5N1 preferentially or exclusively infect the LRT [49, 50].", [["specimens", "ANATOMY", 125, 134], ["influenza", "DISEASE", 10, 19], ["influenza", "DISEASE", 163, 172], ["influenza", "ORGANISM", 163, 172], ["H1N1", "ORGANISM", 183, 187], ["H5N1", "ORGANISM", 192, 196], ["H1N1 and H5N1", "SPECIES", 183, 196], ["H5N1", "SPECIES", 192, 196], ["severe influenza", "PROBLEM", 3, 19], ["viral shedding", "PROBLEM", 34, 48], ["LRT specimens", "TEST", 121, 134], ["influenza", "PROBLEM", 163, 172], ["H1N1", "PROBLEM", 183, 187], ["H5N1", "PROBLEM", 192, 196], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["influenza", "OBSERVATION", 10, 19]]], ["A study of immunocompromised adults with RSV also observed significantly better sensitivity with LRT versus URT specimens [51].", [["URT specimens", "ANATOMY", 108, 121], ["adults", "ORGANISM", 29, 35], ["RSV", "ORGANISM", 41, 44], ["RSV", "SPECIES", 41, 44], ["A study", "TEST", 0, 7], ["immunocompromised adults", "PROBLEM", 11, 35], ["RSV", "PROBLEM", 41, 44], ["LRT versus URT specimens", "TEST", 97, 121]]], ["Consequently, LRT sampling after negative URT testing is advisable when there is strong clinical suspicion for influenza or RSV and is recommended for immunocompromised patients with lung infiltrates.QUESTION 3: HOW DO I INTERPRET THE SIGNIFICANCE OF BACTERIAL DNA DETECTIONS IN THE LOWER RESPIRATORY TRACT?Molecular diagnostics generally detect more bacterial pathogens than culture [12, 46, 47, 52, 53].", [["lung", "ANATOMY", 183, 187], ["influenza", "DISEASE", 111, 120], ["RSV", "DISEASE", 124, 127], ["RSV", "ORGANISM", 124, 127], ["patients", "ORGANISM", 169, 177], ["lung", "ORGAN", 183, 187], ["patients", "SPECIES", 169, 177], ["RSV", "SPECIES", 124, 127], ["LRT sampling", "TEST", 14, 26], ["negative URT testing", "TEST", 33, 53], ["influenza", "PROBLEM", 111, 120], ["RSV", "PROBLEM", 124, 127], ["lung infiltrates", "PROBLEM", 183, 199], ["BACTERIAL DNA DETECTIONS IN THE LOWER RESPIRATORY TRACT", "PROBLEM", 251, 306], ["Molecular diagnostics", "TEST", 307, 328], ["more bacterial pathogens", "PROBLEM", 346, 370], ["culture", "TEST", 376, 383], ["lung", "ANATOMY", 183, 187], ["infiltrates", "OBSERVATION", 188, 199], ["BACTERIAL DNA", "OBSERVATION", 251, 264], ["LOWER", "ANATOMY_MODIFIER", 283, 288], ["RESPIRATORY TRACT", "ANATOMY", 289, 306]]], ["This likely reflects the inherent sensitivity of NAAT combined with potential detection of dead, fastidious, colonizing, or metabolically impaired organisms.", [["NAAT", "CHEMICAL", 49, 53], ["NAAT", "SIMPLE_CHEMICAL", 49, 53], ["NAAT", "TEST", 49, 53], ["dead", "PROBLEM", 91, 95], ["fastidious", "PROBLEM", 97, 107], ["colonizing", "PROBLEM", 109, 119], ["metabolically impaired organisms", "PROBLEM", 124, 156], ["likely reflects", "UNCERTAINTY", 5, 20]]], ["Assessing previous receipt of antibiotics at the time of specimen collection will be critical for interpreting NAAT-positive/culture-negative results.", [["specimen", "ANATOMY", 57, 65], ["NAAT", "GENE_OR_GENE_PRODUCT", 111, 115], ["antibiotics", "TREATMENT", 30, 41], ["specimen collection", "TEST", 57, 76], ["interpreting NAAT", "TEST", 98, 115], ["culture", "TEST", 125, 132]]], ["It is also important to remember that neither culture nor NAAT separates airway colonizers from invasive pathogens.", [["airway", "ANATOMY", 73, 79], ["NAAT", "SIMPLE_CHEMICAL", 58, 62], ["airway", "MULTI-TISSUE_STRUCTURE", 73, 79], ["neither culture", "TEST", 38, 53], ["NAAT separates airway colonizers", "PROBLEM", 58, 90], ["invasive pathogens", "PROBLEM", 96, 114], ["invasive", "OBSERVATION_MODIFIER", 96, 104]]], ["However, use of quantitative methods may improve the clinical specificity of culture for VAP [33, 54], with higher values being more predictive of true infection.", [["VAP", "DISEASE", 89, 92], ["infection", "DISEASE", 152, 161], ["quantitative methods", "TREATMENT", 16, 36], ["culture", "TEST", 77, 84], ["VAP", "PROBLEM", 89, 92], ["true infection", "PROBLEM", 147, 161], ["infection", "OBSERVATION", 152, 161]]], ["One of the FDA-cleared multiplex pneumonia panels does report relative organism abundance for 15 of its bacterial targets [55].", [["pneumonia", "DISEASE", 33, 42], ["the FDA", "TEST", 7, 14], ["cleared multiplex pneumonia panels", "PROBLEM", 15, 49], ["relative organism abundance", "PROBLEM", 62, 89], ["its bacterial targets", "TEST", 100, 121], ["pneumonia", "OBSERVATION", 33, 42]]], ["Bacterial detections are grouped into semiquantitative bins of 104, 105, 106 and more than 107 genomic copies/mL, which are calculated relative to calibrator material in the assay.", [["Bacterial detections", "TEST", 0, 20], ["semiquantitative bins", "TEST", 38, 59]]], ["Values below 103.5 copies/mL are reported as \u201cnot detected.\u201d", [["Values", "TEST", 0, 6], ["copies/mL", "TEST", 19, 28]]], ["In general, there is moderate correlation between genomic units and culture quantitation, with genome copies/mL tending to be higher than the corresponding colony forming units/mL measurements.QUESTION 3: HOW DO I INTERPRET THE SIGNIFICANCE OF BACTERIAL DNA DETECTIONS IN THE LOWER RESPIRATORY TRACT?In the second vignette (Box 2), the patient\u2019s BAL contained much higher concentrations of MRSA nucleic acid than H. influenzae.", [["BAL", "ANATOMY", 346, 349], ["MRSA nucleic acid", "CHEMICAL", 390, 407], ["patient", "ORGANISM", 336, 343], ["BAL", "ORGANISM_SUBSTANCE", 346, 349], ["MRSA nucleic acid", "SIMPLE_CHEMICAL", 390, 407], ["H. influenzae", "ORGANISM", 413, 426], ["patient", "SPECIES", 336, 343], ["MRSA", "SPECIES", 390, 394], ["H. influenzae", "SPECIES", 413, 426], ["H. influenzae", "SPECIES", 413, 426], ["culture quantitation", "TEST", 68, 88], ["BACTERIAL DNA DETECTIONS IN THE LOWER RESPIRATORY TRACT", "PROBLEM", 244, 299], ["the patient\u2019s BAL", "TEST", 332, 349], ["MRSA nucleic acid", "PROBLEM", 390, 407], ["H. influenzae", "PROBLEM", 413, 426], ["moderate", "OBSERVATION_MODIFIER", 21, 29], ["BACTERIAL DNA", "OBSERVATION", 244, 257], ["LOWER", "ANATOMY_MODIFIER", 276, 281], ["RESPIRATORY TRACT", "ANATOMY", 282, 299]]], ["It is possible that the low-level H. influenzae detection simply represents airway colonization and the negative culture is a result of previous antibiotics.", [["airway", "ANATOMY", 76, 82], ["H. influenzae", "ORGANISM", 34, 47], ["airway", "MULTI-TISSUE_STRUCTURE", 76, 82], ["H. influenzae", "SPECIES", 34, 47], ["H. influenzae", "SPECIES", 34, 47], ["the low-level H. influenzae detection", "PROBLEM", 20, 57], ["airway colonization", "PROBLEM", 76, 95], ["the negative culture", "TEST", 100, 120], ["previous antibiotics", "TREATMENT", 136, 156], ["low", "OBSERVATION_MODIFIER", 24, 27], ["airway", "ANATOMY", 76, 82], ["colonization", "OBSERVATION", 83, 95]]], ["However, in a critically ill immunocompromised patient, the consequences of not treating a potential pathogen likely outweigh the risk of toxicity from targeted antimicrobial therapy.", [["critically ill", "DISEASE", 14, 28], ["toxicity", "DISEASE", 138, 146], ["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["a potential pathogen", "PROBLEM", 89, 109], ["toxicity", "PROBLEM", 138, 146], ["targeted antimicrobial therapy", "TREATMENT", 152, 182], ["antimicrobial therapy", "OBSERVATION", 161, 182]]], ["Whether detection of high versus low concentrations of potential pathogens has prognostic value deserves additional study and this will vary by organism.", [["high versus low concentrations of potential pathogens", "PROBLEM", 21, 74], ["additional study", "TEST", 105, 121], ["high", "OBSERVATION_MODIFIER", 21, 25]]], ["A small single-center study did observe increased lengths of intensive care unit stay and more discharge diagnosis codes for pneumonia in patients with higher NAAT genomic copies/mL, which suggests that binning may have clinical value and potentially help clinicians distinguish true infections from colonization [56].QUESTION 4: DOES PARTNERSHIP WITH ANTIBIOTIC STEWARDSHIP ENHANCE THE IMPACT OF RESPIRATORY DIAGNOSTIC TESTING?Antimicrobial stewardship guidelines advocate rapid testing for broad panels of respiratory viruses as an important intervention to reduce the use of inappropriate antibiotics [57].", [["pneumonia", "DISEASE", 125, 134], ["infections", "DISEASE", 284, 294], ["respiratory viruses", "DISEASE", 508, 527], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["pneumonia", "PROBLEM", 125, 134], ["higher NAAT genomic copies/mL", "PROBLEM", 152, 181], ["true infections from colonization", "PROBLEM", 279, 312], ["RESPIRATORY DIAGNOSTIC TESTING", "TEST", 397, 427], ["Antimicrobial stewardship guidelines", "TREATMENT", 428, 464], ["rapid testing", "TEST", 474, 487], ["broad panels", "TEST", 492, 504], ["respiratory viruses", "PROBLEM", 508, 527], ["an important intervention", "TREATMENT", 531, 556], ["inappropriate antibiotics", "TREATMENT", 578, 603], ["small", "OBSERVATION_MODIFIER", 2, 7], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["lengths", "OBSERVATION_MODIFIER", 50, 57], ["pneumonia", "OBSERVATION", 125, 134], ["respiratory viruses", "OBSERVATION", 508, 527]]], ["Nevertheless, there have yet to be any interventional studies assessing the safety and efficacy of antimicrobial de-escalation based on multiplex NAAT results.", [["NAAT", "PROTEIN", 146, 150], ["any interventional studies", "TEST", 35, 61], ["antimicrobial de-escalation", "TREATMENT", 99, 126], ["multiplex NAAT results", "TEST", 136, 158]]], ["Active AS studies have mostly used pre- versus postintervention designs and have focused primarily on viral testing.", [["viral testing", "TEST", 102, 115]]], ["The highest rates of antibiotic discontinuation (51%) with prospective audit and feedback were observed when a virus is detected, bacterial cultures are negative, and chest imaging is normal [58].", [["cultures", "ANATOMY", 140, 148], ["chest", "ANATOMY", 167, 172], ["chest", "ORGAN", 167, 172], ["antibiotic discontinuation", "TREATMENT", 21, 47], ["prospective audit", "TEST", 59, 76], ["a virus", "PROBLEM", 109, 116], ["bacterial cultures", "TEST", 130, 148], ["chest imaging", "TEST", 167, 180], ["chest", "ANATOMY", 167, 172]]], ["Otherwise, only modest antibiotic discontinuation rates (14\u201324% of cases) with active AS in the setting of viral RTIs were accomplished [59\u201361].", [["RTIs", "DISEASE", 113, 117], ["modest antibiotic discontinuation rates", "TREATMENT", 16, 55], ["active AS", "PROBLEM", 79, 88], ["viral RTIs", "PROBLEM", 107, 117]]], ["This is likely due to the inability to exclude bacterial coinfection with confidence in a meaningful time frame.", [["bacterial coinfection", "PROBLEM", 47, 68], ["likely due to", "UNCERTAINTY", 8, 21], ["bacterial", "OBSERVATION_MODIFIER", 47, 56], ["coinfection", "OBSERVATION", 57, 68]]], ["The combination of respiratory virus NAAT with a serum biomarker (eg, procalcitonin) or host immune-response profile suggestive of a viral, but not bacterial, infection may be useful in this regard [62, 63].QUESTION 4: DOES PARTNERSHIP WITH ANTIBIOTIC STEWARDSHIP ENHANCE THE IMPACT OF RESPIRATORY DIAGNOSTIC TESTING?The fact that molecular testing of respiratory specimens for bacteria detects more organisms than traditional culture has led to concerns that multiplex NAAT may paradoxically increase antimicrobial use.", [["serum", "ANATOMY", 49, 54], ["respiratory specimens", "ANATOMY", 352, 373], ["infection", "DISEASE", 159, 168], ["NAAT", "CHEMICAL", 470, 474], ["respiratory virus NAAT", "ORGANISM", 19, 41], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 70, 83], ["NAAT", "SIMPLE_CHEMICAL", 470, 474], ["respiratory virus", "SPECIES", 19, 36], ["respiratory virus NAAT", "PROBLEM", 19, 41], ["a serum biomarker", "TEST", 47, 64], ["procalcitonin", "TEST", 70, 83], ["host immune", "TEST", 88, 99], ["a viral", "PROBLEM", 131, 138], ["bacterial", "PROBLEM", 148, 157], ["infection", "PROBLEM", 159, 168], ["RESPIRATORY DIAGNOSTIC TESTING", "TEST", 286, 316], ["molecular testing of respiratory specimens", "TEST", 331, 373], ["bacteria", "PROBLEM", 378, 386], ["traditional culture", "TEST", 415, 434], ["multiplex NAAT", "TEST", 460, 474], ["respiratory virus", "OBSERVATION", 19, 36], ["viral", "OBSERVATION", 133, 138], ["infection", "OBSERVATION", 159, 168]]], ["Moreover, early experience suggests that genotypic resistance aligns relatively poorly with phenotypic susceptibility results [52, 53, 64].", [["genotypic resistance aligns", "PROBLEM", 41, 68]]], ["Molecular methods detect only the most common resistance determinants and resistance genes present in \u201coff panel\u201d organisms will complicate interpretation.", [["resistance genes", "DNA", 74, 90], ["Molecular methods", "TEST", 0, 17], ["resistance genes", "PROBLEM", 74, 90]]], ["Guidance from an AS team will likely be required to derive maximal benefit from LRT respiratory NAAT, just as it has for bloodstream infections [65].", [["bloodstream", "ANATOMY", 121, 132], ["bloodstream infections", "DISEASE", 121, 143], ["LRT respiratory NAAT", "TEST", 80, 100], ["bloodstream infections", "PROBLEM", 121, 143]]], ["Whether combined use of biomarkers or host immune-response plus molecular pathogen testing and AS monitoring can promote safe reductions in antibiotic use requires additional exploration.", [["biomarkers", "TEST", 24, 34], ["molecular pathogen testing", "TEST", 64, 90], ["safe reductions", "TREATMENT", 121, 136], ["antibiotic use", "TREATMENT", 140, 154], ["additional exploration", "TREATMENT", 164, 186]]], ["Targeting interventions to lower-risk patients with a virus detection, where prescribers may be more adherent to recommendations, may be the most pragmatic place to start.CONCLUSIONS AND CLINICAL RECOMMENDATIONSMolecular diagnostics have revolutionized the detection of respiratory viruses.", [["respiratory viruses", "DISEASE", 270, 289], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["a virus detection", "TEST", 52, 69], ["respiratory viruses", "PROBLEM", 270, 289], ["respiratory viruses", "OBSERVATION", 270, 289]]], ["Compared with classical culture- and antigen-based methods, these tests have high sensitivity and there is potential for a clinically meaningful turnaround time to actionable results that may reduce diagnostic uncertainty and help guide early management decisions.", [["classical culture", "TEST", 14, 31], ["antigen", "TEST", 37, 44], ["these tests", "TEST", 60, 71], ["high sensitivity", "PROBLEM", 77, 93]]], ["Newer molecular assays now target SARS-CoV-2 as well as common causes of bacterial pneumonia.", [["pneumonia", "DISEASE", 83, 92], ["SARS-CoV-2", "ORGANISM", 34, 44], ["SARS-CoV", "SPECIES", 34, 42], ["Newer molecular assays", "TEST", 0, 22], ["bacterial pneumonia", "PROBLEM", 73, 92], ["bacterial", "OBSERVATION_MODIFIER", 73, 82], ["pneumonia", "OBSERVATION", 83, 92]]], ["Whether SARS-CoV-2 will become a seasonal virus is unknown, but we are likely to see this virus included as a part of syndromic respiratory diagnostic panels in the future.CONCLUSIONS AND CLINICAL RECOMMENDATIONSIn general, respiratory NAAT is most useful in the setting of intermediate pretest probability and intermediate disease severity.", [["SARS", "DISEASE", 8, 12], ["SARS-CoV-2", "ORGANISM", 8, 18], ["SARS", "PROBLEM", 8, 12], ["CoV", "TEST", 13, 16], ["a seasonal virus", "PROBLEM", 31, 47], ["this virus", "PROBLEM", 85, 95], ["respiratory NAAT", "TEST", 224, 240], ["intermediate pretest probability", "PROBLEM", 274, 306], ["intermediate disease severity", "PROBLEM", 311, 340], ["intermediate disease", "OBSERVATION", 311, 331]]], ["This is a situation where a negative test may permit withholding of initial empiric coverage of a potential pathogen, whereas a positive test can allow therapy to be focused against a particular pathogen, thus increasing therapeutic efficacy, decreasing avoidable drug toxicity, and potentially reducing unnecessary additional testing.", [["toxicity", "DISEASE", 269, 277], ["a negative test", "TEST", 26, 41], ["initial empiric coverage", "TREATMENT", 68, 92], ["a potential pathogen", "PROBLEM", 96, 116], ["a positive test", "PROBLEM", 126, 141], ["therapy", "TREATMENT", 152, 159], ["a particular pathogen", "PROBLEM", 182, 203], ["decreasing avoidable drug toxicity", "PROBLEM", 243, 277], ["unnecessary additional testing", "TEST", 304, 334]]], ["Under conditions of high pretest probability and/or high risk of an adverse outcome, these tests generally lack sufficient sensitivity for a clinician not to empirically \u201ccover\u201d a potentially life-threatening pathogen.", [["high pretest probability", "PROBLEM", 20, 44], ["an adverse outcome", "PROBLEM", 65, 83], ["these tests", "TEST", 85, 96], ["a potentially life-threatening pathogen", "PROBLEM", 178, 217]]], ["When there is a low pretest probability for a particular pathogen and/or low risk of adverse clinical outcomes, available tests may not add sufficient clinical value to constitute an efficient use of limited medical resources.", [["a low pretest probability", "PROBLEM", 14, 39], ["a particular pathogen", "PROBLEM", 44, 65], ["available tests", "TEST", 112, 127], ["limited medical resources", "TREATMENT", 200, 225]]], ["Decisions regarding deployment of molecular diagnostics at the level of the hospital laboratory, and for a hospital system as a whole, should also consider their value in guiding protocols and policy\u2014for example, in hospital epidemiology and antibiotic stewardship.", [["molecular diagnostics", "TEST", 34, 55], ["antibiotic stewardship", "TREATMENT", 242, 264]]], ["Policies for effective use must be evaluated in an ongoing fashion as technology evolves and evidence in support of best practice emerges.UNMET DIAGNOSTIC NEEDS AND FUTURE DIRECTIONSRapid molecular diagnostics are powerful tools for the evaluation and management of patients with suspected RTI.", [["RTI", "DISEASE", 290, 293], ["patients", "ORGANISM", 266, 274], ["patients", "SPECIES", 266, 274], ["the evaluation", "TEST", 233, 247], ["management", "TREATMENT", 252, 262], ["suspected RTI", "PROBLEM", 280, 293]]], ["However, optimal testing algorithms and the potential impact that these tests have on patient management decisions and outcomes require further study in a variety of clinical settings.", [["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93], ["optimal testing algorithms", "TEST", 9, 35], ["these tests", "TEST", 66, 77], ["patient management", "TREATMENT", 86, 104], ["further study", "TEST", 136, 149]]], ["Table 2 summarizes the investigations that we believe are required to address the most important knowledge gaps and unmet diagnostic needs for RTIs.", [["RTIs", "DISEASE", 143, 147], ["the investigations", "TEST", 19, 37], ["RTIs", "PROBLEM", 143, 147]]], ["Outcome studies should ideally be prospective and include large enough numbers of patients to make statistically meaningful comparisons.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["Outcome studies", "TEST", 0, 15]]], ["Last, funding for interventional trials of respiratory diagnostics is a priority.", [["respiratory diagnostics", "TEST", 43, 66]]]], "PMC7255177": [["The verdict on the success of the global response to the COVID-19 pandemic remains to be written, but the consequences of the disease are indisputable and rapidly coming into focus.", [["the COVID", "TEST", 53, 62], ["pandemic", "PROBLEM", 66, 74], ["the disease", "PROBLEM", 122, 133], ["disease", "OBSERVATION", 126, 133]]], ["In many countries, efforts to contain COVID-19 have resulted in an economic recession, pushing millions out of their jobs, and creating previously unprecedented unemployment in many countries worldwide.", [["COVID", "TEST", 38, 43], ["an economic recession", "PROBLEM", 64, 85], ["economic", "OBSERVATION_MODIFIER", 67, 75], ["recession", "OBSERVATION", 76, 85]]], ["In addition to the millions of people infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hundreds of thousands have died\u2014and will die\u2014from COVID-19.", [["acute respiratory syndrome coronavirus", "DISEASE", 57, 95], ["people", "ORGANISM", 31, 37], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 50, 95], ["SARS-CoV-2", "ORGANISM", 99, 109], ["people", "SPECIES", 31, 37], ["severe acute respiratory syndrome coronavirus", "SPECIES", 50, 95], ["SARS-CoV-2", "SPECIES", 99, 109], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 50, 95], ["CoV", "TEST", 104, 107], ["COVID", "TEST", 162, 167], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory syndrome", "OBSERVATION", 63, 83]]], ["An anticipated wave of mental and behavioural problems is beginning to be documented\u2014compounded by social and economic stressors and uncertainties\u2014that will likely present a population health burden for months and years to come.", [["An anticipated wave of mental and behavioural problems", "PROBLEM", 0, 54], ["wave", "OBSERVATION_MODIFIER", 15, 19]]]], "0323ac71f55635ab6be3b012d05e0324fe265b1e": [["S evere acute respiratory syndrome Coronavirus 2 (SARS-CoV-2, previously named 2019-nCoV) is a new coronavirus causing coronavirus disease 2019 (COVID- 19) which first emerged in December 2019 1 .", [["acute respiratory syndrome", "DISEASE", 8, 34], ["coronavirus", "DISEASE", 99, 110], ["coronavirus disease", "DISEASE", 119, 138], ["S evere acute respiratory syndrome Coronavirus 2", "ORGANISM", 0, 48], ["SARS-CoV-2", "ORGANISM", 50, 60], ["coronavirus", "ORGANISM", 99, 110], ["coronavirus", "SPECIES", 99, 110], ["S evere acute respiratory syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 0, 60], ["acute respiratory syndrome", "PROBLEM", 8, 34], ["Coronavirus", "TEST", 35, 46], ["SARS", "TEST", 50, 54], ["CoV", "TEST", 55, 58], ["a new coronavirus", "PROBLEM", 93, 110], ["coronavirus disease", "PROBLEM", 119, 138], ["COVID", "TEST", 145, 150], ["acute", "OBSERVATION_MODIFIER", 8, 13], ["respiratory syndrome", "OBSERVATION", 14, 34], ["new", "OBSERVATION_MODIFIER", 95, 98], ["coronavirus", "OBSERVATION", 99, 110]]], ["As of August 19, 2020 , according to the World Health Organization (WHO) 2 , 21,938,207 people all over the world have been infection-confirmed and 775,582 people have died.", [["infection", "DISEASE", 124, 133], ["people", "ORGANISM", 88, 94], ["people", "ORGANISM", 156, 162], ["people", "SPECIES", 88, 94], ["people", "SPECIES", 156, 162], ["infection", "PROBLEM", 124, 133], ["infection", "OBSERVATION", 124, 133]]], ["Rapid and early detection of this deadly virus plays a critical role in facilitating early intervention and treatment, which, in turn, may reduce disease transmission risk.", [["this deadly virus", "PROBLEM", 29, 46], ["early intervention", "TREATMENT", 85, 103], ["treatment", "TREATMENT", 108, 117], ["disease transmission risk", "PROBLEM", 146, 171]]]], "8a2d2e38286fa86dcf60a8a1b0b95658f2d70850": [["IntroductionVarious genera of respiratory viruses, including rhinovirus, parainfluenza virus, adenovirus, respiratory syncytial virus, human metapneumovirus, coronavirus, and, particularly, influenza virus circulate each year in the community [1, 2] .", [["respiratory viruses", "DISEASE", 30, 49], ["rhinovirus, parainfluenza virus", "DISEASE", 61, 92], ["respiratory syncytial virus", "DISEASE", 106, 133], ["human metapneumovirus, coronavirus", "DISEASE", 135, 169], ["influenza virus", "DISEASE", 190, 205], ["respiratory viruses", "ORGANISM", 30, 49], ["rhinovirus", "ORGANISM", 61, 71], ["parainfluenza virus", "ORGANISM", 73, 92], ["adenovirus", "ORGANISM", 94, 104], ["respiratory syncytial virus", "ORGANISM", 106, 133], ["human", "ORGANISM", 135, 140], ["metapneumovirus", "ORGANISM", 141, 156], ["coronavirus", "ORGANISM", 158, 169], ["influenza virus", "ORGANISM", 190, 205], ["rhinovirus", "SPECIES", 61, 71], ["parainfluenza virus", "SPECIES", 73, 92], ["respiratory syncytial virus", "SPECIES", 106, 133], ["human", "SPECIES", 135, 140], ["metapneumovirus", "SPECIES", 141, 156], ["influenza virus", "SPECIES", 190, 205], ["parainfluenza virus", "SPECIES", 73, 92], ["respiratory syncytial virus", "SPECIES", 106, 133], ["human metapneumovirus", "SPECIES", 135, 156], ["respiratory viruses", "PROBLEM", 30, 49], ["rhinovirus", "PROBLEM", 61, 71], ["parainfluenza virus", "PROBLEM", 73, 92], ["adenovirus", "PROBLEM", 94, 104], ["respiratory syncytial virus", "PROBLEM", 106, 133], ["human metapneumovirus", "PROBLEM", 135, 156], ["coronavirus", "PROBLEM", 158, 169], ["influenza virus", "PROBLEM", 190, 205], ["respiratory viruses", "OBSERVATION", 30, 49], ["parainfluenza virus", "OBSERVATION", 73, 92], ["respiratory syncytial", "ANATOMY", 106, 127]]], ["They are associated with upper and lower respiratory tract infections (RTIs), from the common cold to viral pneumonia, in children and adults.", [["lower respiratory tract", "ANATOMY", 35, 58], ["upper and lower respiratory tract infections", "DISEASE", 25, 69], ["RTIs", "DISEASE", 71, 75], ["viral pneumonia", "DISEASE", 102, 117], ["upper", "ORGANISM_SUBDIVISION", 25, 30], ["lower", "ORGANISM_SUBDIVISION", 35, 40], ["respiratory tract", "ORGANISM_SUBDIVISION", 41, 58], ["children", "ORGANISM", 122, 130], ["children", "SPECIES", 122, 130], ["upper and lower respiratory tract infections (RTIs)", "PROBLEM", 25, 76], ["viral pneumonia", "PROBLEM", 102, 117], ["associated with", "UNCERTAINTY", 9, 24], ["upper", "ANATOMY_MODIFIER", 25, 30], ["lower", "ANATOMY_MODIFIER", 35, 40], ["respiratory tract", "ANATOMY", 41, 58], ["infections", "OBSERVATION", 59, 69], ["viral", "OBSERVATION_MODIFIER", 102, 107], ["pneumonia", "OBSERVATION", 108, 117]]], ["Community outbreaks of RTIs can be associated with considerable morbidity and mortality either due to the infection per se or due to the exacerbation of other diseases, such as those that affect the cardiovascular and respiratory system [3] .IntroductionThe development of new methods for early recognition or prediction of community outbreaks or the improvement of the currently used methods is of increasing scientific and public health interest [4] .", [["cardiovascular", "ANATOMY", 199, 213], ["RTIs", "DISEASE", 23, 27], ["infection", "DISEASE", 106, 115], ["cardiovascular", "ANATOMICAL_SYSTEM", 199, 213], ["RTIs", "PROBLEM", 23, 27], ["considerable morbidity", "PROBLEM", 51, 73], ["the infection", "PROBLEM", 102, 115], ["the exacerbation of other diseases", "PROBLEM", 133, 167], ["new methods", "TREATMENT", 273, 284], ["community outbreaks", "PROBLEM", 324, 343], ["RTIs", "OBSERVATION", 23, 27], ["infection", "OBSERVATION", 106, 115], ["diseases", "OBSERVATION", 159, 167], ["respiratory system", "ANATOMY", 218, 236], ["new", "OBSERVATION_MODIFIER", 273, 276]]], ["This process is primarily based on monitoring relevant surveillance data for potential clustering of cases of RTIs that exceed an expected threshold.", [["RTIs", "DISEASE", 110, 114], ["monitoring relevant surveillance data", "TEST", 35, 72], ["RTIs", "PROBLEM", 110, 114]]], ["Surveillance for influenza-like illness is primarily conducted through networks of sentinel providers.", [["influenza-like illness", "DISEASE", 17, 39], ["influenza", "PROBLEM", 17, 26], ["illness", "PROBLEM", 32, 39], ["influenza", "OBSERVATION", 17, 26]]], ["Cases are defined as individuals who present clinical manifestations matching specifically defined clinical criteria of the syndrome.IntroductionThe analysis of surveillance data on RTIs for the purpose of identifying the occurrence of epidemics requires advanced statistical methods.", [["RTIs", "DISEASE", 182, 186], ["the syndrome", "PROBLEM", 120, 132], ["surveillance data", "TEST", 161, 178], ["RTIs", "TREATMENT", 182, 186], ["epidemics", "PROBLEM", 236, 245], ["advanced statistical methods", "TREATMENT", 255, 283]]], ["A common family of such methods derives from the innovatory application of a periodic regression model on pneumonia and influenza mortality data, presented by R.E. Serfling in 1963 [5] .", [["pneumonia", "DISEASE", 106, 115], ["influenza", "DISEASE", 120, 129], ["a periodic regression model", "PROBLEM", 75, 102], ["pneumonia", "PROBLEM", 106, 115], ["influenza mortality data", "PROBLEM", 120, 144], ["pneumonia", "OBSERVATION", 106, 115]]], ["The general principle of this type of method is the use of long-term historical data for estimating expected values for future time-dependent upper thresholds of the relevant distribution, to which the actual observations made are subsequently compared [5, 6] .", [["upper", "ORGANISM_SUBDIVISION", 142, 147], ["upper thresholds", "OBSERVATION_MODIFIER", 142, 158]]], ["Alternative sets of statistical methods that use the same general principle, but require input of relatively few recent historical data have also been proposed, yielding favorable results [7, 8] .", [["statistical methods", "TREATMENT", 20, 39]]], ["Cumulative sum (CUSUM) statistics of the latter class, are nowadays widely used in biomedical research [7, 8, 9] and constitute one of the components of the Early Aberration and Reporting System (EARS) that is used for syndromic surveillance by the United States Centers for Disease Control and Prevention [9] .IntroductionWe sought to establish optimal models for recognition of the onset of respiratory tract infection outbreaks in the metropolitan area of Athens, Greece, on the basis of short-term data from house-call visits, by applying either simple regression or CUSUM methods [7] .", [["respiratory tract", "ANATOMY", 393, 410], ["respiratory tract infection", "DISEASE", 393, 420], ["respiratory tract", "ORGANISM_SUBDIVISION", 393, 410], ["Disease Control", "TREATMENT", 275, 290], ["respiratory tract infection", "PROBLEM", 393, 420], ["Early Aberration", "OBSERVATION", 157, 173], ["respiratory tract", "ANATOMY", 393, 410], ["infection", "OBSERVATION", 411, 420]]], ["This network performs emergency, fee-per-service, house-call visits for both adults and children on a 24-hour basis at the metropolitan area of Athens, Attica, Greece, that is populated by approximately 5 million people.", [["children", "ORGANISM", 88, 96], ["people", "ORGANISM", 213, 219], ["children", "SPECIES", 88, 96], ["people", "SPECIES", 213, 219]]], ["Briefly, on each house visit they filled a specially designed form with data for the chief complaint of the patient, present illness, past medical and surgical history, physical examination, overall clinical assessment, likely diagnosis and management plan.", [["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["physical examination", "TEST", 169, 189], ["overall clinical assessment", "TEST", 191, 218], ["management plan", "TREATMENT", 241, 256]]], ["They also filed the primary diagnosis into prespecified diagnostic categories (including upper or lower RTIs).", [["RTIs", "DISEASE", 104, 108], ["upper", "ORGANISM_SUBDIVISION", 89, 94], ["upper or lower RTIs", "TREATMENT", 89, 108], ["upper", "ANATOMY_MODIFIER", 89, 94], ["lower RTIs", "ANATOMY", 98, 108]]], ["As a general rule, lower RTIs were considered those affecting the respiratory tract below the level of the vocal cords.", [["respiratory tract", "ANATOMY", 66, 83], ["vocal cords", "ANATOMY", 107, 118], ["RTIs", "DISEASE", 25, 29], ["respiratory tract", "ORGANISM_SUBDIVISION", 66, 83], ["vocal cords", "ORGAN", 107, 118], ["lower RTIs", "PROBLEM", 19, 29], ["respiratory tract", "ANATOMY", 66, 83], ["vocal cords", "ANATOMY", 107, 118]]], ["The operational characteristics of SOS Doctors including the methodology used for the collection and archiving of clinical data as well as the main characteristics of the patient population they serve have been described previously in detail [10] .", [["patient", "ORGANISM", 171, 178], ["patient", "SPECIES", 171, 178], ["the collection", "TEST", 82, 96], ["clinical data", "TEST", 114, 127]]], ["Subsets of the database we used have also been analyzed in previous studies assessing the effects of meteorological variables on respiratory and lower urinary tract infections [11, 12] .Data sourcesThe primary diagnosis for each house-call visit was registered by the physician who visited and examined the patient in a specifically designed report form, along with other relevant information, and was promptly entered in the computerized database of SOS Doctors by secretarial staff.", [["respiratory", "ANATOMY", 129, 140], ["lower urinary tract", "ANATOMY", 145, 164], ["respiratory and lower urinary tract infections", "DISEASE", 129, 175], ["lower", "ORGANISM_SUBDIVISION", 145, 150], ["urinary tract", "ORGANISM_SUBDIVISION", 151, 164], ["patient", "ORGANISM", 307, 314], ["patient", "SPECIES", 307, 314], ["previous studies", "TEST", 59, 75], ["meteorological variables", "PROBLEM", 101, 125], ["respiratory and lower urinary tract infections", "PROBLEM", 129, 175], ["lower", "ANATOMY_MODIFIER", 145, 150], ["urinary tract", "ANATOMY", 151, 164]]], ["We analyzed visits for upper and lower RTIs separately.Data sourcesThe type of observations chosen for our analysis is the weeklyaveraged proportion of house-call visits for upper (or lower) RTIs to total house-call visits.", [["RTIs", "DISEASE", 39, 43], ["RTIs", "DISEASE", 191, 195], ["upper", "ORGANISM_SUBDIVISION", 23, 28], ["upper", "ORGANISM_SUBDIVISION", 174, 179], ["upper and lower RTIs", "TREATMENT", 23, 43], ["our analysis", "TEST", 103, 115]]], ["Thus, observation y t is the weeklyaveraged proportion of upper (or lower) RTIs to the total house visits during week t.Reference standard for classification of observationsTo obtain an a priori classification of the observations as normal (non-epidemic) or aberrant (epidemic), i.e., a reference standard with which the results of the application of our models could be compared, we used the application developed by Pelat et al. [13] .", [["RTIs", "DISEASE", 75, 79], ["upper", "ORGANISM_SUBDIVISION", 58, 63], ["the observations", "TEST", 213, 229], ["aberrant (epidemic)", "PROBLEM", 258, 277], ["upper", "ANATOMY_MODIFIER", 58, 63], ["aberrant", "OBSERVATION_MODIFIER", 258, 266]]], ["This freeware online application can apply periodic regression models on user-uploaded data (related to infection incidence) so that baseline levels and ''epidemic thresholds'' can be estimated, either retrospectively or prospectively.", [["infection", "DISEASE", 104, 113], ["periodic regression models", "PROBLEM", 43, 69], ["infection incidence", "PROBLEM", 104, 123], ["''epidemic thresholds", "PROBLEM", 153, 174]]], ["When conducting retrospective analysis, the application proceeds to classify each observation as normal (within the epidemic threshold) or aberrant (exceeding the epidemic threshold).Reference standard for classification of observationsThe above described application provides the option for various user-defined settings.", [["conducting retrospective analysis", "TEST", 5, 38], ["normal", "OBSERVATION", 97, 103]]], ["To estimate the reference baseline levels and epidemic thresholds for our data sets (upper and lower RTIs), a periodic regression model with cubic trend and annual periodicity was used.", [["upper", "ORGANISM_SUBDIVISION", 85, 90], ["epidemic thresholds", "TEST", 46, 65], ["our data sets", "TEST", 70, 83], ["upper and lower RTIs", "PROBLEM", 85, 105], ["a periodic regression model with cubic trend", "PROBLEM", 108, 152], ["upper", "ANATOMY_MODIFIER", 85, 90], ["lower RTIs", "ANATOMY", 95, 105]]], ["Trend was chosen as cubic, as we sought to obtain the best possible fit, and annual periodicity was chosen with respect to the expected seasonality for most common RTIs [14] , as previously observed for our data set [12] .", [["RTIs", "DISEASE", 164, 168]]], ["To estimate baseline levels for our data set we removed the highest 20% percentile of the observations, which we considered to represent aberrant values.", [["our data", "TEST", 32, 40], ["aberrant values", "PROBLEM", 137, 152], ["aberrant", "OBSERVATION", 137, 145]]], ["Finally, we used an upper 97.5% one-sided confidence interval around the calculated baseline levels to define the epidemic thresholds.Models for recognition of outbreaks using short-term dataWe applied two types of statistical methods for the recognition of the onset of community outbreaks of respiratory tract infections (simple regression and CUSUM, respectively) requiring historical data for the previous 4-6 weeks.", [["respiratory tract", "ANATOMY", 294, 311], ["respiratory tract infections", "DISEASE", 294, 322], ["tract", "ORGANISM_SUBDIVISION", 306, 311], ["the calculated baseline levels", "TEST", 69, 99], ["the epidemic thresholds", "PROBLEM", 110, 133], ["short-term dataWe", "TREATMENT", 176, 193], ["statistical methods", "TREATMENT", 215, 234], ["respiratory tract infections", "PROBLEM", 294, 322], ["simple regression", "PROBLEM", 324, 341], ["respiratory tract", "ANATOMY", 294, 311]]], ["This comparison has two possible outcomes: if the threshold is exceeded, the observation is flagged as an alert; otherwise it is not flagged and is labeled as ''expected''.Models for recognition of outbreaks using short-term dataSimple regression.", [["short-term dataSimple regression", "PROBLEM", 214, 246]]], ["Using the simple regression model [7] , the threshold for each week t is defined as the upper limit of the Student 100(12a)% confidence interval for the unknown mean (degrees of freedom = m21):Models for recognition of outbreaks using short-term dataIn the above formula\u1ef9 y (m) t ands s (m) t symbolize the m-week running means and running standard deviations, respectively, calculated from weeks t2m,\u2026,t21, while t (m{1, 1{a=2) is the appropriate tstatistic for m21 degrees of freedom and significance level a.", [["upper limit", "OBSERVATION_MODIFIER", 88, 99]]], ["The assumption of the method is that each running set of m observations belongs to a normal distribution.", [["normal", "OBSERVATION", 85, 91]]], ["CUSUMs are methods that are used to detect small aberrations from an in-control process [15, 16, 17] .", [["small aberrations", "PROBLEM", 43, 60], ["small", "OBSERVATION_MODIFIER", 43, 48], ["aberrations", "OBSERVATION", 49, 60]]], ["The m-week standardized upper CUSUM is calculated as:Models for recognition of outbreaks using short-term dataIn this formula k stands for the standardized reference value K of the CUSUM; it is measured in standard deviations, and represents the maximum allowed range of fluctuation around the process mean for the in-control process.", [["upper", "ANATOMY_MODIFIER", 24, 29]]], ["K is usually defined as the intermediate value between the in-control process mean and the out-of-control process target mean.", [["K", "CHEMICAL", 0, 1], ["K", "TEST", 0, 1], ["intermediate value", "OBSERVATION_MODIFIER", 28, 46]]], ["In the context of this analysis, the in-control process is represented by the normal observations (non-epidemic), while the out-of-control process is represented by the epidemic observations.", [["this analysis", "TEST", 18, 31], ["normal", "OBSERVATION", 78, 84]]], ["An alarm is raised by the method if the value of the CUSUM exceeds a pre-specified value h.", [["alarm", "OBSERVATION", 3, 8]]], ["The parameter h, measured in standard deviations, is referred to as the standardized decision value for the CUSUM and represents the threshold of the method.", [["the CUSUM", "TEST", 104, 113], ["the method", "TREATMENT", 146, 156], ["standard deviations", "OBSERVATION", 29, 48]]], ["The selection of appropriate values for the above-mentioned parameters (k, h) for a CUSUM procedure takes into account the in-control (average run length) ARL of the in-control process [18, 19, 20] .", [["a CUSUM procedure", "TREATMENT", 82, 99], ["the in-control", "TREATMENT", 119, 133]]], ["The ARL is a measure of the time interval between false alarms, therefore it is analogous to a Type I error.", [["ARL", "CANCER", 4, 7], ["ARL", "OBSERVATION_MODIFIER", 4, 7], ["false alarms", "OBSERVATION", 50, 62]]], ["In order to understand the comparability of (k, h) parameters it should be mentioned that for a fixed k value, increasing the h value would generally result in lower sensitivity and higher specificity results (and vice-versa).", [["a fixed k value", "TEST", 94, 109], ["lower sensitivity", "PROBLEM", 160, 177]]], ["The same applies for k, for a fixed h value [15] .", [["k", "TEST", 21, 22], ["a fixed h value", "TEST", 28, 43]]], ["For the purposes of this study we tested two sets of values: a) (k, h) = (0.5, 5), which is a commonly used set for a CUSUM procedure [18, 19, 20, 21] , and b) (k, h) = (0.75, 1.53).", [["this study", "TEST", 20, 30], ["a) (k, h)", "TEST", 61, 70], ["a CUSUM procedure", "TEST", 116, 133]]], ["For the second set of values, k was selected for the CUSUM to detect shifts of D = 2k = 1.5s, and h was calculated with respect to a specific ARL approximately representing the desired Type I error rate a = 0.10 (as in the simple regression method).", [["ARL", "CANCER", 142, 145], ["k", "TEST", 30, 31], ["the CUSUM", "TEST", 49, 58], ["D", "TEST", 79, 80]]], ["Hence, this ARL was selected to be 45, roughly one tenth of the total 467 observations.", [["ARL", "CANCER", 12, 15], ["this ARL", "TEST", 7, 15]]], ["The h value, given k and ARL, was computed as 1.53.", [["The h value", "TEST", 0, 11], ["k", "TEST", 19, 20], ["ARL", "TEST", 25, 28]]], ["As in the simple regression model described above, we assigned values for m between 4-6 (weeks).Details for the application of the methodsThe objective in this study is to assess the performance of the methods in identifying the onset of RTI outbreaks.", [["RTI", "DISEASE", 238, 241], ["the methods", "TREATMENT", 127, 138], ["this study", "TEST", 155, 165], ["RTI outbreaks", "PROBLEM", 238, 251]]], ["We considered that the onset of an outbreak corresponds to the first aberrant value according to the reference standard classification.", [["an outbreak", "PROBLEM", 32, 43], ["outbreak", "OBSERVATION", 35, 43]]], ["In this regard, we applied the simple regression and CUSUM models for detection of an outbreak at week t, only if the observations for the prior m-week interval were all classified as non-aberrant by the reference standard classification.", [["CUSUM models", "TEST", 53, 65]]], ["This rule we applied satisfies the simple regression and CUSUM assumptions for normally distributed observations and in-control processes, respectively.", [["the simple regression", "PROBLEM", 31, 52], ["CUSUM assumptions", "TEST", 57, 74]]], ["By taking this action, an unavoidable consequence is the reduction of the total amount of runs for the methods.Evaluation of performance of modelsThe alert generating methods of simple regression and CUSUMs were applied on our retrospective time-series data set.", [["the methods", "TREATMENT", 99, 110], ["Evaluation", "TEST", 111, 121], ["simple regression", "PROBLEM", 178, 195], ["reduction", "OBSERVATION_MODIFIER", 57, 66]]], ["Applying each of the models for every week t assessed, we obtained an output as either alert or non-alert.", [["an output", "TEST", 67, 76]]], ["We compared this output to the classification of the same observation as normal or aberration according to the reference standard method.", [["this output", "TEST", 12, 23], ["normal", "OBSERVATION", 73, 79]]], ["We then constructed for each of the models a 262 table listing the true/false positive and true/false negative observations.", [["false positive", "OBSERVATION", 72, 86], ["false negative", "OBSERVATION", 96, 110]]], ["From these tables, we calculated point estimates and confidence intervals (calculated with the Wilson score method for sensitivity, specificity for each model and specific set of model parameters selected [22] .", [["the Wilson score method", "TEST", 91, 114], ["sensitivity", "TEST", 119, 130], ["specificity", "TEST", 132, 143], ["each model", "TEST", 148, 158]]], ["Analyses took place in MATLAB (2010a, The Mathworks Inc., Natick MA, 2010) and R [23] .ResultsThe Figures 1a and 1b , we provide sequence plots for both groups of observations (upper and lower RTIs, respectively), superimposing the reference standard classification, accompanied by the results of the statistical model fitting.ResultsIn Tables 1 and 2 , we present the summary findings for sensitivity, specificity of simple regression and CUSUM models for the detection of upper and lower RTI outbreaks, respectively, with regard to each set of input parameters used, along with the respective 95% confidence intervals.", [["upper", "ORGANISM_SUBDIVISION", 177, 182], ["upper", "ORGANISM_SUBDIVISION", 474, 479], ["sequence plots", "TEST", 129, 143], ["observations (upper and lower RTIs", "TREATMENT", 163, 197], ["sensitivity", "TEST", 390, 401], ["simple regression", "PROBLEM", 418, 435], ["CUSUM models", "TEST", 440, 452], ["the detection", "TEST", 457, 470], ["upper and lower RTI outbreaks", "PROBLEM", 474, 503], ["upper", "ANATOMY_MODIFIER", 177, 182], ["lower RTIs", "ANATOMY", 187, 197], ["upper", "ANATOMY_MODIFIER", 474, 479], ["lower RTI", "ANATOMY", 484, 493]]], ["The total amount of comparisons executed by the models for the calculation of these indices is also shown.ResultsThe performance of the simple regression and CUSUM models under the different set of parameters we selected, generally yielded high values for sensitivity and specificity for both types of RTIs.", [["RTIs", "DISEASE", 302, 306], ["these indices", "TEST", 78, 91], ["the simple regression", "PROBLEM", 132, 153], ["CUSUM models", "TEST", 158, 170], ["sensitivity", "TEST", 256, 267], ["RTIs", "PROBLEM", 302, 306], ["total", "OBSERVATION_MODIFIER", 4, 9], ["amount", "OBSERVATION_MODIFIER", 10, 16], ["RTIs", "OBSERVATION", 302, 306]]], ["The main exception was observed when the CUSUM model was run with the ''typical'' set of parameters for (k, h) of (0.5, 5), which yielded high values for specificity but low values for sensitivity.ResultsSimple regression displayed excellent sensitivity results for both groups of RTIs.", [["RTIs", "DISEASE", 281, 285], ["the CUSUM model", "TEST", 37, 52], ["low values", "PROBLEM", 170, 180], ["sensitivity", "PROBLEM", 185, 196], ["RTIs", "PROBLEM", 281, 285], ["main", "OBSERVATION_MODIFIER", 4, 8], ["RTIs", "OBSERVATION", 281, 285]]], ["As the m-weeks parameter increased, simple regression displayed slightly lower specificity for both groups of RTIs.", [["RTIs", "DISEASE", 110, 114], ["the m-weeks parameter", "TEST", 3, 24], ["simple regression", "PROBLEM", 36, 53], ["RTIs", "PROBLEM", 110, 114], ["slightly", "OBSERVATION_MODIFIER", 64, 72], ["RTIs", "OBSERVATION", 110, 114]]], ["The best results were obtained with the parameter selection for m = 4 weeks.", [["the parameter selection", "TEST", 36, 59]]], ["Simple regression seemed to perform somewhat better for the upper RTIs compared to the lower RTIs.ResultsConcerning the use of CUSUM models, the typical (k, h) = (0.5, 5) set of parameters yielded high values for specificity but low values for sensitivity for both upper and lower RTIs.", [["RTIs", "DISEASE", 66, 70], ["RTIs", "DISEASE", 93, 97], ["RTIs", "DISEASE", 281, 285], ["upper", "ORGANISM_SUBDIVISION", 60, 65], ["upper", "ORGANISM_SUBDIVISION", 265, 270], ["Simple regression", "PROBLEM", 0, 17], ["the upper RTIs", "PROBLEM", 56, 70], ["CUSUM models", "TEST", 127, 139], ["specificity", "TEST", 213, 224], ["low values", "PROBLEM", 229, 239], ["sensitivity", "TEST", 244, 255], ["both upper and lower RTIs", "PROBLEM", 260, 285], ["regression", "OBSERVATION", 7, 17], ["upper", "ANATOMY_MODIFIER", 60, 65], ["RTIs", "OBSERVATION", 66, 70], ["lower", "ANATOMY_MODIFIER", 87, 92], ["RTIs", "OBSERVATION", 93, 97], ["upper", "ANATOMY_MODIFIER", 265, 270], ["lower RTIs", "ANATOMY", 275, 285]]], ["However, theDiscussionThe application of two different models (simple regression and CUSUM models, respectively) for early detection of community outbreaks of upper or lower RTIs using short-term historical data of house-call visits provided favorable results in terms of sensitivity and specificity, compared with a reference standard procedure based on long-term relevant historical data.", [["RTIs", "DISEASE", 174, 178], ["upper", "ORGANISM_SUBDIVISION", 159, 164], ["CUSUM models", "TEST", 85, 97], ["community outbreaks of upper or lower RTIs", "PROBLEM", 136, 178], ["a reference standard procedure", "TREATMENT", 315, 345], ["upper", "ANATOMY_MODIFIER", 159, 164], ["lower RTIs", "ANATOMY", 168, 178]]], ["In particular, a CUSUM model using a specific set of parameters optimized for our dataset seemed to be the best-fit one.DiscussionSuch methods as those we evaluated could be implemented where extensive databases tracking the incidence of infectious syndromes are unavailable or unreliable.", [["infectious syndromes", "PROBLEM", 238, 258], ["infectious", "OBSERVATION", 238, 248]]], ["As exemplified by the recent H1N1 pandemic, epidemics can emerge in areas with a relatively low level of public health surveillance [24] .", [["H1N1 pandemic", "DISEASE", 29, 42], ["the recent H1N1 pandemic", "PROBLEM", 18, 42], ["epidemics", "PROBLEM", 44, 53]]], ["The simple regression and CUSUM models we evaluated in this study appear to perform reasonably well in detecting the onset of an outbreak at week t, with the only prerequisite being the availability of prior relevant data for a non-epidemic period of only 4-6 weeks duration to be used as the comparator.", [["The simple regression", "PROBLEM", 0, 21], ["CUSUM models", "TEST", 26, 38], ["this study", "TEST", 55, 65], ["simple", "OBSERVATION_MODIFIER", 4, 10], ["regression", "OBSERVATION_MODIFIER", 11, 21]]], ["We believe that the comparison of the index week t with a shortest period would lead to non-significant findings; a longer period might also include data from prior outbreaks which would also be inappropriate for the comparison.", [["non-significant findings", "PROBLEM", 88, 112], ["prior outbreaks", "PROBLEM", 159, 174]]], ["Data for house-call visits performed by a network of medical specialists affiliated to a private company, such as SOS Doctors in Athens, Greece, can have several advantages for use for syndromic surveillance purposes [10, 25] .", [["syndromic surveillance purposes", "TEST", 185, 216]]], ["The data we evaluated are ordinarily collected in a real-time manner by the private company for own purposes.", [["The data", "TEST", 0, 8]]], ["House-call visits refer directly to the community, where outbreaks of viral infections first occur.", [["viral infections", "DISEASE", 70, 86], ["viral infections", "PROBLEM", 70, 86]]], ["Visits are done on an emergency basis, when the patient feels mostly in need for a physician, and, supposedly, clinical manifestations are more obvious.", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55]]], ["In contrast, disease surveillance data collected by visits to sentinel providers may selectively refer to patients that can go by themselves or be transferred to the ambulatory office of the providers at a time that this is feasible [25] .DiscussionThe most important bias in the synthesis of the patient population served by SOS Doctors and other relevant private networks is the financial ability of the patients to pay for the visit.", [["patients", "ORGANISM", 106, 114], ["patient", "ORGANISM", 297, 304], ["patients", "ORGANISM", 406, 414], ["patients", "SPECIES", 106, 114], ["patient", "SPECIES", 297, 304], ["patients", "SPECIES", 406, 414], ["disease surveillance data", "TEST", 13, 38]]], ["This could be particularly important during financial crises, as it may limit the representativeness of the sample with regard to the total population.", [["could be particularly", "UNCERTAINTY", 5, 26]]], ["Another issue is the accessibility of the patients to other types of emergency healthcare services, which can be limited for patients with physical or mental disabilities.", [["physical or mental disabilities", "DISEASE", 139, 170], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 125, 133]]], ["Depending on the operational activity of the private network of physicians, the data for house call visits can refer to a large number of patients.", [["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146]]], ["Minor deviations from the epidemic threshold can then be marked by statistical significance, leading to prompt detection of outbreaks and timely effectuation of the appropriate public health measures [26, 27] .", [["Minor deviations", "PROBLEM", 0, 16], ["outbreaks", "PROBLEM", 124, 133], ["deviations", "OBSERVATION", 6, 16]]], ["Although different segments of the population can be affected at a different extent or severity during specific community viral outbreaks, none of the segments is, most commonly, spared [28, 29] .DiscussionOur analysis is subject to many potential limitations.", [["different", "OBSERVATION_MODIFIER", 9, 18], ["segments", "OBSERVATION_MODIFIER", 19, 27], ["different extent", "OBSERVATION_MODIFIER", 67, 83], ["community", "OBSERVATION_MODIFIER", 112, 121], ["viral outbreaks", "OBSERVATION", 122, 137], ["segments", "ANATOMY_MODIFIER", 151, 159]]], ["At the data level, clinical differentiation between upper and lower RTIs is not always evident.", [["RTIs", "DISEASE", 68, 72], ["upper", "ORGANISM_SUBDIVISION", 52, 57], ["clinical differentiation between upper and lower RTIs", "PROBLEM", 19, 72], ["upper", "ANATOMY_MODIFIER", 52, 57], ["lower RTIs", "ANATOMY", 62, 72], ["not always evident", "UNCERTAINTY", 76, 94]]], ["The use of a standardized case-definition for syndromic surveillance could have helped in this regard [30] .", [["syndromic surveillance", "TEST", 46, 68]]], ["We analyzed both upper and lower RTIs, so that our findings would not be affected from bias by potential misclassifications.", [["upper", "ORGANISM_SUBDIVISION", 17, 22], ["both upper and lower RTIs", "PROBLEM", 12, 37], ["upper", "ANATOMY_MODIFIER", 17, 22], ["lower RTIs", "ANATOMY", 27, 37]]], ["Still, the upper RTIs might more clearly be associated with community outbreak of viral illnesses than lower RTIs.", [["RTIs", "DISEASE", 17, 21], ["viral illnesses", "DISEASE", 82, 97], ["RTIs", "DISEASE", 109, 113], ["the upper RTIs", "PROBLEM", 7, 21], ["viral illnesses", "PROBLEM", 82, 97], ["lower RTIs", "PROBLEM", 103, 113], ["upper", "ANATOMY_MODIFIER", 11, 16], ["viral illnesses", "OBSERVATION", 82, 97]]], ["Accordingly, the models we used for short-term recognition of community outbreaks of respiratory tract infection performed better for upper RTIs.", [["respiratory tract", "ANATOMY", 85, 102], ["respiratory tract infection", "DISEASE", 85, 112], ["RTIs", "DISEASE", 140, 144], ["respiratory tract", "ORGANISM_SUBDIVISION", 85, 102], ["upper", "ORGANISM_SUBDIVISION", 134, 139], ["short-term recognition", "TREATMENT", 36, 58], ["respiratory tract infection", "PROBLEM", 85, 112], ["upper RTIs", "PROBLEM", 134, 144], ["respiratory tract", "ANATOMY", 85, 102]]], ["Instead of daily values, we selected to analyze weekly-averaged values for RTIs to minimize the likelihood for high auto-correlation or variability between successive observations.", [["RTIs", "PROBLEM", 75, 79], ["high auto-correlation", "PROBLEM", 111, 132]]], ["We also chose to analyze the proportion of the visits for upper or lower RTIs to the total house call visits, instead of the absolute counts of RTIs, to minimize the effect of various factors, such as seasonal variation in morbidity, meteorological conditions, vacation periods, or strikes in the public healthcare sector, which could influence the demand for private house-call visits [3, 10] .DiscussionAt the statistical modeling level, potential limitations involve the unavoidably arbitrary, to some extent, selection of model parameters.", [["RTIs", "DISEASE", 73, 77], ["RTIs", "DISEASE", 144, 148], ["upper", "ORGANISM_SUBDIVISION", 58, 63], ["RTIs", "TREATMENT", 144, 148], ["seasonal variation in morbidity", "PROBLEM", 201, 232]]], ["Results for the types of statistical analysis we performed have absolute dependence on parameter input.", [["statistical analysis", "TEST", 25, 45], ["absolute dependence", "PROBLEM", 64, 83], ["parameter input", "TREATMENT", 87, 102]]], ["Parameters need to be robustly calibrated in order to achieve a desired balance in the trade-off between sensitivity and specificity, keeping in mind the consequences of false alarms and the benefits of true alarms [20] .", [["specificity", "TEST", 121, 132], ["false alarms", "TEST", 170, 182], ["false alarms", "OBSERVATION", 170, 182]]], ["This concept applies to both the reference standard, and to the alert-generating methods application procedures.", [["methods application procedures", "TREATMENT", 81, 111]]], ["For example, decrease in specificity for the alertgenerating methods we evaluated might have resulted from earlier identification of an outbreak than the reference standard method.DiscussionParticularly for the CUSUM methods, global standard values for (k, h) cannot be determined, as they are dependent to the process' in control average run length, which is in turn dependent on observation distribution.", [["the alertgenerating methods", "TEST", 41, 68], ["an outbreak", "PROBLEM", 133, 144], ["the CUSUM methods", "TEST", 207, 224], ["global standard values", "TEST", 226, 248], ["decrease", "OBSERVATION_MODIFIER", 13, 21]]], ["This could also constitute a shortcoming of the CUSUM methodology compared to the substantially simpler in principle simple regression methodology when executing prospective analysis.", [["the CUSUM methodology", "TEST", 44, 65], ["executing prospective analysis", "TEST", 152, 182]]], ["Determination of the best-fit CUSUM model for a specific data set would require the evaluation of long-term historical data which might not be available.", [["a specific data", "TEST", 46, 61], ["the evaluation", "TEST", 80, 94], ["long-term historical data", "TEST", 98, 123]]], ["We analyzed a large data-set of historical data as the reference standard for characterization of the outbreaks.", [["historical data", "TEST", 32, 47], ["the outbreaks", "PROBLEM", 98, 111], ["large", "OBSERVATION_MODIFIER", 14, 19]]], ["Future studies aiming to prospectively evaluate data from house call visits for the detection of outbreaks of respiratory infections could use data from official sentinel surveillance networks, if available, as the reference standard [25] .", [["respiratory", "ANATOMY", 110, 121], ["respiratory infections", "DISEASE", 110, 132], ["Future studies", "TEST", 0, 14], ["respiratory infections", "PROBLEM", 110, 132], ["respiratory", "ANATOMY", 110, 121], ["infections", "OBSERVATION", 122, 132]]], ["We can only assume the performance of the models used for the detection of outbreaks after the outbreak has begun.", [["outbreaks", "PROBLEM", 75, 84]]], ["A broad review of the contextual application of these methods has been conducted by Unkel et al. [37] .DiscussionIn conclusion, electronic health records for house call visits might serve as an alternative surveillance network for the prediction of respiratory tract outbreaks in the community using short-term data (for the previous 4-6 weeks).", [["respiratory tract", "ANATOMY", 249, 266], ["respiratory tract outbreaks", "DISEASE", 249, 276], ["respiratory tract", "ORGANISM_SUBDIVISION", 249, 266], ["these methods", "TREATMENT", 48, 61], ["respiratory tract outbreaks", "PROBLEM", 249, 276], ["broad", "OBSERVATION_MODIFIER", 2, 7], ["respiratory tract", "ANATOMY", 249, 266]]], ["The determination of the optimal set of parameters may, however, be database-specific, and it could require the evaluation of long historical time-series.", [["the evaluation", "TEST", 108, 122]]], ["Simple regression models could be elected if long-term historical data are lacking.", [["Simple regression models", "PROBLEM", 0, 24]]], ["Additional studies are needed in order to validate the performance of the above models in the prospective detection of the onset of RTI outbreaks on the basis of data for house call visits.", [["RTI", "DISEASE", 132, 135], ["Additional studies", "TEST", 0, 18], ["RTI outbreaks", "PROBLEM", 132, 145]]]], "PMC7415410": [["IntroductionCoronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan in December 2019.", [["COVID-19", "CHEMICAL", 38, 46], ["acute respiratory syndrome coronavirus", "DISEASE", 66, 104], ["severe acute respiratory syndrome coronavirus", "SPECIES", 59, 104], ["SARS-CoV-2", "SPECIES", 108, 118], ["IntroductionCoronavirus Disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 59, 104], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["respiratory syndrome", "OBSERVATION", 72, 92]]], ["The disease rapidly spread throughout the world and was announced as a global pandemic by the World Health Organization.", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11], ["rapidly", "OBSERVATION_MODIFIER", 12, 19], ["spread", "OBSERVATION_MODIFIER", 20, 26]]], ["Italy was among the first and most severely affected countries and by the time we are writing (end of May 2020) 225.549 cases and 30.332 deaths occurred, most of which in the Northern part of the country, with the Lombardy region accounting for more than a third of cases and half deaths (https://www.epicentro.iss.it).IntroductionSince the infection can have a broad range of severity going from an asymptomatic state, to symptoms similar to those of the common cold, to severe forms of interstitial pneumonia that need urgent medical attention, knowledge of risk factors for adverse clinical outcomes would be of great utility [1].", [["interstitial", "ANATOMY", 488, 500], ["deaths", "DISEASE", 137, 143], ["deaths", "DISEASE", 281, 287], ["infection", "DISEASE", 341, 350], ["interstitial pneumonia", "DISEASE", 488, 510], ["the infection", "PROBLEM", 337, 350], ["an asymptomatic state", "PROBLEM", 397, 418], ["symptoms", "PROBLEM", 423, 431], ["interstitial pneumonia", "PROBLEM", 488, 510], ["urgent medical attention", "TREATMENT", 521, 545], ["adverse clinical outcomes", "PROBLEM", 577, 602], ["infection", "OBSERVATION", 341, 350], ["interstitial", "ANATOMY_MODIFIER", 488, 500], ["pneumonia", "OBSERVATION", 501, 510]]], ["It soon became apparent that age and number of comorbidities were crucial to predict the need of intensive care unit (ICU) admission and death [2].IntroductionDiabetes is common among patients who die from COVID-19, with data from Italy showing a prevalence of approximately 30% [3].", [["death", "DISEASE", 137, 142], ["IntroductionDiabetes", "DISEASE", 147, 167], ["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 184, 192], ["comorbidities", "PROBLEM", 47, 60], ["COVID", "TEST", 206, 211]]], ["Moreover, it is well known that patients with diabetes have higher risk of infections because of alterations in the immune response [4].", [["diabetes", "DISEASE", 46, 54], ["infections", "DISEASE", 75, 85], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["diabetes", "PROBLEM", 46, 54], ["infections", "PROBLEM", 75, 85], ["infections", "OBSERVATION", 75, 85]]], ["Nonetheless, it remains controversial whether diabetes could be considered an independent risk factor for greater severity of illness and death, with some studies showing a detrimental effect [5\u20137] and others a neutral influence [8\u201310], also depending on adjustment for confounding variables.", [["diabetes", "DISEASE", 46, 54], ["illness", "DISEASE", 126, 133], ["death", "DISEASE", 138, 143], ["diabetes", "PROBLEM", 46, 54], ["illness", "PROBLEM", 126, 133], ["death", "PROBLEM", 138, 143], ["some studies", "TEST", 150, 162], ["confounding variables", "PROBLEM", 270, 291]]], ["Moreover, the vast majority of the published literature comes from China, and little is known in western countries and Italy in particular [11].IntroductionTherefore, the present study was conceived to obtain more conclusive information on the relationship between a history of diabetes and the risk of in-hospital mortality.Study sample ::: MethodsThis single center retrospective study was conducted at Policlinico di Monza hospital in Monza, a ~ 240-bed community based hospital designated to treat patients with COVID-19, located in the Lombardy region, Italy.", [["diabetes", "DISEASE", 278, 286], ["patients", "ORGANISM", 502, 510], ["patients", "SPECIES", 502, 510], ["the present study", "TEST", 167, 184], ["diabetes", "PROBLEM", 278, 286], ["Methods", "TREATMENT", 342, 349], ["retrospective study", "TEST", 368, 387], ["COVID", "TEST", 516, 521], ["diabetes", "OBSERVATION", 278, 286], ["Lombardy", "ANATOMY", 541, 549], ["region", "ANATOMY_MODIFIER", 550, 556]]], ["We included all patients aged \u2265 18 years who were admitted from 22 February 2020 and experienced a definite outcome (either in-hospital death or discharge) as of 15 May 2020.", [["death", "DISEASE", 136, 141], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["These patients have not been reported before and represent a large spectrum of disease severity, including critically ill patients treated in the ICU.Study sample ::: MethodsCOVID-19 cases were defined according to a positive result on real-time reverse transcriptase-polymerase chain reaction (RT-PCR) of nasopharyngeal or oropharyngeal swab specimens and/or clinically by the presence of typical signs and symptoms, exposure to known affected individuals and radiographic findings consistent with interstitial pneumonia.Study sample ::: MethodsThe investigations were conducted in accordance with the current Declaration of Helsinki.", [["nasopharyngeal", "ANATOMY", 306, 320], ["oropharyngeal swab specimens", "ANATOMY", 324, 352], ["interstitial", "ANATOMY", 499, 511], ["critically ill", "DISEASE", 107, 121], ["interstitial pneumonia", "DISEASE", 499, 521], ["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 122, 130], ["nasopharyngeal", "CANCER", 306, 320], ["oropharyngeal swab specimens", "CANCER", 324, 352], ["reverse transcriptase", "PROTEIN", 246, 267], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 122, 130], ["a large spectrum of disease severity", "PROBLEM", 59, 95], ["MethodsCOVID", "TEST", 167, 179], ["polymerase chain reaction", "PROBLEM", 268, 293], ["RT-PCR", "TEST", 295, 301], ["nasopharyngeal or oropharyngeal swab specimens", "TEST", 306, 352], ["typical signs and symptoms", "PROBLEM", 390, 416], ["known affected individuals", "PROBLEM", 430, 456], ["radiographic findings", "TEST", 461, 482], ["interstitial pneumonia", "PROBLEM", 499, 521], ["Methods", "TREATMENT", 539, 546], ["The investigations", "TEST", 546, 564], ["large", "OBSERVATION_MODIFIER", 61, 66], ["disease", "OBSERVATION", 79, 86], ["nasopharyngeal", "ANATOMY", 306, 320], ["oropharyngeal", "ANATOMY", 324, 337], ["consistent with", "UNCERTAINTY", 483, 498], ["interstitial", "ANATOMY_MODIFIER", 499, 511], ["pneumonia", "OBSERVATION", 512, 521]]], ["The study was approved by the local ethical committee and the requirement for informed consent was waived because of the retrospective design and the ongoing public health emergency.Procedures and definitions ::: MethodsUsing electronical medical records, we reviewed data related to demographic variables (age, gender, and occupational status), previous medical history and comorbidities and prescription medications.", [["The study", "TEST", 0, 9], ["comorbidities", "PROBLEM", 375, 388], ["prescription medications", "TREATMENT", 393, 417]]], ["Date of admission, total hospital length of stay, presenting symptoms (including fever, cough, dyspnea, diarrhea and conjunctivitis), plasma and serum based biomarkers drawn within 48 h of hospital admission or transfer from different hospitals, and radiographic findings at presentation were also reviewed by a team of experienced clinicians.", [["plasma", "ANATOMY", 134, 140], ["serum", "ANATOMY", 145, 150], ["fever", "DISEASE", 81, 86], ["cough", "DISEASE", 88, 93], ["dyspnea", "DISEASE", 95, 102], ["diarrhea", "DISEASE", 104, 112], ["conjunctivitis", "DISEASE", 117, 131], ["plasma", "ORGANISM_SUBSTANCE", 134, 140], ["serum", "ORGANISM_SUBSTANCE", 145, 150], ["presenting symptoms", "PROBLEM", 50, 69], ["fever", "PROBLEM", 81, 86], ["cough", "PROBLEM", 88, 93], ["dyspnea", "PROBLEM", 95, 102], ["diarrhea", "PROBLEM", 104, 112], ["conjunctivitis", "PROBLEM", 117, 131], ["plasma and serum based biomarkers", "TEST", 134, 167], ["radiographic findings", "TEST", 250, 271]]], ["Routine laboratory examinations included a complete blood cell count, liver (aspartate aminotransferase, [AST] and alanine aminotransferase, [ALT]) and renal function testing, lactic dehydrogenase (LDH), creatine kinase and c-reactive protein (CRP).Procedures and definitions ::: MethodsFever was defined as an axillary temperature \u2265 37.5 \u00b0C. Medical comorbidities of interest included diabetes, hypertension, previous cardiovascular disease (CVD), a composite of coronary artery disease, stable angina, stroke and transient ischemic attack, previous or active malignant neoplasia, chronic obstructive pulmonary disease (COPD), asthma, neurological conditions (such as dementia and parkinsonism), chronic kidney disease (CKD) and hematological disorders.Statistical analysis ::: MethodsData are expressed as means \u00b1 standard deviation (SD) for continuous variables or as numbers and percentages for categorical variables.", [["blood cell", "ANATOMY", 52, 62], ["liver", "ANATOMY", 70, 75], ["renal", "ANATOMY", 152, 157], ["cardiovascular", "ANATOMY", 419, 433], ["coronary artery", "ANATOMY", 464, 479], ["malignant neoplasia", "ANATOMY", 561, 580], ["pulmonary", "ANATOMY", 602, 611], ["neurological", "ANATOMY", 636, 648], ["kidney", "ANATOMY", 705, 711], ["hematological", "ANATOMY", 730, 743], ["aspartate", "CHEMICAL", 77, 86], ["alanine", "CHEMICAL", 115, 122], ["creatine", "CHEMICAL", 204, 212], ["diabetes", "DISEASE", 386, 394], ["hypertension", "DISEASE", 396, 408], ["cardiovascular disease", "DISEASE", 419, 441], ["CVD", "DISEASE", 443, 446], ["coronary artery disease", "DISEASE", 464, 487], ["stable angina", "DISEASE", 489, 502], ["stroke", "DISEASE", 504, 510], ["transient ischemic attack", "DISEASE", 515, 540], ["malignant neoplasia", "DISEASE", 561, 580], ["chronic obstructive pulmonary disease", "DISEASE", 582, 619], ["COPD", "DISEASE", 621, 625], ["asthma", "DISEASE", 628, 634], ["neurological conditions", "DISEASE", 636, 659], ["dementia", "DISEASE", 669, 677], ["parkinsonism", "DISEASE", 682, 694], ["chronic kidney disease", "DISEASE", 697, 719], ["CKD", "DISEASE", 721, 724], ["hematological disorders", "DISEASE", 730, 753], ["aspartate", "CHEMICAL", 77, 86], ["alanine", "CHEMICAL", 115, 122], ["creatine", "CHEMICAL", 204, 212], ["blood cell", "CELL", 52, 62], ["liver", "ORGAN", 70, 75], ["aspartate", "SIMPLE_CHEMICAL", 77, 86], ["aminotransferase", "SIMPLE_CHEMICAL", 87, 103], ["AST", "SIMPLE_CHEMICAL", 106, 109], ["alanine", "AMINO_ACID", 115, 122], ["aminotransferase", "SIMPLE_CHEMICAL", 123, 139], ["ALT", "SIMPLE_CHEMICAL", 142, 145], ["renal", "ORGAN", 152, 157], ["lactic dehydrogenase", "GENE_OR_GENE_PRODUCT", 176, 196], ["LDH", "GENE_OR_GENE_PRODUCT", 198, 201], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 204, 219], ["c-reactive protein", "GENE_OR_GENE_PRODUCT", 224, 242], ["CRP", "GENE_OR_GENE_PRODUCT", 244, 247], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 464, 479], ["malignant neoplasia", "CANCER", 561, 580], ["pulmonary", "ORGAN", 602, 611], ["kidney", "ORGAN", 705, 711], ["aspartate aminotransferase", "PROTEIN", 77, 103], ["AST", "PROTEIN", 106, 109], ["alanine aminotransferase", "PROTEIN", 115, 139], ["ALT", "PROTEIN", 142, 145], ["lactic dehydrogenase", "PROTEIN", 176, 196], ["LDH", "PROTEIN", 198, 201], ["creatine kinase", "PROTEIN", 204, 219], ["c-reactive protein", "PROTEIN", 224, 242], ["CRP", "PROTEIN", 244, 247], ["Routine laboratory examinations", "TEST", 0, 31], ["a complete blood cell count", "TEST", 41, 68], ["liver", "TEST", 70, 75], ["aspartate aminotransferase", "TEST", 77, 103], ["AST", "TEST", 106, 109], ["alanine aminotransferase", "TEST", 115, 139], ["ALT", "TEST", 142, 145], ["renal function testing", "TEST", 152, 174], ["lactic dehydrogenase", "TEST", 176, 196], ["LDH", "TEST", 198, 201], ["creatine kinase", "TEST", 204, 219], ["c-reactive protein", "TEST", 224, 242], ["CRP", "TEST", 244, 247], ["an axillary temperature", "TEST", 308, 331], ["diabetes", "PROBLEM", 386, 394], ["hypertension", "PROBLEM", 396, 408], ["previous cardiovascular disease", "PROBLEM", 410, 441], ["CVD", "PROBLEM", 443, 446], ["coronary artery disease", "PROBLEM", 464, 487], ["stable angina", "PROBLEM", 489, 502], ["stroke", "PROBLEM", 504, 510], ["transient ischemic attack", "PROBLEM", 515, 540], ["active malignant neoplasia", "PROBLEM", 554, 580], ["chronic obstructive pulmonary disease", "PROBLEM", 582, 619], ["COPD)", "PROBLEM", 621, 626], ["asthma", "PROBLEM", 628, 634], ["neurological conditions", "PROBLEM", 636, 659], ["dementia", "PROBLEM", 669, 677], ["parkinsonism", "PROBLEM", 682, 694], ["chronic kidney disease", "PROBLEM", 697, 719], ["CKD)", "PROBLEM", 721, 725], ["hematological disorders", "PROBLEM", 730, 753], ["standard deviation (SD)", "PROBLEM", 816, 839], ["continuous variables", "PROBLEM", 844, 864], ["categorical variables", "TEST", 899, 920], ["liver", "ANATOMY", 70, 75], ["renal", "ANATOMY", 152, 157], ["axillary", "ANATOMY", 311, 319], ["diabetes", "OBSERVATION", 386, 394], ["hypertension", "OBSERVATION", 396, 408], ["cardiovascular", "ANATOMY", 419, 433], ["disease", "OBSERVATION", 434, 441], ["coronary artery", "ANATOMY", 464, 479], ["disease", "OBSERVATION", 480, 487], ["stable", "OBSERVATION_MODIFIER", 489, 495], ["angina", "OBSERVATION", 496, 502], ["stroke", "OBSERVATION", 504, 510], ["transient", "OBSERVATION_MODIFIER", 515, 524], ["ischemic attack", "OBSERVATION", 525, 540], ["active", "OBSERVATION_MODIFIER", 554, 560], ["malignant", "OBSERVATION_MODIFIER", 561, 570], ["neoplasia", "OBSERVATION", 571, 580], ["chronic", "OBSERVATION_MODIFIER", 582, 589], ["obstructive", "OBSERVATION_MODIFIER", 590, 601], ["pulmonary", "ANATOMY", 602, 611], ["disease", "OBSERVATION", 612, 619], ["COPD", "OBSERVATION", 621, 625], ["asthma", "OBSERVATION", 628, 634], ["neurological conditions", "OBSERVATION", 636, 659], ["parkinsonism", "OBSERVATION", 682, 694], ["chronic", "OBSERVATION_MODIFIER", 697, 704], ["kidney", "ANATOMY", 705, 711], ["disease", "OBSERVATION", 712, 719], ["CKD", "OBSERVATION", 721, 724], ["hematological disorders", "OBSERVATION", 730, 753]]], ["Analyses were performed using the SPSS software (version 24.0; SPSS, Chicago, IL).", [["Analyses", "TEST", 0, 8], ["the SPSS software", "TEST", 30, 47], ["version", "TEST", 49, 56], ["SPSS", "TEST", 63, 67]]], ["Normal distribution was assessed by the d\u2019Agostino D-normality test [12] and skewed data were properly transformed before the analysis.Statistical analysis ::: MethodsCategorical variables were compared by Pearson chi-square test.", [["the d\u2019Agostino D-normality test", "TEST", 36, 67], ["skewed data", "TEST", 77, 88], ["the analysis", "TEST", 122, 134], ["MethodsCategorical variables", "TEST", 160, 188], ["Pearson chi-square test", "TEST", 206, 229], ["distribution", "OBSERVATION_MODIFIER", 7, 19]]], ["Independent sample T-test or Mann\u2013Whitney test were used to compare groups.", [["Mann\u2013Whitney test", "TEST", 29, 46]]], ["Levene\u2019s test was performed to assess equality of variance.", [["Levene\u2019s test", "TEST", 0, 13]]], ["The percentage of missing values was equal to 9.12% and a listwise deletion approach was used to manage missing data.Statistical analysis ::: MethodsBinomial logistic regression analysis was performed to ascertain the effects of several variables on the likelihood of mortality.", [["a listwise deletion approach", "TREATMENT", 56, 84], ["Binomial logistic regression analysis", "TEST", 149, 186], ["percentage", "OBSERVATION_MODIFIER", 4, 14]]], ["Linearity of the continuous variables was assessed via the Box-Tidwell procedure and multi-collinearity was tested.Statistical analysis ::: MethodsGiven the number of deaths in our population, we included eleven independent variables in our model to avoid overfitting.", [["deaths", "DISEASE", 167, 173], ["the Box-Tidwell procedure", "TREATMENT", 55, 80], ["overfitting", "PROBLEM", 256, 267]]], ["Age and gender were included as males and older individuals were shown to have a higher mortality risk in previous studies [13].", [["individuals", "ORGANISM", 48, 59], ["a higher mortality risk", "PROBLEM", 79, 102], ["previous studies", "TEST", 106, 122]]], ["Beside diabetes, we included other comorbidities that were significantly more common among deceased participants, such as hypertension, CVD, COPD and CKD.", [["diabetes", "DISEASE", 7, 15], ["hypertension", "DISEASE", 122, 134], ["CVD", "DISEASE", 136, 139], ["COPD", "DISEASE", 141, 145], ["CKD", "DISEASE", 150, 153], ["participants", "SPECIES", 100, 112], ["diabetes", "PROBLEM", 7, 15], ["other comorbidities", "PROBLEM", 29, 48], ["hypertension", "PROBLEM", 122, 134], ["CVD", "PROBLEM", 136, 139], ["COPD", "PROBLEM", 141, 145], ["CKD", "PROBLEM", 150, 153], ["diabetes", "OBSERVATION", 7, 15], ["hypertension", "OBSERVATION", 122, 134], ["COPD", "OBSERVATION", 141, 145], ["CKD", "OBSERVATION", 150, 153]]], ["Finally, laboratory exams that were previously reported as predictive of severe disease or distributed unequally between discharged and deceased patients were included (platelet count, LDH, CRP and creatinine).", [["platelet", "ANATOMY", 169, 177], ["creatinine", "CHEMICAL", 198, 208], ["creatinine", "CHEMICAL", 198, 208], ["patients", "ORGANISM", 145, 153], ["platelet", "CELL", 169, 177], ["LDH", "GENE_OR_GENE_PRODUCT", 185, 188], ["CRP", "GENE_OR_GENE_PRODUCT", 190, 193], ["creatinine", "SIMPLE_CHEMICAL", 198, 208], ["LDH", "PROTEIN", 185, 188], ["CRP", "PROTEIN", 190, 193], ["patients", "SPECIES", 145, 153], ["laboratory exams", "TEST", 9, 25], ["severe disease", "PROBLEM", 73, 87], ["platelet count", "TEST", 169, 183], ["LDH", "TEST", 185, 188], ["CRP", "TEST", 190, 193], ["creatinine", "TEST", 198, 208], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["disease", "OBSERVATION", 80, 87]]], ["Despite being associated with both diabetes and mortality, we did not include AST levels in the multivariate models as they were missing in a substantial number of patients.Statistical analysis ::: MethodsDue to missing data, analysis was carried out in a subgroup of 339 subject from the 371 of the entire population.Statistical analysis ::: MethodsThe False Discovery Rate approach was used to control for multiple comparisons and the Benjamini and Hochberg procedure was assessed to minimize possible type I errors using a q value equal to 0.10 [14]; adjusted p values were reported.Statistical analysis ::: MethodsA p value \u2264 0.05 was considered to be significant.Population characteristics ::: ResultsOf the 373 patients included in the study 129 were females (34.6%) and 244 were males (65.4%).", [["diabetes", "DISEASE", 35, 43], ["AST", "SIMPLE_CHEMICAL", 78, 81], ["patients", "ORGANISM", 164, 172], ["patients", "ORGANISM", 717, 725], ["AST", "PROTEIN", 78, 81], ["patients", "SPECIES", 164, 172], ["patients", "SPECIES", 717, 725], ["both diabetes", "PROBLEM", 30, 43], ["AST levels", "TEST", 78, 88], ["analysis", "TEST", 226, 234], ["Statistical analysis", "TEST", 318, 338], ["the Benjamini and Hochberg procedure", "TREATMENT", 433, 469], ["type I errors", "PROBLEM", 504, 517], ["a q value", "TEST", 524, 533], ["MethodsA", "TEST", 611, 619], ["the study", "TEST", 738, 747], ["females", "TEST", 757, 764], ["diabetes", "OBSERVATION", 35, 43]]], ["Mean age was 72 \u00b1 14 years (range 17\u201398) and only 51 individuals (13.7%) were younger than 55.", [["Mean age", "TEST", 0, 8], ["individuals", "TEST", 53, 64]]], ["319 patients (85.5%) had a positive RT-PCR result and the remaining 54 (14.5%) tested negative and were diagnosed clinically.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["a positive RT-PCR result", "PROBLEM", 25, 49]]], ["Apart from being significantly older than confirmed cases (76 vs 71 years, p = 0.12), patients with clinically diagnosed COVID-19 exhibited similar clinical features and comorbidities.Population characteristics ::: ResultsAs shown in Table 1, most patients had comorbidities, the most common being hypertension (64.8%), followed by CVD (37.7%) and 69 patients had diabetes (prevalence of 18.5%).", [["hypertension", "DISEASE", 298, 310], ["CVD", "DISEASE", 332, 335], ["diabetes", "DISEASE", 364, 372], ["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 248, 256], ["patients", "ORGANISM", 351, 359], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 248, 256], ["patients", "SPECIES", 351, 359], ["COVID", "TEST", 121, 126], ["comorbidities", "PROBLEM", 170, 183], ["comorbidities", "PROBLEM", 261, 274], ["hypertension", "PROBLEM", 298, 310], ["CVD", "TEST", 332, 335], ["diabetes", "PROBLEM", 364, 372], ["hypertension", "OBSERVATION", 298, 310]]], ["The most common presenting symptom was fever (82.6%), followed by dyspnea (71.3%) and cough (39.1%).", [["fever", "DISEASE", 39, 44], ["dyspnea", "DISEASE", 66, 73], ["cough", "DISEASE", 86, 91], ["fever", "PROBLEM", 39, 44], ["dyspnea", "PROBLEM", 66, 73], ["cough", "PROBLEM", 86, 91]]], ["Non-respiratory symptoms and signs, such as diarrhea and conjunctivitis were much less commonly reported.", [["diarrhea", "DISEASE", 44, 52], ["conjunctivitis", "DISEASE", 57, 71], ["Non-respiratory symptoms", "PROBLEM", 0, 24], ["signs", "PROBLEM", 29, 34], ["diarrhea", "PROBLEM", 44, 52], ["conjunctivitis", "PROBLEM", 57, 71], ["conjunctivitis", "OBSERVATION", 57, 71]]], ["58 patients were admitted to the ICU, of which 14 (24.1%) were transferred from other hospitals on mechanical ventilation.Comparison between deceased and discharged patients ::: ResultsIn total 142 patients (38.1%) died.", [["patients", "ORGANISM", 3, 11], ["patients", "ORGANISM", 165, 173], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 165, 173], ["patients", "SPECIES", 198, 206], ["mechanical ventilation", "TREATMENT", 99, 121], ["mechanical ventilation", "OBSERVATION", 99, 121]]], ["As expected, patients who experienced in-hospital death were older (78 vs 68 years, p < 0.001) and had a higher prevalence of most comorbidities including CVD (46.4% vs 32.5%, p = 0.007) and hypertension (78.1 vs 56.8%, p < 0.001), whereas only a trend was found for diabetes (23.2 vs 15.6%, p = 0.064) and no significant differences were found in gender distribution.", [["death", "DISEASE", 50, 55], ["CVD", "DISEASE", 155, 158], ["hypertension", "DISEASE", 191, 203], ["diabetes", "DISEASE", 267, 275], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["most comorbidities", "PROBLEM", 126, 144], ["CVD", "TEST", 155, 158], ["p", "TEST", 176, 177], ["hypertension", "PROBLEM", 191, 203], ["diabetes", "PROBLEM", 267, 275], ["p", "TEST", 292, 293], ["significant differences", "PROBLEM", 310, 333], ["hypertension", "OBSERVATION", 191, 203]]], ["Cough was a more common presenting symptom among discharged patients (45.9% vs 28.2%, p = 0.001), whereas dyspnea was more frequently encountered in those who died (85.9% vs 62.3%, p < 0.001).Comparison between deceased and discharged patients ::: ResultsDeceased patients also exhibited less favorable laboratory features at the time of hospital admission, including lower lymphocyte (0.91 vs 1.13 \u00d7 109/l, p < 0.001) and platelet count (196 vs 242 \u00d7 109/l, p < 0.001) and higher CRP (141 vs 79 mg/l, p < 0.001) and LDH (822 vs 527 U/l) values (Fig. 1).Comparison between patients with and without diabetes ::: ResultsFeatures of the entire population according to diabetes status are shown in Table 2.", [["lymphocyte", "ANATOMY", 374, 384], ["platelet", "ANATOMY", 423, 431], ["Cough", "DISEASE", 0, 5], ["dyspnea", "DISEASE", 106, 113], ["diabetes", "DISEASE", 599, 607], ["diabetes", "DISEASE", 666, 674], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 235, 243], ["patients", "ORGANISM", 264, 272], ["lymphocyte", "CELL", 374, 384], ["platelet", "CELL", 423, 431], ["CRP", "GENE_OR_GENE_PRODUCT", 481, 484], ["LDH", "GENE_OR_GENE_PRODUCT", 517, 520], ["patients", "ORGANISM", 573, 581], ["CRP", "PROTEIN", 481, 484], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 235, 243], ["patients", "SPECIES", 264, 272], ["patients", "SPECIES", 573, 581], ["Cough", "PROBLEM", 0, 5], ["p", "TEST", 86, 87], ["dyspnea", "PROBLEM", 106, 113], ["lower lymphocyte", "TEST", 368, 384], ["p", "TEST", 408, 409], ["platelet count", "TEST", 423, 437], ["vs", "TEST", 443, 445], ["l", "TEST", 456, 457], ["p", "TEST", 459, 460], ["CRP", "TEST", 481, 484], ["p", "TEST", 502, 503], ["LDH", "TEST", 517, 520], ["U/l) values", "TEST", 533, 544], ["Fig", "TEST", 546, 549], ["diabetes", "PROBLEM", 599, 607], ["diabetes status", "PROBLEM", 666, 681], ["less", "OBSERVATION_MODIFIER", 288, 292], ["favorable", "OBSERVATION_MODIFIER", 293, 302], ["lower lymphocyte", "ANATOMY", 368, 384]]], ["No significant differences were found between patients with and without diabetes with regards to sex, age (74 vs 71 years, p = 0.518) and frequency of symptoms at hospital admission.Comparison between patients with and without diabetes ::: ResultsAs expected both hypertension and CKD were more common among patients with diabetes, but no differences were found in the prevalence of COPD, cancer and CVD.", [["cancer", "ANATOMY", 389, 395], ["diabetes", "DISEASE", 72, 80], ["diabetes", "DISEASE", 227, 235], ["hypertension", "DISEASE", 264, 276], ["CKD", "DISEASE", 281, 284], ["diabetes", "DISEASE", 322, 330], ["COPD", "DISEASE", 383, 387], ["cancer", "DISEASE", 389, 395], ["CVD", "DISEASE", 400, 403], ["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 201, 209], ["patients", "ORGANISM", 308, 316], ["cancer", "CANCER", 389, 395], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 201, 209], ["patients", "SPECIES", 308, 316], ["diabetes", "PROBLEM", 72, 80], ["symptoms", "PROBLEM", 151, 159], ["diabetes", "PROBLEM", 227, 235], ["hypertension", "PROBLEM", 264, 276], ["CKD", "PROBLEM", 281, 284], ["diabetes", "PROBLEM", 322, 330], ["COPD", "PROBLEM", 383, 387], ["cancer", "PROBLEM", 389, 395], ["CVD", "PROBLEM", 400, 403], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["both", "OBSERVATION_MODIFIER", 259, 263], ["hypertension", "OBSERVATION", 264, 276], ["CKD", "OBSERVATION", 281, 284], ["diabetes", "OBSERVATION", 322, 330], ["COPD", "OBSERVATION", 383, 387], ["cancer", "OBSERVATION", 389, 395]]], ["Most laboratory features were not different between groups, except for lower AST, ALT and hemoglobin values and a trend towards a higher creatinine in patients with diabetes.Comparison between patients with and without diabetes ::: ResultsWe found a significant difference in length of stay (LOS) between discharged and deceased patients (16.1 \u00b1 9.7 vs 10.7 \u00b1 11.0 days respectively, p < 0.001).", [["creatinine", "CHEMICAL", 137, 147], ["diabetes", "DISEASE", 165, 173], ["diabetes", "DISEASE", 219, 227], ["creatinine", "CHEMICAL", 137, 147], ["AST", "SIMPLE_CHEMICAL", 77, 80], ["ALT", "SIMPLE_CHEMICAL", 82, 85], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 90, 100], ["creatinine", "SIMPLE_CHEMICAL", 137, 147], ["patients", "ORGANISM", 151, 159], ["patients", "ORGANISM", 193, 201], ["patients", "ORGANISM", 329, 337], ["AST", "PROTEIN", 77, 80], ["ALT", "PROTEIN", 82, 85], ["hemoglobin", "PROTEIN", 90, 100], ["patients", "SPECIES", 151, 159], ["patients", "SPECIES", 193, 201], ["patients", "SPECIES", 329, 337], ["lower AST", "TEST", 71, 80], ["ALT", "TEST", 82, 85], ["hemoglobin values", "TEST", 90, 107], ["a higher creatinine", "PROBLEM", 128, 147], ["diabetes", "PROBLEM", 165, 173], ["diabetes", "PROBLEM", 219, 227], ["vs", "TEST", 350, 352], ["significant", "OBSERVATION_MODIFIER", 250, 261], ["difference", "OBSERVATION_MODIFIER", 262, 272], ["length", "OBSERVATION_MODIFIER", 276, 282]]], ["However no significant difference in LOS was found between non-diabetic and diabetic patients (14.3 \u00b1 10.8 vs 12.8 \u00b1 9.2 days respectively, p = 0.397) even when the analysis was conducted in discharged and deceased patients separately (p = 0.934 and p = 0.520, respectively).Comparison between patients with and without diabetes ::: ResultsAs far as antidiabetic treatment regimen was concerned 40.6% of patients with diabetes were on insulin, 43.5% on oral antidiabetic drugs and 15.9% were on non-pharmacological treatment.", [["oral", "ANATOMY", 453, 457], ["non-diabetic", "DISEASE", 59, 71], ["diabetic", "DISEASE", 76, 84], ["diabetes", "DISEASE", 320, 328], ["diabetes", "DISEASE", 418, 426], ["patients", "ORGANISM", 85, 93], ["patients", "ORGANISM", 215, 223], ["patients", "ORGANISM", 294, 302], ["patients", "ORGANISM", 404, 412], ["insulin", "GENE_OR_GENE_PRODUCT", 435, 442], ["oral", "ORGANISM_SUBDIVISION", 453, 457], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 215, 223], ["patients", "SPECIES", 294, 302], ["patients", "SPECIES", 404, 412], ["significant difference in LOS", "PROBLEM", 11, 40], ["vs", "TEST", 107, 109], ["the analysis", "TEST", 161, 173], ["diabetes", "PROBLEM", 320, 328], ["ResultsAs", "TREATMENT", 333, 342], ["antidiabetic treatment regimen", "TREATMENT", 350, 380], ["diabetes", "PROBLEM", 418, 426], ["insulin", "TREATMENT", 435, 442], ["oral antidiabetic drugs", "TREATMENT", 453, 476], ["non-pharmacological treatment", "TREATMENT", 495, 524], ["no", "UNCERTAINTY", 8, 10], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["difference", "OBSERVATION_MODIFIER", 23, 33], ["diabetic", "OBSERVATION_MODIFIER", 76, 84]]], ["Finally, steroid therapy was not used differently in patients with and without diabetes (11.8% and 13.0% respectively, p = 0.782).Comparison between patients with and without diabetes ::: ResultsIn the multivariable logistic regression model (Table 3) older age (Relative Risk [RR] 1.06 [95% confidence interval (CI) 1.04\u20131.09] per 1 year increase, p < 0.001), COPD (RR 1.82 [95% CI 1.13\u20132.35]), diabetes (RR 1.56 [95% CI 1.06\u20132.02]), higher levels of CRP (RR 1.70 [95% CI 1.36\u20132.07] per standard deviation increase, p < 0.001) and higher concentrations of LDH (RR 2.14 [95% CI 1.65\u20132.68] per standard deviation increase, p < 0.001) were independently associated with in-hospital mortality, whereas sex, CKD, CVD and hypertension were not.", [["steroid", "CHEMICAL", 9, 16], ["diabetes", "DISEASE", 79, 87], ["diabetes", "DISEASE", 175, 183], ["COPD", "DISEASE", 361, 365], ["diabetes", "DISEASE", 396, 404], ["CKD", "DISEASE", 704, 707], ["CVD", "DISEASE", 709, 712], ["hypertension", "DISEASE", 717, 729], ["steroid", "CHEMICAL", 9, 16], ["steroid", "SIMPLE_CHEMICAL", 9, 16], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 149, 157], ["CRP", "GENE_OR_GENE_PRODUCT", 452, 455], ["LDH", "GENE_OR_GENE_PRODUCT", 557, 560], ["CRP", "PROTEIN", 452, 455], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 149, 157], ["steroid therapy", "TREATMENT", 9, 24], ["diabetes", "PROBLEM", 79, 87], ["diabetes", "PROBLEM", 175, 183], ["RR", "TEST", 278, 280], ["CI", "TEST", 313, 315], ["COPD", "PROBLEM", 361, 365], ["RR", "TEST", 367, 369], ["CI", "TEST", 380, 382], ["diabetes", "PROBLEM", 396, 404], ["RR", "TEST", 406, 408], ["CI", "TEST", 419, 421], ["CRP", "TEST", 452, 455], ["RR", "TEST", 457, 459], ["CI", "TEST", 470, 472], ["p", "TEST", 517, 518], ["higher concentrations of LDH", "PROBLEM", 532, 560], ["RR", "TEST", 562, 564], ["CI", "TEST", 575, 577], ["CKD", "PROBLEM", 704, 707], ["CVD", "PROBLEM", 709, 712], ["hypertension", "PROBLEM", 717, 729], ["COPD", "OBSERVATION", 361, 365], ["LDH", "ANATOMY", 557, 560], ["CKD", "OBSERVATION", 704, 707], ["hypertension", "OBSERVATION", 717, 729]]], ["Mortality rate in patients included in the multivariable model was not different from overall mortality (36.2% vs 38%, p = 0.22).Comparison between patients with and without diabetes ::: ResultsFinally, in a model considering only demographic variables and pre-existing comorbidities, increasing age and male sex were significantly associated with higher mortality (Table 4).DiscussionIn the present study we show that among patients hospitalized for COVID-19 in a single center in Northern Italy, a history of diabetes was associated with an increased mortality risk, which was independent from several confounding factors and comorbidities.DiscussionAn association between diabetes, glycemic control and COVID-19 outcomes has been previously suggested in several studies, mostly coming from China [15, 16].", [["diabetes", "DISEASE", 174, 182], ["diabetes", "DISEASE", 511, 519], ["diabetes", "DISEASE", 675, 683], ["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 148, 156], ["patients", "ORGANISM", 425, 433], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 148, 156], ["patients", "SPECIES", 425, 433], ["Mortality rate", "TEST", 0, 14], ["p", "TEST", 119, 120], ["diabetes", "PROBLEM", 174, 182], ["pre-existing comorbidities", "PROBLEM", 257, 283], ["diabetes", "PROBLEM", 511, 519], ["an increased mortality risk", "PROBLEM", 540, 567], ["comorbidities", "PROBLEM", 628, 641], ["diabetes", "PROBLEM", 675, 683], ["glycemic control", "TREATMENT", 685, 701], ["COVID", "TEST", 706, 711], ["diabetes", "OBSERVATION", 511, 519], ["increased", "OBSERVATION_MODIFIER", 543, 552], ["mortality", "OBSERVATION", 553, 562]]], ["It is important to note, however, that clinical features of patients reported in previous studies were different from ours on several aspects and that adjustment for confounding variables was heterogeneous [8, 17].", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["previous studies", "TEST", 81, 97], ["confounding variables", "PROBLEM", 166, 187], ["heterogeneous", "OBSERVATION_MODIFIER", 192, 205]]], ["As a consequence, most comorbidities were also more common, including hypertension, diabetes and CVD.", [["hypertension", "DISEASE", 70, 82], ["diabetes", "DISEASE", 84, 92], ["CVD", "DISEASE", 97, 100], ["hypertension", "PROBLEM", 70, 82], ["diabetes", "PROBLEM", 84, 92], ["CVD", "PROBLEM", 97, 100], ["hypertension", "OBSERVATION", 70, 82], ["diabetes", "OBSERVATION", 84, 92]]], ["Given the high burden of comorbid conditions in our population we made an effort to control for factors that were more likely to influence prognosis and still identified diabetes as a factor that could moderately increase the risk of in-hospital mortality.DiscussionIt should be noted that our study was performed in a hospital setting including patients managed in the ICU and therefore represents the severe spectrum of COVID-19 affecting frail patients.", [["diabetes", "DISEASE", 170, 178], ["patients", "ORGANISM", 346, 354], ["patients", "ORGANISM", 447, 455], ["patients", "SPECIES", 346, 354], ["patients", "SPECIES", 447, 455], ["comorbid conditions", "PROBLEM", 25, 44], ["diabetes", "PROBLEM", 170, 178], ["our study", "TEST", 290, 299], ["COVID", "TEST", 422, 427], ["high", "OBSERVATION_MODIFIER", 10, 14], ["burden", "OBSERVATION_MODIFIER", 15, 21], ["diabetes", "OBSERVATION", 170, 178]]], ["As a result, while the mean age of our population was significantly higher when compared to Italian data from the Istituto Superiore di Sanit\u00e0 on all infected patients (62 years), the features of deceased patients were similar (median age of 80 years and a prevalence of diabetes of ~ 30%).DiscussionSeveral explanations of the association between diabetes and worse clinical outcome can be proposed [18].", [["diabetes", "DISEASE", 271, 279], ["diabetes", "DISEASE", 348, 356], ["patients", "ORGANISM", 159, 167], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 159, 167], ["patients", "SPECIES", 205, 213], ["diabetes", "PROBLEM", 271, 279], ["diabetes", "PROBLEM", 348, 356]]], ["In general, patients with diabetes are more susceptible to a wide range of infections because of alterations in neutrophil chemotaxis, cytokine production and impaired T-cell responses as a consequence of hyperglycemia [19\u201321].", [["neutrophil", "ANATOMY", 112, 122], ["T-cell", "ANATOMY", 168, 174], ["diabetes", "DISEASE", 26, 34], ["infections", "DISEASE", 75, 85], ["hyperglycemia", "DISEASE", 205, 218], ["patients", "ORGANISM", 12, 20], ["neutrophil", "CELL", 112, 122], ["T-cell", "CELL", 168, 174], ["cytokine", "PROTEIN", 135, 143], ["patients", "SPECIES", 12, 20], ["diabetes", "PROBLEM", 26, 34], ["infections", "PROBLEM", 75, 85], ["neutrophil chemotaxis", "PROBLEM", 112, 133], ["cytokine production", "PROBLEM", 135, 154], ["impaired T-cell responses", "PROBLEM", 159, 184], ["hyperglycemia", "PROBLEM", 205, 218], ["infections", "OBSERVATION", 75, 85], ["neutrophil chemotaxis", "OBSERVATION", 112, 133]]], ["With this regard a recent non peer-reviewed study clearly showed that diabetic patients experienced a delayed clearance of SARS-CoV-2 [22].DiscussionA possible role of antidiabetic therapy cannot be excluded and special interest has been devoted to dipeptidyl-peptidase 4 (DPP4) inhibitors, as DPP4 was one of the receptors involved in the infection from a related coronavirus (Middle East Respiratory Syndrome\u2014Coronavirus).", [["diabetic", "DISEASE", 70, 78], ["SARS", "DISEASE", 123, 127], ["infection", "DISEASE", 340, 349], ["coronavirus", "DISEASE", 365, 376], ["Middle East Respiratory Syndrome\u2014Coronavirus", "DISEASE", 378, 422], ["patients", "ORGANISM", 79, 87], ["dipeptidyl-peptidase 4", "GENE_OR_GENE_PRODUCT", 249, 271], ["DPP4", "GENE_OR_GENE_PRODUCT", 273, 277], ["DPP4", "GENE_OR_GENE_PRODUCT", 294, 298], ["coronavirus", "ORGANISM", 365, 376], ["Middle East Respiratory Syndrome\u2014Coronavirus", "ORGANISM", 378, 422], ["dipeptidyl-peptidase 4", "PROTEIN", 249, 271], ["DPP4", "PROTEIN", 273, 277], ["DPP4", "PROTEIN", 294, 298], ["patients", "SPECIES", 79, 87], ["Middle East Respiratory Syndrome\u2014Coronavirus", "SPECIES", 378, 422], ["reviewed study", "TEST", 35, 49], ["a delayed clearance of SARS", "PROBLEM", 100, 127], ["CoV", "TEST", 128, 131], ["antidiabetic therapy", "TREATMENT", 168, 188], ["dipeptidyl-peptidase 4 (DPP4) inhibitors", "TREATMENT", 249, 289], ["DPP4", "TREATMENT", 294, 298], ["the infection", "PROBLEM", 336, 349], ["a related coronavirus", "PROBLEM", 355, 376], ["Middle East Respiratory Syndrome", "PROBLEM", 378, 410], ["Coronavirus", "PROBLEM", 411, 422], ["infection", "OBSERVATION", 340, 349], ["coronavirus", "OBSERVATION", 365, 376], ["Middle", "ANATOMY_MODIFIER", 378, 384], ["Respiratory Syndrome", "OBSERVATION", 390, 410]]], ["To date, evidence of a possible role of this class of drugs on clinical outcomes is limited to our knowledge to a small study showing a neutral effect [23].", [["a small study", "TEST", 112, 125], ["a neutral effect", "PROBLEM", 134, 150]]], ["On the same lines sodium-glucose transporter 2 (SGLT2) inhibitors may exert a positive effect in these patients by raising hematocrit, reducing intracellular sodium and calcium and reduce inflammation [24].", [["intracellular", "ANATOMY", 144, 157], ["sodium", "CHEMICAL", 18, 24], ["glucose", "CHEMICAL", 25, 32], ["sodium", "CHEMICAL", 158, 164], ["calcium", "CHEMICAL", 169, 176], ["inflammation", "DISEASE", 188, 200], ["sodium", "CHEMICAL", 18, 24], ["glucose", "CHEMICAL", 25, 32], ["sodium", "CHEMICAL", 158, 164], ["calcium", "CHEMICAL", 169, 176], ["sodium-glucose transporter 2", "GENE_OR_GENE_PRODUCT", 18, 46], ["SGLT2", "GENE_OR_GENE_PRODUCT", 48, 53], ["patients", "ORGANISM", 103, 111], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 144, 157], ["sodium", "SIMPLE_CHEMICAL", 158, 164], ["calcium", "SIMPLE_CHEMICAL", 169, 176], ["SGLT2", "PROTEIN", 48, 53], ["patients", "SPECIES", 103, 111], ["the same lines sodium", "TREATMENT", 3, 24], ["glucose transporter", "TREATMENT", 25, 44], ["SGLT2) inhibitors", "TREATMENT", 48, 65], ["a positive effect", "PROBLEM", 76, 93], ["hematocrit", "TEST", 123, 133], ["intracellular sodium", "TEST", 144, 164], ["calcium", "TEST", 169, 176], ["reduce inflammation", "PROBLEM", 181, 200]]], ["A recent study, however, did not show any benefits in terms of length of hospital stay in Italian patients with COVID-19 [25].", [["COVID-19", "CHEMICAL", 112, 120], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["A recent study", "TEST", 0, 14], ["COVID", "TEST", 112, 117]]], ["Unfortunately, the number of patients with diabetes in our cohort was not large enough to evaluate a possible contribution of specific anti-diabetic drugs.DiscussionFinally, patients with diabetes often have comorbid hypertension, heart failure or proteinuria and are frequently treated with blockers of the renin\u2013angiotensin\u2013aldosterone system.", [["heart", "ANATOMY", 231, 236], ["diabetes", "DISEASE", 43, 51], ["diabetes", "DISEASE", 188, 196], ["hypertension", "DISEASE", 217, 229], ["heart failure", "DISEASE", 231, 244], ["proteinuria", "DISEASE", 248, 259], ["renin\u2013angiotensin\u2013aldosterone", "CHEMICAL", 308, 337], ["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 174, 182], ["heart", "ORGAN", 231, 236], ["renin\u2013angiotensin\u2013aldosterone", "GENE_OR_GENE_PRODUCT", 308, 337], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 174, 182], ["diabetes", "PROBLEM", 43, 51], ["specific anti-diabetic drugs", "TREATMENT", 126, 154], ["diabetes", "PROBLEM", 188, 196], ["comorbid hypertension", "PROBLEM", 208, 229], ["heart failure", "PROBLEM", 231, 244], ["proteinuria", "PROBLEM", 248, 259], ["blockers", "TREATMENT", 292, 300], ["the renin\u2013angiotensin\u2013aldosterone system", "TREATMENT", 304, 344], ["diabetes", "OBSERVATION", 43, 51], ["heart", "ANATOMY", 231, 236], ["failure", "OBSERVATION", 237, 244], ["proteinuria", "OBSERVATION", 248, 259]]], ["Since angiotensin converting enzyme 2 participates in SARS-CoV-2 cell entry process, it was hypothesized that these drugs could increase the risk of infection or worsen the prognosis related to COVID-19.", [["cell", "ANATOMY", 65, 69], ["angiotensin", "CHEMICAL", 6, 17], ["infection", "DISEASE", 149, 158], ["COVID-19", "CHEMICAL", 194, 202], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 6, 37], ["CoV-2 cell", "CELL", 59, 69], ["angiotensin converting enzyme 2", "PROTEIN", 6, 37], ["angiotensin converting enzyme", "TEST", 6, 35], ["SARS", "PROBLEM", 54, 58], ["CoV", "PROBLEM", 59, 62], ["these drugs", "TREATMENT", 110, 121], ["infection", "PROBLEM", 149, 158], ["COVID", "TEST", 194, 199], ["cell", "OBSERVATION", 65, 69], ["entry process", "OBSERVATION", 70, 83], ["infection", "OBSERVATION", 149, 158]]], ["A recent study from the Lombardy region, however, disproved this theory [26].DiscussionSome previous studies suggested that a history of hypertension and CVD had a detrimental effect on COVID-19 severity and death.", [["hypertension", "DISEASE", 137, 149], ["CVD", "DISEASE", 154, 157], ["death", "DISEASE", 208, 213], ["A recent study", "TEST", 0, 14], ["Some previous studies", "TEST", 87, 108], ["hypertension", "PROBLEM", 137, 149], ["CVD", "PROBLEM", 154, 157], ["COVID", "TEST", 186, 191], ["death", "PROBLEM", 208, 213], ["hypertension", "OBSERVATION", 137, 149]]], ["We believe that older age and a more complex set of comorbidities in our patients compared with previous studies may modulate the effect of these conditions on survival.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["previous studies", "TEST", 96, 112], ["survival", "TREATMENT", 160, 168]]], ["Our data align, on the other hand, with recent results obtained from a multicenter Italian study investigating this issue, which showed that diabetes, but not hypertension or CAD were associated with death [27].DiscussionThe present study has several limitations that need to be addressed.", [["diabetes", "DISEASE", 141, 149], ["hypertension", "DISEASE", 159, 171], ["CAD", "DISEASE", 175, 178], ["death", "DISEASE", 200, 205], ["a multicenter Italian study", "TEST", 69, 96], ["diabetes", "PROBLEM", 141, 149], ["hypertension", "PROBLEM", 159, 171], ["CAD", "PROBLEM", 175, 178], ["death", "PROBLEM", 200, 205], ["The present study", "TEST", 221, 238], ["diabetes", "OBSERVATION", 141, 149]]], ["First, the lack of data on anthropometric parameters in most patients did not allow us to calculate body mass index and to control for the impact of obesity on the primary outcome.", [["body", "ANATOMY", 100, 104], ["obesity", "DISEASE", 149, 156], ["patients", "ORGANISM", 61, 69], ["body", "ORGANISM_SUBDIVISION", 100, 104], ["patients", "SPECIES", 61, 69], ["anthropometric parameters", "TEST", 27, 52], ["body mass index", "TEST", 100, 115], ["obesity", "PROBLEM", 149, 156], ["mass", "OBSERVATION", 105, 109], ["obesity", "OBSERVATION", 149, 156]]], ["Second, we did not have data on glycemic control for most subjects and cannot infer whether any difference in clinical outcomes existed between controlled and uncontrolled diabetes.", [["diabetes", "DISEASE", 172, 180], ["glycemic control", "TREATMENT", 32, 48], ["uncontrolled diabetes", "PROBLEM", 159, 180], ["uncontrolled", "OBSERVATION_MODIFIER", 159, 171], ["diabetes", "OBSERVATION", 172, 180]]], ["Third, given that it was performed in the hospital setting and included mostly elderly patients, our results cannot be extended to all individuals with COVID-19.", [["COVID-19", "CHEMICAL", 152, 160], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["COVID", "TEST", 152, 157]]], ["Finally, we were not able to collect data on the fraction of inspired oxygen patients were exposed to, and therefore could not interpret the oxygen saturation at admission, which was associated with progression to death in elderly patients in a recent study [28].DiscussionIn conclusion, among patients hospitalized with COVID-19 in a single center in northern Italy, risk of in-hospital death was higher in patients with diabetes compared to non-diabetic individuals.", [["oxygen", "CHEMICAL", 70, 76], ["oxygen", "CHEMICAL", 141, 147], ["death", "DISEASE", 214, 219], ["death", "DISEASE", 388, 393], ["diabetes", "DISEASE", 422, 430], ["non-diabetic", "DISEASE", 443, 455], ["oxygen", "CHEMICAL", 70, 76], ["oxygen", "CHEMICAL", 141, 147], ["oxygen", "SIMPLE_CHEMICAL", 70, 76], ["patients", "ORGANISM", 77, 85], ["oxygen", "SIMPLE_CHEMICAL", 141, 147], ["patients", "ORGANISM", 231, 239], ["patients", "ORGANISM", 294, 302], ["patients", "ORGANISM", 408, 416], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 231, 239], ["patients", "SPECIES", 294, 302], ["patients", "SPECIES", 408, 416], ["inspired oxygen", "TREATMENT", 61, 76], ["the oxygen saturation", "TEST", 137, 158], ["a recent study", "TEST", 243, 257], ["diabetes", "PROBLEM", 422, 430], ["non-diabetic individuals", "PROBLEM", 443, 467]]], ["Predictors of the primary outcome were increasing age, COPD and higher LDH and CRP values.", [["COPD", "DISEASE", 55, 59], ["LDH", "GENE_OR_GENE_PRODUCT", 71, 74], ["CRP", "GENE_OR_GENE_PRODUCT", 79, 82], ["LDH", "PROTEIN", 71, 74], ["CRP", "PROTEIN", 79, 82], ["COPD", "PROBLEM", 55, 59], ["higher LDH", "TEST", 64, 74], ["CRP values", "TEST", 79, 89], ["COPD", "OBSERVATION", 55, 59]]], ["More intensive surveillance of patients with these conditions may be warranted.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]]], "e3685b5952266dbdc2ad923ea3a7f5383e195c42": [["J o u r n a l P r e -p r o o fIn this very particular moment through which we are living, we read with great interest the text by Tuech et al. on surgical practice during the Covid-19 epidemic (1) .", [["surgical practice", "TREATMENT", 146, 163], ["the Covid", "TEST", 171, 180]]], ["We salute the high quality of this work and the effort it represents in this particularly difficult period.J o u r n a l P r e -p r o o fHowever, we would like to highlight a few technical points.", [["high quality", "OBSERVATION_MODIFIER", 14, 26]]], ["Precautions to protect personnel from potentially contaminated surgical aerosols deserve to be detailed.", [["Precautions", "TREATMENT", 0, 11], ["contaminated surgical aerosols", "PROBLEM", 50, 80]]], ["First of all, during an active epidemic, given the large number of healthy carriers (2), it must be emphasized that protective measures must be used in the care of all patients.", [["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["protective measures", "TREATMENT", 116, 135], ["active", "OBSERVATION_MODIFIER", 24, 30], ["epidemic", "OBSERVATION", 31, 39], ["large", "OBSERVATION_MODIFIER", 51, 56]]], ["Wearing of glasses for eye protection should be made mandatory for the entire surgical team in all rooms where laparoscopy is in progress.", [["eye", "ANATOMY", 23, 26], ["eye", "ORGAN", 23, 26], ["glasses", "TREATMENT", 11, 18], ["eye protection", "TREATMENT", 23, 37], ["laparoscopy", "TREATMENT", 111, 122], ["laparoscopy", "OBSERVATION", 111, 122]]], ["The authors emphasize the prevention of pneumoperitoneal leakage through the use of a balloon trocar and the need to aspirate the pneumoperitoneum before removal of the trocars.J o u r n a l P r e -p r o o fWe would like to add two additional precautions.", [["pneumoperitoneal", "ANATOMY", 40, 56], ["pneumoperitoneal leakage", "PROBLEM", 40, 64], ["a balloon trocar", "TREATMENT", 84, 100], ["the pneumoperitoneum", "PROBLEM", 126, 146], ["removal of the trocars", "TREATMENT", 154, 176], ["additional precautions", "TREATMENT", 232, 254], ["pneumoperitoneal leakage", "OBSERVATION", 40, 64], ["balloon trocar", "OBSERVATION", 86, 100], ["pneumoperitoneum", "OBSERVATION", 130, 146], ["trocars", "ANATOMY", 169, 176]]], ["First of all it seems desirable to avoid the use of sutures with extracorporeal knots, which are carried out through 5 mm trocars at the cost of a permanent air leak; while such an air leak is not very annoying in normal times since it is easily compensated by modern insufflators, it constitutes a potential danger in the context of the ongoing epidemic.J o u r n a l P r e -p r o o fAnother delicate phase in laparoscopic surgery is the extraction of resected specimens.J o u r n a l P r e -p r o o fRemoval of the specimen, whether transabdominal or transvaginal, is often accompanied by partial or complete exsufflation that is often abrupt and poorly controlled.", [["specimens", "ANATOMY", 462, 471], ["specimen", "ANATOMY", 517, 525], ["transabdominal", "ANATOMY", 535, 549], ["transvaginal", "ANATOMY", 553, 565], ["air leak", "DISEASE", 157, 165], ["specimens", "CANCER", 462, 471], ["sutures", "TREATMENT", 52, 59], ["extracorporeal knots", "TREATMENT", 65, 85], ["5 mm trocars", "TREATMENT", 117, 129], ["a permanent air leak", "PROBLEM", 145, 165], ["an air leak", "PROBLEM", 178, 189], ["laparoscopic surgery", "TREATMENT", 411, 431], ["resected specimens", "PROBLEM", 453, 471], ["the specimen", "TEST", 513, 525], ["transabdominal or transvaginal", "PROBLEM", 535, 565], ["partial or complete exsufflation", "PROBLEM", 591, 623], ["sutures", "OBSERVATION", 52, 59], ["extracorporeal knots", "OBSERVATION", 65, 85], ["permanent", "OBSERVATION_MODIFIER", 147, 156], ["air leak", "OBSERVATION", 157, 165], ["air leak", "OBSERVATION", 181, 189], ["laparoscopic surgery", "OBSERVATION", 411, 431], ["resected", "OBSERVATION", 453, 461]]], ["To limit this risk, we must compel ourselves to aspirate the pneumoperitoneum as completely as possible before specimen extraction.J o u r n a l P r e -p r o o fThe search for air leaks and control of exsufflation are very important to prevent tumor seeding in oncological surgery.", [["specimen", "ANATOMY", 111, 119], ["tumor", "ANATOMY", 244, 249], ["tumor", "DISEASE", 244, 249], ["tumor", "CANCER", 244, 249], ["the pneumoperitoneum", "PROBLEM", 57, 77], ["specimen extraction", "TREATMENT", 111, 130], ["The search", "TEST", 161, 171], ["air leaks", "PROBLEM", 176, 185], ["control of exsufflation", "TREATMENT", 190, 213], ["tumor seeding", "PROBLEM", 244, 257], ["oncological surgery", "TREATMENT", 261, 280], ["pneumoperitoneum", "OBSERVATION", 61, 77], ["air leaks", "OBSERVATION", 176, 185], ["tumor", "OBSERVATION", 244, 249], ["oncological surgery", "OBSERVATION", 261, 280]]], ["They become even more worrying when they endanger the safety of personnel and operators during this time of epidemic.J o u r n a l P r e -p r o o fThis drastic hunt to eliminate the chimney effect will undoubtedly be improved by the worries each of us face from a danger that we know so little about.", [["epidemic", "PROBLEM", 108, 116], ["fThis", "PROBLEM", 146, 151], ["drastic hunt", "PROBLEM", 152, 164], ["chimney", "OBSERVATION", 182, 189], ["improved", "OBSERVATION", 217, 225]]], ["It is obvious that some of the reflexes that we must acquire during this period will have to be preserved and incorporated into teaching and everyday practice to optimize the care of tomorrow's patients.", [["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 194, 202]]], ["This situation argues in favor of low-pressure insufflation (< 10 mm Hg) whenever possible and the use of an automatic smoke extractor (3) .", [["Hg", "CHEMICAL", 69, 71], ["low-pressure insufflation", "TREATMENT", 34, 59], ["an automatic smoke extractor", "TREATMENT", 106, 134], ["pressure insufflation", "OBSERVATION", 38, 59]]], ["At the inception of endoscopic cancer treatment, experimental", [["cancer", "ANATOMY", 31, 37], ["cancer", "DISEASE", 31, 37], ["cancer", "CANCER", 31, 37], ["endoscopic cancer treatment", "TREATMENT", 20, 47], ["endoscopic", "OBSERVATION_MODIFIER", 20, 30], ["cancer", "OBSERVATION", 31, 37]]]], "PMC7358573": [["IntroductionHypertension, diabetes, cardiovascular disorders, pulmonary disorders, and cancer have been associated with an increased risk of severe Coronavirus disease 2019 (Covid-19) and mortality (1\u20136).", [["cardiovascular", "ANATOMY", 36, 50], ["pulmonary", "ANATOMY", 62, 71], ["cancer", "ANATOMY", 87, 93], ["Hypertension", "DISEASE", 12, 24], ["diabetes", "DISEASE", 26, 34], ["cardiovascular disorders", "DISEASE", 36, 60], ["pulmonary disorders", "DISEASE", 62, 81], ["cancer", "DISEASE", 87, 93], ["Coronavirus disease", "DISEASE", 148, 167], ["pulmonary", "ORGAN", 62, 71], ["cancer", "CANCER", 87, 93], ["Hypertension", "PROBLEM", 12, 24], ["diabetes", "PROBLEM", 26, 34], ["cardiovascular disorders", "PROBLEM", 36, 60], ["pulmonary disorders", "PROBLEM", 62, 81], ["cancer", "PROBLEM", 87, 93], ["severe Coronavirus disease", "PROBLEM", 141, 167], ["Covid", "TEST", 174, 179], ["Hypertension", "OBSERVATION", 12, 24], ["diabetes", "OBSERVATION", 26, 34], ["cardiovascular", "ANATOMY", 36, 50], ["pulmonary", "ANATOMY", 62, 71], ["disorders", "OBSERVATION", 72, 81], ["cancer", "OBSERVATION", 87, 93], ["increased", "OBSERVATION_MODIFIER", 123, 132], ["severe", "OBSERVATION_MODIFIER", 141, 147], ["Coronavirus", "OBSERVATION", 148, 159]]], ["Since the first edition of the clinical management protocol of Covid-19 with severe acute respiratory infection, the World Health Organization (WHO) recommended that those patients, even if they present with mild symptoms, should be admitted to a designated unit for close monitoring (7).IntroductionThe frequency, type and implications of neurological comorbidity in Covid-19 patients is largely unexplored.", [["respiratory", "ANATOMY", 90, 101], ["neurological", "ANATOMY", 340, 352], ["acute respiratory infection", "DISEASE", 84, 111], ["neurological comorbidity", "DISEASE", 340, 364], ["patients", "ORGANISM", 172, 180], ["patients", "ORGANISM", 377, 385], ["patients", "SPECIES", 172, 180], ["patients", "SPECIES", 377, 385], ["Covid", "TEST", 63, 68], ["severe acute respiratory infection", "PROBLEM", 77, 111], ["mild symptoms", "PROBLEM", 208, 221], ["close monitoring", "TEST", 267, 283], ["neurological comorbidity", "PROBLEM", 340, 364], ["Covid", "TEST", 368, 373], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["respiratory", "ANATOMY", 90, 101], ["infection", "OBSERVATION", 102, 111]]], ["A recent review found a frequency ranging from 1.4 to 40%, with a pooled percentage of having a pre-existing neurological disease of 8.0% (8).", [["neurological", "ANATOMY", 109, 121], ["neurological disease", "DISEASE", 109, 129], ["a pre-existing neurological disease", "PROBLEM", 94, 129]]], ["The possible reasons for the heterogeneous results were the varying definitions, the lack of specific studies and underreported frequency.", [["specific studies", "TEST", 93, 109], ["possible reasons for", "UNCERTAINTY", 4, 24]]], ["The impact of neurological comorbidities in Covid-19 disease is yet unknown.", [["neurological", "ANATOMY", 14, 26], ["neurological comorbidities", "DISEASE", 14, 40], ["Covid-19 disease", "DISEASE", 44, 60], ["neurological comorbidities", "PROBLEM", 14, 40], ["Covid-19 disease", "PROBLEM", 44, 60]]], ["Covid-19 patients requiring intensive care unit (ICU) admission had prior history of cerebrovascular disease more frequently (3), but in some series, cerebrovascular disorders were classified together with cardiovascular disease (9).", [["cerebrovascular", "ANATOMY", 85, 100], ["cerebrovascular", "ANATOMY", 150, 165], ["cardiovascular", "ANATOMY", 206, 220], ["cerebrovascular disease", "DISEASE", 85, 108], ["cerebrovascular disorders", "DISEASE", 150, 175], ["cardiovascular disease", "DISEASE", 206, 228], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["cerebrovascular disease", "PROBLEM", 85, 108], ["cerebrovascular disorders", "PROBLEM", 150, 175], ["cardiovascular disease", "PROBLEM", 206, 228], ["cerebrovascular", "ANATOMY", 85, 100], ["disease", "OBSERVATION", 101, 108], ["cerebrovascular", "ANATOMY", 150, 165]]], ["The aim of this study was to evaluate if the presence of comorbid chronic neurological disorders is associated with a worse prognosis in patients with Covid-19 disease.Data Sources ::: Study Design ::: MethodsWe collected data from the electronic medical records.", [["neurological", "ANATOMY", 74, 86], ["neurological disorders", "DISEASE", 74, 96], ["Covid-19 disease", "DISEASE", 151, 167], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["this study", "TEST", 11, 21], ["comorbid chronic neurological disorders", "PROBLEM", 57, 96], ["Covid-19 disease", "PROBLEM", 151, 167], ["comorbid", "OBSERVATION_MODIFIER", 57, 65], ["chronic", "OBSERVATION_MODIFIER", 66, 73], ["neurological", "OBSERVATION", 74, 86]]], ["The local authorities created a reference contact phone line, that followed patients with typical Covid-19 symptoms daily or every other day.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84]]], ["Patients were treated according to the national Covid-19 management protocol standard of care (SOC) (11).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["The study period included all consecutive patients that were admitted to the hospital with a Covid-19 confirmed diagnosis between March 8th and April 11th, 2020.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["The study", "TEST", 0, 9], ["a Covid", "TEST", 91, 98]]], ["The source of the data was the admission department and the department of microbiology records, whilst notification of every Covid-19 positive was mandatory during the time of the study.Covid-19 Disease Diagnosis ::: Study Design ::: MethodsCovid-19 diagnosis was based on real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay (LightMIx Modular SARS-CoV (COVID19) E-gene and LightMIx Modular SARS-CoV (COVID19) RdRP, Roche Diagnostics S.L.) of oropharyngeal-nasopharyngeal swab, sputum or lower respiratory tract sample; or was based on the presence of anti-SARS-CoV-2 IgM+IgA antibodies (COVID-19 ELISA IgM+IgA; Vircell, S.L. Granada, Spain) in serological test in patients with clinical symptoms, according to the WHO protocols (12).", [["oropharyngeal-nasopharyngeal swab", "ANATOMY", 463, 496], ["sputum", "ANATOMY", 498, 504], ["lower respiratory tract sample", "ANATOMY", 508, 538], ["oropharyngeal", "ORGANISM_SUBDIVISION", 463, 476], ["-nasopharyngeal swab", "ORGANISM_SUBSTANCE", 476, 496], ["sputum", "ORGANISM_SUBSTANCE", 498, 504], ["lower", "ORGANISM_SUBDIVISION", 508, 513], ["respiratory tract", "ORGANISM_SUBDIVISION", 514, 531], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 572, 587], ["IgA", "GENE_OR_GENE_PRODUCT", 592, 595], ["patients", "ORGANISM", 685, 693], ["reverse-transcriptase", "PROTEIN", 283, 304], ["LightMIx Modular SARS-CoV (COVID19) E-gene", "DNA", 347, 389], ["COVID19", "DNA", 421, 428], ["RdRP", "DNA", 430, 434], ["anti-SARS", "PROTEIN", 572, 581], ["CoV", "PROTEIN", 582, 585], ["IgM", "PROTEIN", 588, 591], ["IgA antibodies", "PROTEIN", 592, 606], ["COVID", "PROTEIN", 608, 613], ["IgM", "PROTEIN", 623, 626], ["IgA", "PROTEIN", 627, 630], ["patients", "SPECIES", 685, 693], ["SARS-CoV", "SPECIES", 364, 372], ["SARS-CoV", "SPECIES", 411, 419], ["Covid", "TEST", 125, 130], ["the study", "TEST", 176, 185], ["PCR", "TEST", 335, 338], ["assay", "TEST", 340, 345], ["Modular SARS", "TEST", 356, 368], ["CoV (COVID19) E-gene", "TREATMENT", 369, 389], ["LightMIx Modular SARS-CoV (COVID19) RdRP", "TREATMENT", 394, 434], ["oropharyngeal-nasopharyngeal swab", "TEST", 463, 496], ["sputum", "TEST", 498, 504], ["lower respiratory tract sample", "PROBLEM", 508, 538], ["anti-SARS", "TEST", 572, 581], ["CoV", "TEST", 582, 585], ["IgM", "TEST", 588, 591], ["IgA antibodies", "TEST", 592, 606], ["COVID", "TEST", 608, 613], ["ELISA", "TEST", 617, 622], ["IgM", "TEST", 623, 626], ["IgA", "TEST", 627, 630], ["Vircell", "TEST", 632, 639], ["serological test", "TEST", 665, 681], ["clinical symptoms", "PROBLEM", 699, 716], ["oropharyngeal", "ANATOMY", 463, 476], ["nasopharyngeal", "ANATOMY", 477, 491], ["respiratory tract", "ANATOMY", 514, 531]]], ["Patients without laboratory-confirmed diagnosis were not included.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Recruitment was probabilistic and all consecutive patients were included.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58]]], ["Only hospitalized patients were included.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["Data was extracted according to a predefined protocol by 13 neurologists that were involved in the treatment of Covid-19 patients.", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["Covid", "TEST", 112, 117]]], ["The needed time to review it patient was 20\u201330 min.Chronic Neurological Disorders Definition ::: Study Design ::: MethodsWe used the WHO definition of disabling chronic neurological disorders (CND), as those neurological disorders that (a) caused persistent disability, (b) limited the individual's functioning, and (c) interfered with the person's ability to engage in activities (13).", [["neurological", "ANATOMY", 169, 181], ["neurological", "ANATOMY", 208, 220], ["Neurological Disorders", "DISEASE", 59, 81], ["chronic neurological disorders", "DISEASE", 161, 191], ["CND", "DISEASE", 193, 196], ["neurological disorders", "DISEASE", 208, 230], ["disability", "DISEASE", 258, 268], ["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["person", "SPECIES", 340, 346], ["Chronic Neurological Disorders", "PROBLEM", 51, 81], ["disabling chronic neurological disorders", "PROBLEM", 151, 191], ["those neurological disorders", "PROBLEM", 202, 230], ["persistent disability", "PROBLEM", 247, 268], ["disabling", "OBSERVATION_MODIFIER", 151, 160], ["chronic", "OBSERVATION_MODIFIER", 161, 168]]], ["CND included dementia, movement disorders, prior stroke with long-term sequelae, neuromuscular disorders, spinal disorders, symptomatic central nervous system cancer, chronic encephalopathies or neuro-inflammatory disorders.", [["neuromuscular", "ANATOMY", 81, 94], ["spinal", "ANATOMY", 106, 112], ["central nervous system cancer", "ANATOMY", 136, 165], ["CND", "DISEASE", 0, 3], ["dementia", "DISEASE", 13, 21], ["movement disorders", "DISEASE", 23, 41], ["stroke", "DISEASE", 49, 55], ["neuromuscular disorders", "DISEASE", 81, 104], ["spinal disorders", "DISEASE", 106, 122], ["central nervous system cancer", "DISEASE", 136, 165], ["chronic encephalopathies", "DISEASE", 167, 191], ["neuro-inflammatory disorders", "DISEASE", 195, 223], ["central nervous system cancer", "CANCER", 136, 165], ["dementia", "PROBLEM", 13, 21], ["movement disorders", "PROBLEM", 23, 41], ["prior stroke", "PROBLEM", 43, 55], ["long-term sequelae", "PROBLEM", 61, 79], ["neuromuscular disorders", "PROBLEM", 81, 104], ["spinal disorders", "PROBLEM", 106, 122], ["symptomatic central nervous system cancer", "PROBLEM", 124, 165], ["chronic encephalopathies", "PROBLEM", 167, 191], ["neuro-inflammatory disorders", "PROBLEM", 195, 223], ["dementia", "OBSERVATION", 13, 21], ["movement disorders", "OBSERVATION", 23, 41], ["stroke", "OBSERVATION", 49, 55], ["long-term", "OBSERVATION_MODIFIER", 61, 70], ["neuromuscular", "ANATOMY", 81, 94], ["spinal", "ANATOMY", 106, 112], ["symptomatic", "OBSERVATION_MODIFIER", 124, 135], ["central", "ANATOMY_MODIFIER", 136, 143], ["nervous system", "ANATOMY", 144, 158], ["cancer", "OBSERVATION", 159, 165], ["chronic", "OBSERVATION_MODIFIER", 167, 174], ["encephalopathies", "OBSERVATION", 175, 191]]], ["Researchers specifically assessed the presence of prior history of neurological diseases and only those conditions fulfilling (a), (b), and (c) criteria were included.Variables ::: Study Design ::: MethodsWe analyzed demographic variables, prior medical history, clinical presentation, the course of the disease and treatment.", [["neurological", "ANATOMY", 67, 79], ["neurological diseases", "DISEASE", 67, 88], ["neurological diseases", "PROBLEM", 67, 88], ["the disease", "PROBLEM", 300, 311], ["treatment", "TREATMENT", 316, 325], ["diseases", "OBSERVATION", 80, 88]]], ["Demographic variables included age, sex, date of symptoms onset.", [["symptoms onset", "PROBLEM", 49, 63]]], ["Regarding comorbidities, we analyzed the presence of hypertension (systemic blood pressure higher than 140/90 mmHg in two prior determinations), diabetes (fasting blood glucose >126 mg/dl on two separate tests, HbA1c > 6,5%, blood glucose level >200 mg after oral glucose overload or blood glucose level >200 mg/dl with diabetes symptoms), smoking habit (current or in the preceding 6 months), cardiovascular diseases (coronary artery disease, congenital heart diseases, cardiomyopathies, arrythmias, valvular heart disease, aortic aneurysms, and peripheral artery disease), chronic respiratory diseases (chronic obstructive pulmonary disease (COPD), asthma, occupational lung diseases, interstitial lung diseases and pulmonary hypertension), cancer (excluding epidermoid and basal cell carcinoma), immunocompromised state (congenital or acquired).", [["blood", "ANATOMY", 76, 81], ["blood", "ANATOMY", 163, 168], ["blood", "ANATOMY", 225, 230], ["oral", "ANATOMY", 259, 263], ["blood", "ANATOMY", 284, 289], ["cardiovascular", "ANATOMY", 394, 408], ["coronary artery", "ANATOMY", 419, 434], ["heart", "ANATOMY", 455, 460], ["valvular", "ANATOMY", 501, 509], ["heart", "ANATOMY", 510, 515], ["aortic", "ANATOMY", 525, 531], ["peripheral artery", "ANATOMY", 547, 564], ["respiratory", "ANATOMY", 583, 594], ["pulmonary", "ANATOMY", 625, 634], ["lung", "ANATOMY", 672, 676], ["lung", "ANATOMY", 700, 704], ["pulmonary", "ANATOMY", 718, 727], ["cancer", "ANATOMY", 743, 749], ["epidermoid", "ANATOMY", 761, 771], ["basal cell carcinoma", "ANATOMY", 776, 796], ["hypertension", "DISEASE", 53, 65], ["diabetes", "DISEASE", 145, 153], ["glucose", "CHEMICAL", 169, 176], ["glucose", "CHEMICAL", 231, 238], ["glucose", "CHEMICAL", 264, 271], ["glucose", "CHEMICAL", 290, 297], ["diabetes symptoms", "DISEASE", 320, 337], ["cardiovascular diseases", "DISEASE", 394, 417], ["coronary artery disease", "DISEASE", 419, 442], ["congenital heart diseases", "DISEASE", 444, 469], ["cardiomyopathies", "DISEASE", 471, 487], ["arrythmias", "DISEASE", 489, 499], ["valvular heart disease", "DISEASE", 501, 523], ["aortic aneurysms", "DISEASE", 525, 541], ["peripheral artery disease", "DISEASE", 547, 572], ["chronic respiratory diseases", "DISEASE", 575, 603], ["chronic obstructive pulmonary disease", "DISEASE", 605, 642], ["COPD", "DISEASE", 644, 648], ["asthma", "DISEASE", 651, 657], ["occupational lung diseases", "DISEASE", 659, 685], ["interstitial lung diseases", "DISEASE", 687, 713], ["pulmonary hypertension", "DISEASE", 718, 740], ["cancer", "DISEASE", 743, 749], ["epidermoid and basal cell carcinoma", "DISEASE", 761, 796], ["glucose", "CHEMICAL", 169, 176], ["glucose", "CHEMICAL", 231, 238], ["glucose", "CHEMICAL", 264, 271], ["glucose", "CHEMICAL", 290, 297], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["blood", "ORGANISM_SUBSTANCE", 163, 168], ["glucose", "SIMPLE_CHEMICAL", 169, 176], ["blood", "ORGANISM_SUBSTANCE", 225, 230], ["glucose", "SIMPLE_CHEMICAL", 231, 238], ["oral", "ORGANISM_SUBDIVISION", 259, 263], ["glucose", "SIMPLE_CHEMICAL", 264, 271], ["blood", "ORGANISM_SUBSTANCE", 284, 289], ["glucose", "SIMPLE_CHEMICAL", 290, 297], ["cardiovascular", "ANATOMICAL_SYSTEM", 394, 408], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 419, 434], ["heart", "ORGAN", 455, 460], ["heart", "ORGAN", 510, 515], ["aortic", "MULTI-TISSUE_STRUCTURE", 525, 531], ["peripheral artery", "MULTI-TISSUE_STRUCTURE", 547, 564], ["pulmonary", "ORGAN", 625, 634], ["lung", "ORGAN", 672, 676], ["lung", "ORGAN", 700, 704], ["pulmonary", "ORGAN", 718, 727], ["cancer", "CANCER", 743, 749], ["epidermoid", "CANCER", 761, 771], ["basal cell carcinoma", "CANCER", 776, 796], ["comorbidities", "PROBLEM", 10, 23], ["hypertension", "PROBLEM", 53, 65], ["systemic blood pressure", "TEST", 67, 90], ["diabetes", "PROBLEM", 145, 153], ["fasting blood glucose", "TEST", 155, 176], ["two separate tests", "TEST", 191, 209], ["HbA1c", "TEST", 211, 216], ["blood glucose level", "TEST", 225, 244], ["oral glucose overload", "PROBLEM", 259, 280], ["blood glucose level", "TEST", 284, 303], ["diabetes symptoms", "PROBLEM", 320, 337], ["cardiovascular diseases (coronary artery disease", "PROBLEM", 394, 442], ["congenital heart diseases", "PROBLEM", 444, 469], ["cardiomyopathies", "PROBLEM", 471, 487], ["arrythmias", "PROBLEM", 489, 499], ["valvular heart disease", "PROBLEM", 501, 523], ["aortic aneurysms", "PROBLEM", 525, 541], ["peripheral artery disease)", "PROBLEM", 547, 573], ["chronic respiratory diseases", "PROBLEM", 575, 603], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 605, 649], ["asthma", "PROBLEM", 651, 657], ["occupational lung diseases", "PROBLEM", 659, 685], ["interstitial lung diseases", "PROBLEM", 687, 713], ["pulmonary hypertension)", "PROBLEM", 718, 741], ["cancer", "PROBLEM", 743, 749], ["epidermoid and basal cell carcinoma", "PROBLEM", 761, 796], ["immunocompromised state", "PROBLEM", 799, 822], ["hypertension", "OBSERVATION", 53, 65], ["cardiovascular", "ANATOMY", 394, 408], ["diseases", "OBSERVATION", 409, 417], ["coronary artery", "ANATOMY", 419, 434], ["heart", "ANATOMY", 455, 460], ["diseases", "OBSERVATION", 461, 469], ["arrythmias", "OBSERVATION", 489, 499], ["valvular heart", "ANATOMY", 501, 515], ["disease", "OBSERVATION", 516, 523], ["aortic", "ANATOMY", 525, 531], ["aneurysms", "OBSERVATION", 532, 541], ["peripheral artery", "ANATOMY", 547, 564], ["disease", "OBSERVATION", 565, 572], ["chronic", "OBSERVATION_MODIFIER", 575, 582], ["respiratory diseases", "OBSERVATION", 583, 603], ["chronic", "OBSERVATION_MODIFIER", 605, 612], ["obstructive", "OBSERVATION_MODIFIER", 613, 624], ["pulmonary", "ANATOMY", 625, 634], ["disease", "OBSERVATION", 635, 642], ["COPD", "OBSERVATION", 644, 648], ["asthma", "OBSERVATION", 651, 657], ["lung", "ANATOMY", 672, 676], ["diseases", "OBSERVATION", 677, 685], ["interstitial", "ANATOMY_MODIFIER", 687, 699], ["lung", "ANATOMY", 700, 704], ["diseases", "OBSERVATION", 705, 713], ["pulmonary", "ANATOMY", 718, 727], ["hypertension", "OBSERVATION", 728, 740], ["cancer", "OBSERVATION", 743, 749], ["basal", "ANATOMY_MODIFIER", 776, 781], ["cell carcinoma", "OBSERVATION", 782, 796]]], ["We specifically evaluated the presence of CND.", [["CND", "DISEASE", 42, 45], ["CND", "PROBLEM", 42, 45], ["CND", "OBSERVATION", 42, 45]]], ["We analyzed baseline performance status by using the modified Ranking scale (mRS), ranging from 0 (no symptoms) to 6 (dead), being defined 3 as the presence of moderate disability and need of assistance (14).Variables ::: Study Design ::: MethodsConcerning the clinical presentation, we evaluated if the source of contagion was suspected or not, the time between the first symptom and the emergency department (ED) presentation.", [["disability", "DISEASE", 169, 179], ["mRS", "TEST", 77, 80], ["symptoms", "PROBLEM", 102, 110], ["moderate disability", "PROBLEM", 160, 179], ["contagion", "PROBLEM", 314, 323], ["moderate", "OBSERVATION_MODIFIER", 160, 168], ["disability", "OBSERVATION", 169, 179]]], ["We analyzed the general symptoms, including fever (defined as axillary temperature equal or higher than 37.5%), asthenia, cough, cutaneous rash, dyspnea, diarrhea, chest pain, expectoration, headache, myalgia, nausea, odynophagia, rhinorrhea, and vomiting.", [["axillary", "ANATOMY", 62, 70], ["cutaneous", "ANATOMY", 129, 138], ["chest", "ANATOMY", 164, 169], ["fever", "DISEASE", 44, 49], ["asthenia", "DISEASE", 112, 120], ["cough", "DISEASE", 122, 127], ["cutaneous rash", "DISEASE", 129, 143], ["dyspnea", "DISEASE", 145, 152], ["diarrhea", "DISEASE", 154, 162], ["chest pain", "DISEASE", 164, 174], ["expectoration", "DISEASE", 176, 189], ["headache", "DISEASE", 191, 199], ["myalgia", "DISEASE", 201, 208], ["nausea", "DISEASE", 210, 216], ["odynophagia", "DISEASE", 218, 229], ["rhinorrhea", "DISEASE", 231, 241], ["vomiting", "DISEASE", 247, 255], ["chest", "ORGANISM_SUBDIVISION", 164, 169], ["the general symptoms", "PROBLEM", 12, 32], ["fever", "PROBLEM", 44, 49], ["axillary temperature", "TEST", 62, 82], ["asthenia", "PROBLEM", 112, 120], ["cough", "PROBLEM", 122, 127], ["cutaneous rash", "PROBLEM", 129, 143], ["dyspnea", "PROBLEM", 145, 152], ["diarrhea", "PROBLEM", 154, 162], ["chest pain", "PROBLEM", 164, 174], ["expectoration", "PROBLEM", 176, 189], ["headache", "PROBLEM", 191, 199], ["myalgia", "PROBLEM", 201, 208], ["nausea", "PROBLEM", 210, 216], ["odynophagia", "PROBLEM", 218, 229], ["rhinorrhea", "PROBLEM", 231, 241], ["vomiting", "PROBLEM", 247, 255], ["axillary", "ANATOMY", 62, 70], ["cutaneous", "ANATOMY", 129, 138], ["chest", "ANATOMY", 164, 169], ["myalgia", "OBSERVATION", 201, 208], ["rhinorrhea", "OBSERVATION", 231, 241]]], ["We describe the type of Covid-19 diagnosis, either by RT-PCR or serological tests.", [["RT-PCR", "TEST", 54, 60], ["serological tests", "TEST", 64, 81]]], ["We analyzed the frequency of abnormal chest imaging, either by X-ray or Computerized Tomography (CT).", [["chest", "ANATOMY", 38, 43], ["chest", "ORGAN", 38, 43], ["abnormal chest imaging", "TEST", 29, 51], ["X-ray", "TEST", 63, 68], ["Computerized Tomography (CT", "TEST", 72, 99], ["chest", "ANATOMY", 38, 43]]], ["The analyzed parameters were leukocytes [cell count \u00d7 109 / L, reference value (RV):4\u201310], lymphocytes (count \u00d7 109/L, RV: 0.9\u20135.2), platelets (count \u00d7 109 /L, RV: 150\u2013400), hemoglobin (g/dL, RV: 12\u201316), international normalized ratio (INR, RV: 0.8\u20131.3), D-dimer (ng/dL, RV: <500), lactate dehydrogenase (U/L, RV: 135\u2013250), creatine-kinase (U/L, RV: 20\u2013170), glomerular filtration rate corrected by body area (ml/min/1.73 m2, RV > 90), C-reactive protein (mg/L, RV: 1\u20135), procalcitonin (ng/mL, RV: < 5), interleukine-6 (pg/mL, RV < 5.9), ferritin (ng/mL, RV: 15\u2013150).", [["leukocytes", "ANATOMY", 29, 39], ["cell", "ANATOMY", 41, 45], ["lymphocytes", "ANATOMY", 91, 102], ["platelets", "ANATOMY", 133, 142], ["glomerular", "ANATOMY", 359, 369], ["body area", "ANATOMY", 399, 408], ["lactate", "CHEMICAL", 282, 289], ["creatine", "CHEMICAL", 324, 332], ["lactate", "CHEMICAL", 282, 289], ["creatine", "CHEMICAL", 324, 332], ["leukocytes", "CELL", 29, 39], ["cell", "CELL", 41, 45], ["lymphocytes", "CELL", 91, 102], ["platelets", "CELL", 133, 142], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 174, 184], ["D-dimer", "GENE_OR_GENE_PRODUCT", 255, 262], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 282, 303], ["creatine-kinase", "GENE_OR_GENE_PRODUCT", 324, 339], ["glomerular", "TISSUE", 359, 369], ["body", "ORGANISM_SUBDIVISION", 399, 403], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 436, 454], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 472, 485], ["interleukine-6", "GENE_OR_GENE_PRODUCT", 504, 518], ["ferritin", "GENE_OR_GENE_PRODUCT", 538, 546], ["leukocytes", "CELL_TYPE", 29, 39], ["lymphocytes", "CELL_TYPE", 91, 102], ["platelets", "CELL_TYPE", 133, 142], ["hemoglobin", "PROTEIN", 174, 184], ["D-dimer", "PROTEIN", 255, 262], ["lactate dehydrogenase", "PROTEIN", 282, 303], ["creatine-kinase", "PROTEIN", 324, 339], ["C-reactive protein", "PROTEIN", 436, 454], ["procalcitonin", "PROTEIN", 472, 485], ["ferritin", "PROTEIN", 538, 546], ["The analyzed parameters", "TEST", 0, 23], ["leukocytes", "TEST", 29, 39], ["cell count", "TEST", 41, 51], ["reference value", "TEST", 63, 78], ["RV", "TEST", 80, 82], ["lymphocytes", "TEST", 91, 102], ["count", "TEST", 104, 109], ["RV", "TEST", 119, 121], ["platelets", "TEST", 133, 142], ["count", "TEST", 144, 149], ["L", "TEST", 157, 158], ["RV", "TEST", 160, 162], ["hemoglobin", "TEST", 174, 184], ["dL", "TEST", 188, 190], ["RV", "TEST", 192, 194], ["international normalized ratio", "TEST", 204, 234], ["INR", "TEST", 236, 239], ["RV", "TEST", 241, 243], ["D-dimer", "TEST", 255, 262], ["RV", "TEST", 271, 273], ["lactate dehydrogenase", "TEST", 282, 303], ["U/L", "TEST", 305, 308], ["RV", "TEST", 310, 312], ["creatine", "TEST", 324, 332], ["kinase", "TEST", 333, 339], ["U", "TEST", 341, 342], ["RV", "TEST", 346, 348], ["glomerular filtration rate", "TEST", 359, 385], ["body area", "TEST", 399, 408], ["RV", "TEST", 426, 428], ["C-reactive protein", "TEST", 436, 454], ["mg", "TEST", 456, 458], ["RV", "TEST", 462, 464], ["procalcitonin", "TEST", 472, 485], ["RV", "TEST", 494, 496], ["interleukine", "TEST", 504, 516], ["RV", "TEST", 527, 529], ["ferritin", "TEST", 538, 546], ["RV", "TEST", 555, 557], ["dL", "ANATOMY", 267, 269], ["RV", "ANATOMY", 271, 273], ["RV", "ANATOMY", 346, 348], ["glomerular", "ANATOMY", 359, 369]]], ["Interleukine-6 and ferritin were not available on admission.", [["Interleukine-6", "GENE_OR_GENE_PRODUCT", 0, 14], ["ferritin", "GENE_OR_GENE_PRODUCT", 19, 27], ["Interleukine-6", "PROTEIN", 0, 14], ["ferritin", "PROTEIN", 19, 27], ["Interleukine", "TEST", 0, 12], ["ferritin", "TEST", 19, 27]]], ["We evaluated the percentage of patients that presented abnormal results on admission and during the hospitalization.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["We describe the received treatment, that according to the local SOC, being the possible drug dose regimes hydroxychloroquine 400 mg bid for 5 days, lopinavir/ritonavir 400/100 mg bid, methylprednisolone 250 mg three consecutive days and interferon beta-1b (11).", [["hydroxychloroquine", "CHEMICAL", 106, 124], ["lopinavir/ritonavir", "CHEMICAL", 148, 167], ["methylprednisolone", "CHEMICAL", 184, 202], ["interferon beta-1b", "CHEMICAL", 237, 255], ["hydroxychloroquine", "CHEMICAL", 106, 124], ["lopinavir", "CHEMICAL", 148, 157], ["ritonavir", "CHEMICAL", 158, 167], ["methylprednisolone", "CHEMICAL", 184, 202], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 106, 124], ["lopinavir", "SIMPLE_CHEMICAL", 148, 157], ["ritonavir", "SIMPLE_CHEMICAL", 158, 167], ["methylprednisolone", "SIMPLE_CHEMICAL", 184, 202], ["interferon beta-1b", "GENE_OR_GENE_PRODUCT", 237, 255], ["interferon beta", "PROTEIN", 237, 252], ["treatment", "TREATMENT", 25, 34], ["drug dose regimes", "TREATMENT", 88, 105], ["hydroxychloroquine", "TREATMENT", 106, 124], ["lopinavir", "TREATMENT", 148, 157], ["ritonavir", "TREATMENT", 158, 167], ["methylprednisolone", "TREATMENT", 184, 202], ["interferon beta", "TREATMENT", 237, 252]]], ["We also report the need of oxygen therapy, the use of mechanical ventilation, the need of Intensive Care Unit (ICU) admission and the all-cause mortality.", [["oxygen", "CHEMICAL", 27, 33], ["oxygen", "CHEMICAL", 27, 33], ["oxygen", "SIMPLE_CHEMICAL", 27, 33], ["oxygen therapy", "TREATMENT", 27, 41], ["mechanical ventilation", "TREATMENT", 54, 76], ["oxygen therapy", "OBSERVATION", 27, 41], ["mechanical ventilation", "OBSERVATION", 54, 76]]], ["The severity of the Covid-19 disease was defined according to the American Thoracic Society guidelines for community-acquired pneumonia (15) (Supplementary Material).", [["pneumonia", "DISEASE", 126, 135], ["the Covid-19 disease", "PROBLEM", 16, 36], ["community-acquired pneumonia", "PROBLEM", 107, 135], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["Thoracic", "ANATOMY", 75, 83], ["pneumonia", "OBSERVATION", 126, 135]]], ["We defined severe Covid-19 disease as the presence of either severe pneumonia or acute respiratory distress syndrome (ARDS) (16).Study Endpoints ::: MethodsThe primary endpoint was in-hospital mortality of Covid-19 in patients with CND, calculated by multivariate regression and survival probability by Cox regression, adjusted by the possible confounders and effect modifiers.", [["respiratory", "ANATOMY", 87, 98], ["Covid-19 disease", "DISEASE", 18, 34], ["pneumonia", "DISEASE", 68, 77], ["acute respiratory distress syndrome", "DISEASE", 81, 116], ["ARDS", "DISEASE", 118, 122], ["CND", "DISEASE", 232, 235], ["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 218, 226], ["severe Covid-19 disease", "PROBLEM", 11, 34], ["severe pneumonia", "PROBLEM", 61, 77], ["acute respiratory distress syndrome", "PROBLEM", 81, 116], ["ARDS", "PROBLEM", 118, 122], ["Methods", "TREATMENT", 149, 156], ["Covid", "TEST", 206, 211], ["CND", "PROBLEM", 232, 235], ["Cox regression", "PROBLEM", 303, 317], ["severe", "OBSERVATION_MODIFIER", 11, 17], ["19 disease", "OBSERVATION", 24, 34], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["pneumonia", "OBSERVATION", 68, 77], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["respiratory distress syndrome", "OBSERVATION", 87, 116]]], ["As secondary endpoints, we aimed to analyze the Covid-19 severity in CND patients and the presence of Covid-19 related laboratory abnormalities.Statistical Analysis ::: MethodsQualitative and ordinal variables are expressed as frequency and percentage.", [["CND", "DISEASE", 69, 72], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["the Covid", "TEST", 44, 53], ["Covid", "TEST", 102, 107], ["laboratory abnormalities", "PROBLEM", 119, 143], ["MethodsQualitative and ordinal variables", "TREATMENT", 169, 209]]], ["Continuous variables are presented as medians, interquartile range (IQR), and minimum-maximum value or mean and standard deviation (SD).", [["mean", "TEST", 103, 107]]], ["In the statistical analysis we employed Chi2 test or Fisher's Exact test for the contrast of categorical variables, adjusting p-value by Bonferroni method for multiple comparisons correction.", [["Chi2 test", "TEST", 40, 49], ["Fisher's Exact test", "TEST", 53, 72], ["multiple comparisons correction", "TREATMENT", 159, 190]]], ["Due to the exploratory nature of the study, we did not calculate sample size.Statistical Analysis ::: MethodsFor the primary endpoint, we conducted a univariate regression analysis of all baseline variables and all the variables that showed statistical association with higher odds of death and a p-value lower or equal than 0.1, were included in a multivariate regression analysis.", [["death", "DISEASE", 285, 290], ["the study", "TEST", 33, 42], ["a univariate regression analysis", "TEST", 148, 180], ["death", "PROBLEM", 285, 290], ["a p-value", "TEST", 295, 304], ["a multivariate regression analysis", "TEST", 347, 381], ["size", "OBSERVATION_MODIFIER", 72, 76]]], ["All CND were analyzed together.", [["CND", "CANCER", 4, 7]]], ["We present the odds ratio (OR) and the 95% confidence interval (CI).", [["CI", "TEST", 64, 66]]], ["Survival probability over time was assessed by Cox-regression analysis with hazard ratio (HR) and the corresponding 95% CI analysis, adjusted by all the covariates that were significant in the univariate regression analysis.", [["Cox-regression analysis", "TEST", 47, 70], ["hazard ratio", "TEST", 76, 88], ["HR", "TEST", 90, 92], ["CI analysis", "TEST", 120, 131], ["the univariate regression analysis", "TEST", 189, 223], ["significant", "OBSERVATION_MODIFIER", 174, 185]]], ["Differences in Kaplan Meier Curves were analyzed by the log-rank test.Statistical Analysis ::: MethodsFor the secondary endpoint severe-Covid-19 disease, we repeated the same analysis as for the primary endpoint.", [["Kaplan Meier Curves", "TEST", 15, 34], ["the log-rank test", "TEST", 52, 69], ["Methods", "TREATMENT", 95, 102], ["the secondary endpoint severe-Covid-19 disease", "PROBLEM", 106, 152], ["the same analysis", "TEST", 166, 183]]], ["To evaluate if laboratory parameters were more often abnormal in patients with CND, we created a regression analysis adjusting for age, mRS and sex.", [["CND", "DISEASE", 79, 82], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["laboratory parameters", "TEST", 15, 36], ["a regression analysis", "TEST", 95, 116]]], ["Statistical analysis was performed with SPSS v.26 (IBM Corp. Armonk, NY) by DGA.", [["DGA", "CHEMICAL", 76, 79], ["Statistical analysis", "TEST", 0, 20], ["SPSS", "TEST", 40, 44]]], ["All datasheets are available for other researchers under reasonable request.Ethical Aspects ::: MethodsThe study protocol was approved by the institutional review board of Valladolid Este health area (PI-20-1751).", [["PI-20-1751", "CHEMICAL", 201, 211], ["Methods", "TREATMENT", 96, 103], ["The study protocol", "TEST", 103, 121]]], ["Written informed consent was waived given the risk of contagion and the urgent need of data.Data Availability ::: MethodsDatasheets are available for other researchers under reasonable request.Latency Between Symptom Onset and ED Presentation ::: ResultsThe mean time between symptom onset and ED visit in patients with neurological comorbidities was 5.27 (sd: 7.72) days, compared with 7.81 (sd: 5.66) days in those without prior neurological history.", [["neurological", "ANATOMY", 320, 332], ["neurological", "ANATOMY", 431, 443], ["neurological comorbidities", "DISEASE", 320, 346], ["patients", "ORGANISM", 306, 314], ["patients", "SPECIES", 306, 314], ["neurological comorbidities", "PROBLEM", 320, 346], ["prior neurological history", "PROBLEM", 425, 451]]], ["After adjusting for age, mRS, sex, vascular risk factors and comorbidities, linear regression analysis was significant (B coefficient \u22121.436, 95% CI: \u22122.844-\u22120.28, p = 0.046).", [["vascular", "ANATOMY", 35, 43], ["vascular", "MULTI-TISSUE_STRUCTURE", 35, 43], ["comorbidities", "PROBLEM", 61, 74], ["linear regression analysis", "TEST", 76, 102], ["B coefficient", "TEST", 120, 133], ["CI", "TEST", 146, 148], ["p", "TEST", 164, 165], ["vascular", "ANATOMY", 35, 43]]], ["Figure 1 shows the interval between symptom onset and ED visit in patients with and without neurological comorbidities in patients with and without CND.Diagnosis and Management of Patients ::: ResultsDiagnosis was confirmed by RT-PCR in 546 (94.8%) of cases and/or serology in 175 (30.4%).", [["neurological", "ANATOMY", 92, 104], ["neurological comorbidities", "DISEASE", 92, 118], ["CND", "DISEASE", 148, 151], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 122, 130], ["Patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 122, 130], ["Patients", "SPECIES", 180, 188], ["symptom", "PROBLEM", 36, 43], ["neurological comorbidities", "PROBLEM", 92, 118], ["CND", "PROBLEM", 148, 151], ["RT", "TEST", 227, 229], ["PCR", "TEST", 230, 233], ["cases", "TEST", 252, 257], ["serology", "TEST", 265, 273]]], ["Chest imaging was abnormal in 549 patients (95.3%).", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["Chest imaging", "TEST", 0, 13], ["abnormal", "PROBLEM", 18, 26]]], ["Patients with CND received hydroxychloroquine (83.8 vs. 92.6%, p = 0.008) and lopinavir/ritonavir (81.9 vs. 92.1%, p = 0.003) less frequently.", [["CND", "DISEASE", 14, 17], ["hydroxychloroquine", "CHEMICAL", 27, 45], ["lopinavir/ritonavir", "CHEMICAL", 78, 97], ["hydroxychloroquine", "CHEMICAL", 27, 45], ["lopinavir", "CHEMICAL", 78, 87], ["ritonavir", "CHEMICAL", 88, 97], ["Patients", "ORGANISM", 0, 8], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 27, 45], ["lopinavir", "SIMPLE_CHEMICAL", 78, 87], ["ritonavir", "SIMPLE_CHEMICAL", 88, 97], ["Patients", "SPECIES", 0, 8], ["hydroxychloroquine", "TREATMENT", 27, 45], ["lopinavir", "TREATMENT", 78, 87], ["ritonavir", "TREATMENT", 88, 97]]], ["Frequency of methylprednisolone or interferon use was similar.", [["methylprednisolone", "CHEMICAL", 13, 31], ["interferon", "CHEMICAL", 35, 45], ["methylprednisolone", "CHEMICAL", 13, 31], ["methylprednisolone", "SIMPLE_CHEMICAL", 13, 31], ["interferon", "GENE_OR_GENE_PRODUCT", 35, 45], ["interferon", "PROTEIN", 35, 45], ["methylprednisolone", "TREATMENT", 13, 31], ["interferon use", "TREATMENT", 35, 49]]], ["Need of oxygen therapy was more frequent in CND patients (83.8 vs. 66.2%, p = 0.001).", [["oxygen", "CHEMICAL", 8, 14], ["CND", "DISEASE", 44, 47], ["oxygen", "CHEMICAL", 8, 14], ["oxygen", "SIMPLE_CHEMICAL", 8, 14], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["oxygen therapy", "TREATMENT", 8, 22], ["p", "TEST", 74, 75], ["oxygen therapy", "OBSERVATION", 8, 22]]], ["Frequency of ventilatory support or ICU admission was similar.Course of the Disease ::: ResultsConcerning the clinical course, 393 (68.2%) of patients had a severe pneumonia or ADRS and 127 (22.0%) died.", [["pneumonia", "DISEASE", 164, 173], ["ADRS", "DISEASE", 177, 181], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["ventilatory support", "TREATMENT", 13, 32], ["a severe pneumonia", "PROBLEM", 155, 173], ["ADRS", "PROBLEM", 177, 181], ["ventilatory support", "OBSERVATION", 13, 32], ["Disease", "OBSERVATION", 76, 83], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["pneumonia", "OBSERVATION", 164, 173]]], ["Nine patients had not pneumonia but had severe illness because of septic shock 5 (0.8%), pulmonary embolism without pneumonia 2 (0.3%), and one case (0.1%) of lithium intoxication and one case (0.1%) of fatal gastrointestinal bleed.", [["pulmonary", "ANATOMY", 89, 98], ["gastrointestinal", "ANATOMY", 209, 225], ["pneumonia", "DISEASE", 22, 31], ["illness", "DISEASE", 47, 54], ["septic shock", "DISEASE", 66, 78], ["pulmonary embolism", "DISEASE", 89, 107], ["pneumonia", "DISEASE", 116, 125], ["lithium", "CHEMICAL", 159, 166], ["gastrointestinal bleed", "DISEASE", 209, 231], ["lithium", "CHEMICAL", 159, 166], ["patients", "ORGANISM", 5, 13], ["pulmonary", "ORGAN", 89, 98], ["lithium", "SIMPLE_CHEMICAL", 159, 166], ["gastrointestinal bleed", "PATHOLOGICAL_FORMATION", 209, 231], ["patients", "SPECIES", 5, 13], ["pneumonia", "PROBLEM", 22, 31], ["severe illness", "PROBLEM", 40, 54], ["septic shock", "PROBLEM", 66, 78], ["pulmonary embolism", "PROBLEM", 89, 107], ["pneumonia", "PROBLEM", 116, 125], ["lithium intoxication", "PROBLEM", 159, 179], ["fatal gastrointestinal bleed", "PROBLEM", 203, 231], ["not", "UNCERTAINTY", 18, 21], ["pneumonia", "OBSERVATION", 22, 31], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["illness", "OBSERVATION", 47, 54], ["septic", "OBSERVATION", 66, 72], ["pulmonary", "ANATOMY", 89, 98], ["embolism", "OBSERVATION", 99, 107], ["without", "UNCERTAINTY", 108, 115], ["pneumonia", "OBSERVATION", 116, 125], ["fatal", "OBSERVATION_MODIFIER", 203, 208], ["gastrointestinal", "ANATOMY", 209, 225], ["bleed", "OBSERVATION", 226, 231]]], ["Patients with CND had non-severe pneumonia less frequently (12.4 vs. 27.4%, p = 0.002) and ADRS more frequently (30.5 vs. 19.6%, p = 0.020).", [["CND", "DISEASE", 14, 17], ["pneumonia", "DISEASE", 33, 42], ["ADRS", "DISEASE", 91, 95], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["non-severe pneumonia", "PROBLEM", 22, 42], ["p", "TEST", 76, 77], ["ADRS", "TEST", 91, 95], ["p", "TEST", 129, 130], ["non-severe", "OBSERVATION_MODIFIER", 22, 32], ["pneumonia", "OBSERVATION", 33, 42]]], ["Mortality of CNS patients was 44.8%, compared with 17% in the rest of the sample (p < 0.001).", [["CNS", "ANATOMY", 13, 16], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["CNS", "ANATOMY", 13, 16]]], ["Supplementary Table 4 describes treatment and severity of Covid-19 disease.Primary Endpoint: Predictors of Mortality ::: ResultsIn the univariate regression analysis, baseline disability, age, hypertension, diabetes, smoking habit, cardiac disorders, cancer and chronic neurological disorders were associated with higher odds of mortality, whereas female sex was associated with a lower odd of death.", [["cardiac", "ANATOMY", 232, 239], ["cancer", "ANATOMY", 251, 257], ["neurological", "ANATOMY", 270, 282], ["disability", "DISEASE", 176, 186], ["hypertension", "DISEASE", 193, 205], ["diabetes", "DISEASE", 207, 215], ["cardiac disorders", "DISEASE", 232, 249], ["cancer", "DISEASE", 251, 257], ["chronic neurological disorders", "DISEASE", 262, 292], ["death", "DISEASE", 394, 399], ["cancer", "CANCER", 251, 257], ["treatment", "TREATMENT", 32, 41], ["Covid-19 disease", "PROBLEM", 58, 74], ["baseline disability", "PROBLEM", 167, 186], ["hypertension", "PROBLEM", 193, 205], ["diabetes", "PROBLEM", 207, 215], ["cardiac disorders", "PROBLEM", 232, 249], ["cancer", "PROBLEM", 251, 257], ["chronic neurological disorders", "PROBLEM", 262, 292], ["death", "PROBLEM", 394, 399], ["hypertension", "OBSERVATION", 193, 205], ["cardiac", "ANATOMY", 232, 239], ["disorders", "OBSERVATION", 240, 249], ["cancer", "OBSERVATION", 251, 257], ["chronic", "OBSERVATION_MODIFIER", 262, 269]]], ["In the multivariate regression analysis, including all the variables that were statistically significant in the univariate analysis, baseline disability, age and chronic neurological disorders remained statistically significant (OR: 1.76, 95% CI: 1.014\u20133.06).", [["neurological", "ANATOMY", 170, 182], ["disability", "DISEASE", 142, 152], ["chronic neurological disorders", "DISEASE", 162, 192], ["the multivariate regression analysis", "TEST", 3, 39], ["baseline disability", "PROBLEM", 133, 152], ["chronic neurological disorders", "PROBLEM", 162, 192], ["CI", "TEST", 243, 245], ["significant", "OBSERVATION_MODIFIER", 93, 104], ["chronic", "OBSERVATION_MODIFIER", 162, 169]]], ["Table 2 presents the results of the univariate and multivariate regression analysis.Primary Endpoint: Predictors of Mortality ::: ResultsCox regression analysis patients with CND had lower survival over time than patients without prior history of CND (HR: 2.13, 95% CI: 1.382\u20133.280, p = 0.001), adjusted by all the variables included in the multivariate regression analysis (age, mRS, sex, presence of hypertension, diabetes, smoking habit, prior history of cardiac disorders, pulmonary diseases, and history of cancer).", [["cardiac", "ANATOMY", 458, 465], ["pulmonary", "ANATOMY", 477, 486], ["cancer", "ANATOMY", 512, 518], ["CND", "DISEASE", 247, 250], ["hypertension", "DISEASE", 402, 414], ["diabetes", "DISEASE", 416, 424], ["cardiac disorders", "DISEASE", 458, 475], ["pulmonary diseases", "DISEASE", 477, 495], ["cancer", "DISEASE", 512, 518], ["patients", "ORGANISM", 161, 169], ["patients", "ORGANISM", 213, 221], ["cardiac", "ORGAN", 458, 465], ["pulmonary", "ORGAN", 477, 486], ["cancer", "CANCER", 512, 518], ["patients", "SPECIES", 161, 169], ["patients", "SPECIES", 213, 221], ["the univariate", "TEST", 32, 46], ["multivariate regression analysis", "TEST", 51, 83], ["Cox regression analysis", "TEST", 137, 160], ["CND", "TEST", 175, 178], ["CND", "TEST", 247, 250], ["HR", "TEST", 252, 254], ["CI", "TEST", 266, 268], ["p", "TEST", 283, 284], ["hypertension", "PROBLEM", 402, 414], ["diabetes", "PROBLEM", 416, 424], ["cardiac disorders", "PROBLEM", 458, 475], ["pulmonary diseases", "PROBLEM", 477, 495], ["cancer", "PROBLEM", 512, 518], ["hypertension", "OBSERVATION", 402, 414], ["diabetes", "OBSERVATION", 416, 424], ["cardiac", "ANATOMY", 458, 465], ["disorders", "OBSERVATION", 466, 475], ["pulmonary", "ANATOMY", 477, 486], ["diseases", "OBSERVATION", 487, 495], ["cancer", "OBSERVATION", 512, 518]]], ["Figure 2 shows cumulative survival curves.", [["cumulative survival curves", "PROBLEM", 15, 41]]], ["Supplementary Table 5 presents the results of all the variables included in the analysis.Predictors of Severe Covid-19 Disease ::: ResultsAll the variables that were associated with higher odds of mortality except by cancer were associated with a higher odd of severe Covid-19 disease in the univariate regression analysis.", [["cancer", "ANATOMY", 217, 223], ["cancer", "DISEASE", 217, 223], ["cancer", "CANCER", 217, 223], ["the analysis", "TEST", 76, 88], ["cancer", "PROBLEM", 217, 223], ["severe Covid-19 disease", "PROBLEM", 261, 284], ["the univariate regression analysis", "TEST", 288, 322], ["Severe", "OBSERVATION_MODIFIER", 103, 109], ["cancer", "OBSERVATION", 217, 223], ["severe", "OBSERVATION_MODIFIER", 261, 267]]], ["In the multivariate analysis, only age, female sex and diabetes remained statistically significant, with a trend to signification in smoking habit (p = 0.066) and CND (p = 0.063).", [["diabetes", "DISEASE", 55, 63], ["smoking", "CHEMICAL", 133, 140], ["CND", "DISEASE", 163, 166], ["the multivariate analysis", "TEST", 3, 28], ["diabetes", "PROBLEM", 55, 63], ["CND", "TEST", 163, 166]]], ["Table 3 shows results of univariate and multivariate regression analysis.Laboratory Findings ::: ResultsThe median laboratory values on admission and the worst values during hospitalization is available in Supplementary Table 6.", [["multivariate regression analysis", "TEST", 40, 72]]], ["All the laboratory parameters were more frequently abnormal during the hospitalization than upon admission (all p < 0.001), Supplementary Table 7.", [["All the laboratory parameters", "TEST", 0, 29]]], ["Patients with CND had higher odds of having increased INR during hospitalization (OR: 1.85, 95% CI: 1.14\u20133.01) and higher odds of having increased procalcitonin levels during hospitalization (OR: 1.845, 95% CI: 1.08\u20133.15), after adjusting for age, mRS, sex, and prior history of hypertension, diabetes, smoking habit and other comorbidities.", [["CND", "DISEASE", 14, 17], ["hypertension", "DISEASE", 279, 291], ["diabetes", "DISEASE", 293, 301], ["smoking habit", "DISEASE", 303, 316], ["Patients", "ORGANISM", 0, 8], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 147, 160], ["INR", "PROTEIN", 54, 57], ["procalcitonin", "PROTEIN", 147, 160], ["Patients", "SPECIES", 0, 8], ["increased INR", "PROBLEM", 44, 57], ["CI", "TEST", 96, 98], ["increased procalcitonin levels", "PROBLEM", 137, 167], ["CI", "TEST", 207, 209], ["mRS", "TEST", 248, 251], ["hypertension", "PROBLEM", 279, 291], ["diabetes", "PROBLEM", 293, 301], ["other comorbidities", "PROBLEM", 321, 340], ["hypertension", "OBSERVATION", 279, 291], ["diabetes", "OBSERVATION", 293, 301]]], ["Supplementary Table 8 shows the full results of the regression analysis.DiscussionMost of the Covid-19 management protocols coincide that patients with comorbidities should be closely monitored (7, 11), however specific recommendations for neurological comorbidities are sparse.", [["neurological", "ANATOMY", 240, 252], ["neurological comorbidities", "DISEASE", 240, 266], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["the regression analysis", "TEST", 48, 71], ["the Covid-19 management protocols", "TREATMENT", 90, 123], ["comorbidities", "PROBLEM", 152, 165], ["neurological comorbidities", "PROBLEM", 240, 266]]], ["Frequency of CND comorbidities in Covid-19 patients have not been considered in most of the studies (8).", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["CND comorbidities", "PROBLEM", 13, 30], ["Covid", "TEST", 34, 39], ["the studies", "TEST", 88, 99], ["CND", "OBSERVATION_MODIFIER", 13, 16], ["comorbidities", "OBSERVATION", 17, 30]]], ["To our knowledge, this is the first study that analyzes the implication of CND presence.", [["CND", "GENE_OR_GENE_PRODUCT", 75, 78], ["the first study", "TEST", 26, 41]]], ["CND was an independent predictor of in-hospital mortality, and death occurred faster in CND patients.DiscussionAs expected, patients with CND were older, more disabled and had higher frequency of vascular risk factors and other comorbidities.", [["vascular", "ANATOMY", 196, 204], ["CND", "DISEASE", 0, 3], ["death", "DISEASE", 63, 68], ["CND", "DISEASE", 88, 91], ["CND", "DISEASE", 138, 141], ["patients", "ORGANISM", 92, 100], ["patients", "ORGANISM", 124, 132], ["vascular", "MULTI-TISSUE_STRUCTURE", 196, 204], ["vascular risk factors", "PROTEIN", 196, 217], ["patients", "SPECIES", 92, 100], ["patients", "SPECIES", 124, 132], ["death", "PROBLEM", 63, 68], ["vascular risk factors", "PROBLEM", 196, 217], ["other comorbidities", "PROBLEM", 222, 241], ["vascular", "ANATOMY", 196, 204]]], ["All of those have been associated with higher mortality in most of the Covid-19 series (1\u20136).", [["higher", "OBSERVATION_MODIFIER", 39, 45], ["mortality", "OBSERVATION", 46, 55]]], ["The clinical presentation of Covid-19 disease was pauci symptomatic in CND patients, as some typical symptoms such as cough, chest pain or asthenia were less frequent.", [["chest", "ANATOMY", 125, 130], ["Covid-19 disease", "DISEASE", 29, 45], ["CND", "DISEASE", 71, 74], ["cough", "DISEASE", 118, 123], ["chest pain", "DISEASE", 125, 135], ["asthenia", "DISEASE", 139, 147], ["Covid-19", "CANCER", 29, 37], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["Covid", "TEST", 29, 34], ["disease", "PROBLEM", 38, 45], ["pauci symptomatic", "PROBLEM", 50, 67], ["some typical symptoms", "PROBLEM", 88, 109], ["cough", "PROBLEM", 118, 123], ["chest pain", "PROBLEM", 125, 135], ["asthenia", "PROBLEM", 139, 147], ["chest", "ANATOMY", 125, 130]]], ["Also, the most frequently reported neurological symptoms, myalgia, and headache (17\u201319), were less common.", [["neurological", "ANATOMY", 35, 47], ["neurological symptoms", "DISEASE", 35, 56], ["myalgia", "DISEASE", 58, 65], ["headache", "DISEASE", 71, 79], ["neurological symptoms", "PROBLEM", 35, 56], ["myalgia", "PROBLEM", 58, 65], ["headache", "PROBLEM", 71, 79], ["myalgia", "OBSERVATION", 58, 65]]], ["Despite of that, CND patients experienced ADRS more often and had a higher death rate.DiscussionConsidering the more severe disease, the worst baseline performance and the scanty clinical expression, the reason for the different outcome could be related with a delayed ED presentation.", [["CND", "DISEASE", 17, 20], ["ADRS", "DISEASE", 42, 46], ["death", "DISEASE", 75, 80], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["ADRS", "PROBLEM", 42, 46], ["a higher death rate", "PROBLEM", 66, 85], ["the more severe disease", "PROBLEM", 108, 131], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["disease", "OBSERVATION", 124, 131]]], ["However, in our sample, patients with CND came earlier, even after adjusting for age, mRs, sex, and the rest of comorbidities.", [["CND", "DISEASE", 38, 41], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32]]], ["Hence, we could not attribute the worse prognosis to the delay in the care provision (6).DiscussionThen, we tried to find out if patients with CND received standard care and/or intensive care less often.", [["CND", "DISEASE", 143, 146], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["CND", "TREATMENT", 143, 146], ["standard care", "TREATMENT", 156, 169]]], ["More than 80% of CND patients received pharmacological treatment according to the local SOC.", [["CND", "DISEASE", 17, 20], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["pharmacological treatment", "TREATMENT", 39, 64]]], ["Even though the clinical benefit of those drugs is not yet clear (20), we could not attribute the worse prognosis to the restriction of the received therapy.", [["those drugs", "TREATMENT", 36, 47], ["therapy", "TREATMENT", 149, 156]]], ["Due to the collapse of the sanitary system, ICU guidelines deemed to prioritize the resource allocation to those patients with a higher potential benefit (21).", [["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["the collapse of the sanitary system", "PROBLEM", 7, 42], ["ICU guidelines", "TREATMENT", 44, 58], ["collapse", "OBSERVATION", 11, 19], ["sanitary system", "ANATOMY", 27, 42]]], ["Nevertheless, in our sample, patients with CND benefited from ICU admission as frequently as those without it.DiscussionSince the need of oxygen therapy was more frequent in patients with CND, a possible explanation of the higher mortality was the more severe Covid-19 disease.", [["CND", "DISEASE", 43, 46], ["oxygen", "CHEMICAL", 138, 144], ["CND", "DISEASE", 188, 191], ["oxygen", "CHEMICAL", 138, 144], ["patients", "ORGANISM", 29, 37], ["oxygen", "SIMPLE_CHEMICAL", 138, 144], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 174, 182], ["oxygen therapy", "TREATMENT", 138, 152], ["CND", "TREATMENT", 188, 191], ["the higher mortality", "PROBLEM", 219, 239], ["the more severe Covid-19 disease", "PROBLEM", 244, 276], ["oxygen therapy", "OBSERVATION", 138, 152]]], ["As the simple comparison of mean or median values of laboratory findings was not adequate due to the imbalanced populations, we analyzed if patients with CND had abnormal laboratory values more frequently than the rest of the patients, adjusting by all the variables that deemed potential confounders.", [["CND", "DISEASE", 154, 157], ["patients", "ORGANISM", 140, 148], ["patients", "ORGANISM", 226, 234], ["patients", "SPECIES", 140, 148], ["patients", "SPECIES", 226, 234], ["laboratory findings", "TEST", 53, 72], ["the imbalanced populations", "PROBLEM", 97, 123], ["abnormal laboratory values", "PROBLEM", 162, 188]]], ["Only increased INR and procalcitonin remained statistically significant.", [["procalcitonin", "GENE_OR_GENE_PRODUCT", 23, 36], ["INR", "PROTEIN", 15, 18], ["procalcitonin", "PROTEIN", 23, 36], ["increased INR", "PROBLEM", 5, 18], ["procalcitonin", "TEST", 23, 36], ["increased", "OBSERVATION_MODIFIER", 5, 14], ["INR", "OBSERVATION", 15, 18], ["significant", "OBSERVATION_MODIFIER", 60, 71]]], ["The reason why INR is more frequently increased in patients with CND is elusive and could be related with hepatic failure caused by sepsis, low K vitamin levels, or acute liver failure (22).", [["hepatic", "ANATOMY", 106, 113], ["liver", "ANATOMY", 171, 176], ["CND", "DISEASE", 65, 68], ["hepatic failure", "DISEASE", 106, 121], ["sepsis", "DISEASE", 132, 138], ["K vitamin", "CHEMICAL", 144, 153], ["acute liver failure", "DISEASE", 165, 184], ["K vitamin", "CHEMICAL", 144, 153], ["INR", "GENE_OR_GENE_PRODUCT", 15, 18], ["patients", "ORGANISM", 51, 59], ["hepatic", "ORGAN", 106, 113], ["K vitamin", "SIMPLE_CHEMICAL", 144, 153], ["liver", "ORGAN", 171, 176], ["INR", "PROTEIN", 15, 18], ["patients", "SPECIES", 51, 59], ["INR", "TEST", 15, 18], ["CND", "PROBLEM", 65, 68], ["hepatic failure", "PROBLEM", 106, 121], ["sepsis", "PROBLEM", 132, 138], ["low K vitamin levels", "PROBLEM", 140, 160], ["acute liver failure", "PROBLEM", 165, 184], ["more frequently", "OBSERVATION_MODIFIER", 22, 37], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["could be related with", "UNCERTAINTY", 84, 105], ["hepatic", "ANATOMY", 106, 113], ["failure", "OBSERVATION", 114, 121], ["sepsis", "OBSERVATION", 132, 138], ["low K vitamin levels", "OBSERVATION_MODIFIER", 140, 160], ["acute", "OBSERVATION_MODIFIER", 165, 170], ["liver", "ANATOMY", 171, 176], ["failure", "OBSERVATION", 177, 184]]], ["In the case of procalcitonin, patients with CND are more vulnerable to nosocomial infections (23), so the bacterial co-infection could be the most likely explanation (24, 25).", [["CND", "DISEASE", 44, 47], ["nosocomial infections", "DISEASE", 71, 92], ["bacterial co-infection", "DISEASE", 106, 128], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 15, 28], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["procalcitonin", "TREATMENT", 15, 28], ["CND", "PROBLEM", 44, 47], ["nosocomial infections", "PROBLEM", 71, 92], ["the bacterial co-infection", "PROBLEM", 102, 128], ["nosocomial", "OBSERVATION_MODIFIER", 71, 81], ["infections", "OBSERVATION", 82, 92], ["bacterial", "OBSERVATION_MODIFIER", 106, 115], ["co-infection", "OBSERVATION", 116, 128], ["could be the most likely", "UNCERTAINTY", 129, 153]]], ["It has been pointed as an independent predictor of fatal outcome in Covid-19 patients (26).DiscussionHenceforth, if we could not attribute the worse prognosis of CND patients neither to a delayed presentation to the ED nor a different management (27), a plausible explanation could be the higher fragility and lower reserve of CND population.", [["CND", "DISEASE", 162, 165], ["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 166, 174], ["the higher fragility", "PROBLEM", 285, 305], ["lower reserve of CND population", "PROBLEM", 310, 341]]], ["It is well-known that CND are independent predictors of mortality in hospitalized patients (28, 29).", [["CND", "SIMPLE_CHEMICAL", 22, 25], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90]]], ["Prior history of stroke has been related with a higher odds of severe Covid-19 illness, as well (30).", [["stroke", "DISEASE", 17, 23], ["Covid-19 illness", "DISEASE", 70, 86], ["stroke", "PROBLEM", 17, 23], ["severe Covid-19 illness", "PROBLEM", 63, 86], ["stroke", "OBSERVATION", 17, 23], ["severe", "OBSERVATION_MODIFIER", 63, 69]]], ["The possible reasons seem varied, including frequency of delirium (18, 19), malnutrition (31), impaired respiratory function (32), and worse self-management (33).", [["respiratory", "ANATOMY", 104, 115], ["delirium", "DISEASE", 57, 65], ["malnutrition", "DISEASE", 76, 88], ["impaired respiratory function", "DISEASE", 95, 124], ["delirium", "PROBLEM", 57, 65], ["malnutrition", "PROBLEM", 76, 88], ["impaired respiratory function", "PROBLEM", 95, 124], ["possible", "UNCERTAINTY", 4, 12], ["respiratory function", "OBSERVATION", 104, 124]]], ["Many of them can be worsened by Covid-19 disease and the use of personal protective equipment makes its management arduous.", [["Covid-19 disease", "PROBLEM", 32, 48], ["personal protective equipment", "TREATMENT", 64, 93], ["its management", "TREATMENT", 100, 114], ["worsened", "OBSERVATION_MODIFIER", 20, 28]]], ["Covid-19 should be prevented and detected early in CND patients, whose close monitoring could prevent complications and improve the prognosis (34).", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["Covid", "TEST", 0, 5], ["complications", "PROBLEM", 102, 115]]], ["In addition, the worse prognosis of patients with CND could be linked with immuno-senescence, an enhanced inflammatory state, favored by an angiotensin II induced vasoconstriction and inflammatory response, leading to lymphopenia, cytokine release and macrophage activation (35).DiscussionThis study has notable limitations.", [["macrophage", "ANATOMY", 252, 262], ["CND", "DISEASE", 50, 53], ["angiotensin II", "CHEMICAL", 140, 154], ["lymphopenia", "DISEASE", 218, 229], ["patients", "ORGANISM", 36, 44], ["CND", "CANCER", 50, 53], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 140, 154], ["macrophage", "CELL", 252, 262], ["angiotensin II", "PROTEIN", 140, 154], ["cytokine", "PROTEIN", 231, 239], ["patients", "SPECIES", 36, 44], ["CND", "PROBLEM", 50, 53], ["immuno-senescence", "PROBLEM", 75, 92], ["an enhanced inflammatory state", "PROBLEM", 94, 124], ["an angiotensin II induced vasoconstriction", "PROBLEM", 137, 179], ["inflammatory response", "PROBLEM", 184, 205], ["lymphopenia", "PROBLEM", 218, 229], ["cytokine release", "TREATMENT", 231, 247], ["macrophage activation", "TEST", 252, 273], ["This study", "TEST", 289, 299], ["inflammatory state", "OBSERVATION", 106, 124], ["inflammatory response", "OBSERVATION", 184, 205], ["lymphopenia", "OBSERVATION", 218, 229]]], ["First, the sample size was modest, implying the possibility of some false-negative results.", [["sample", "ANATOMY", 11, 17], ["the sample size", "TEST", 7, 22], ["size", "OBSERVATION_MODIFIER", 18, 22], ["implying the possibility of", "UNCERTAINTY", 35, 62], ["negative results", "OBSERVATION", 74, 90]]], ["The number of CND was not high enough to perform sub-studies by different specific conditions, but all the patients were consecutive.", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["CND", "OBSERVATION", 14, 17]]], ["We tried to create an operative definition of CND, based on the persistent impact on functionality, however the definition is imperfect and not every neurological disorder might be equally relevant.", [["neurological", "ANATOMY", 150, 162], ["CND", "DISEASE", 46, 49], ["neurological disorder", "DISEASE", 150, 171], ["CND", "TREATMENT", 46, 49], ["every neurological disorder", "PROBLEM", 144, 171], ["persistent", "OBSERVATION_MODIFIER", 64, 74]]], ["Further studies should focus on the specific impact of the different neurological comorbidities and analyze them separately.", [["neurological", "ANATOMY", 69, 81], ["Further studies", "TEST", 0, 15], ["the different neurological comorbidities", "PROBLEM", 55, 95]]], ["Second, this was a single center study, it would be desirable to create multicentric studies to clarify the impact of other variables, such as the type of hospital care and the different management of patients.", [["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 201, 209], ["a single center study", "TEST", 17, 38], ["multicentric studies", "TEST", 72, 92], ["hospital care", "TREATMENT", 155, 168], ["the different management", "TREATMENT", 173, 197]]], ["Future studies should be multinational, as the reported adjusted mortality rates are highly variable between the different countries.", [["Future studies", "TEST", 0, 14]]], ["It is not yet known if it could be attributed to genetic predisposition for severe Covid-19 or different healthcare systems.", [["severe Covid", "PROBLEM", 76, 88]]], ["This was a retrospective study and despite the information was carefully reviewed, some information could be incomplete.", [["a retrospective study", "TEST", 9, 30]]], ["It was a limitation that there were many different researchers involved in the study, albeit all of them were neurologists and followed a pre-defined protocol.", [["the study", "TEST", 75, 84], ["a pre-defined protocol", "TEST", 136, 158]]], ["We did not include long-term follow up of the patients, some patients remained admitted at the time of data cutoff, mortality might be underestimated in some cases.", [["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 61, 69]]], ["Also, the sample is not representative of the whole population, as it only included hospitalized patients, which could influence the results.ConclusionThe presence of pre-existing chronic neurological disorders was an independent predictor of mortality in hospitalized Covid-19 patients.ConclusionDeath occurred faster after admission in patients with CND, and CND was associated with an earlier presentation at ED.", [["neurological", "ANATOMY", 188, 200], ["chronic neurological disorders", "DISEASE", 180, 210], ["Death", "DISEASE", 297, 302], ["CND", "DISEASE", 352, 355], ["CND", "DISEASE", 361, 364], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 278, 286], ["patients", "ORGANISM", 338, 346], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 278, 286], ["patients", "SPECIES", 338, 346], ["pre-existing chronic neurological disorders", "PROBLEM", 167, 210], ["ConclusionDeath", "PROBLEM", 287, 302], ["CND", "PROBLEM", 352, 355], ["chronic", "OBSERVATION_MODIFIER", 180, 187], ["neurological disorders", "OBSERVATION", 188, 210]]], ["Presence of CND was not associated with a worse inflammatory response or with differences in the level of care provided to the patients.ConclusionThe course of Covid-19 in patients with CND appears to be faster and more aggressive, and therefore protocols should consider these patients as a very high-risk population.ConclusionFuture Covid-19 studies should consider the presence of CND in the evaluation of risk of mortality.Data Availability StatementThe raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.", [["CND", "DISEASE", 12, 15], ["CND", "DISEASE", 186, 189], ["CND", "DISEASE", 384, 387], ["patients", "ORGANISM", 127, 135], ["patients", "ORGANISM", 172, 180], ["patients", "ORGANISM", 278, 286], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 172, 180], ["patients", "SPECIES", 278, 286], ["CND", "PROBLEM", 12, 15], ["a worse inflammatory response", "PROBLEM", 40, 69], ["Covid", "TEST", 160, 165], ["CND", "TREATMENT", 186, 189], ["a very high-risk population", "PROBLEM", 290, 317], ["ConclusionFuture", "TEST", 318, 334], ["Covid", "TEST", 335, 340], ["CND", "PROBLEM", 384, 387], ["the evaluation", "TEST", 391, 405], ["mortality", "PROBLEM", 417, 426], ["CND", "OBSERVATION", 12, 15], ["not associated with", "UNCERTAINTY", 20, 39], ["worse", "OBSERVATION_MODIFIER", 42, 47], ["inflammatory", "OBSERVATION", 48, 60], ["mortality", "OBSERVATION", 417, 426]]], ["Datasheets are available upon reasonable request to the corresponding author.Ethics StatementThe studies involving human participants were reviewed and approved by Valladolid Este Ethics Review Board.", [["human", "ORGANISM", 115, 120], ["human", "SPECIES", 115, 120], ["participants", "SPECIES", 121, 133], ["human", "SPECIES", 115, 120]]], ["The ethics committee waived the requirement of written informed consent for participation.Author ContributionsDG-A and JA designed and conceptualized the study.", [["the study", "TEST", 150, 159]]], ["DG-A, EM-P, JT, IH-P, GV-P, BT, PS-C, ML, AC-M, CL-S, MG-S, EM-V, and MP collected the data.", [["DG", "SIMPLE_CHEMICAL", 0, 2], ["PS-C", "SIMPLE_CHEMICAL", 32, 36], ["AC-M", "SIMPLE_CHEMICAL", 42, 46], ["CL-S", "SIMPLE_CHEMICAL", 48, 52], ["MG-S", "SIMPLE_CHEMICAL", 54, 58], ["EM-V", "SIMPLE_CHEMICAL", 60, 64], ["DG", "TEST", 0, 2], ["JT", "TEST", 12, 14], ["IH", "TEST", 16, 18], ["GV", "TEST", 22, 24], ["P", "TEST", 25, 26], ["BT", "TEST", 28, 30], ["PS", "TEST", 32, 34], ["C", "TEST", 35, 36], ["ML", "TEST", 38, 40], ["AC", "TEST", 42, 44], ["M", "TEST", 45, 46], ["CL", "TEST", 48, 50], ["S", "TEST", 51, 52], ["MG", "TEST", 54, 56], ["EM", "TEST", 60, 62], ["V", "TEST", 63, 64], ["MP collected the data", "TEST", 70, 91], ["JT", "ANATOMY", 12, 14]]], ["DG-A and JA analyzed and interpreted the data.", [["DG", "SIMPLE_CHEMICAL", 0, 2], ["JA", "SIMPLE_CHEMICAL", 9, 11]]], ["DG-A drafted the manuscript.", [["DG", "SIMPLE_CHEMICAL", 0, 2]]], ["\u00c1S, BG-V, \u00c1G, DE, MJP, JG-H, EB-M, CA-M, AO-D, GR-M, MJ-C, SJ, CP-V, CD-G, JP, BC-\u00c1, and JV revised the manuscript for intellectual content.", [["AO-D", "SIMPLE_CHEMICAL", 41, 45], ["MJ-C", "SIMPLE_CHEMICAL", 53, 57], ["CD-G", "SIMPLE_CHEMICAL", 69, 73], ["GR", "PROTEIN", 47, 49], ["\u00c1S", "TEST", 0, 2], ["BG", "TEST", 4, 6], ["\u00c1G", "TEST", 10, 12], ["MJP", "TEST", 18, 21], ["CA", "TEST", 35, 37], ["AO", "TEST", 41, 43], ["GR", "TEST", 47, 49], ["MJ", "TEST", 53, 55], ["C", "TEST", 56, 57], ["SJ", "TEST", 59, 61], ["CP", "TEST", 63, 65], ["V", "TEST", 66, 67], ["CD", "TEST", 69, 71], ["G", "TEST", 72, 73], ["JP", "TEST", 75, 77], ["BC", "TEST", 79, 81], ["JV", "TEST", 89, 91], ["intellectual content", "PROBLEM", 119, 139], ["EB", "ANATOMY", 29, 31], ["GR", "ANATOMY", 47, 49], ["SJ", "ANATOMY", 59, 61], ["JP", "ANATOMY", 75, 77], ["BC", "ANATOMY", 79, 81]]], ["The handling editor declared a past co-authorship with several of the authors DG-A, MG-S.", [["DG-A", "CHEMICAL", 78, 82], ["DG-A", "SIMPLE_CHEMICAL", 78, 82]]]], "PMC7428677": [["Background ::: IntroductionThere is no consistent definition in the literature but (Durose et al. 2017, P135) describe co-production as \u2018joint working between people or groups who have traditionally been separated into categories of user and producer\u2019.Background ::: IntroductionCo-production originated in public service administration, with recognition that drawing on the expertise of a plurality of actors was a practical and reinvigorating solution to complex problems (Sorrentino et al., 2016).", [["people", "ORGANISM", 159, 165], ["people", "SPECIES", 159, 165], ["a practical and reinvigorating solution", "TREATMENT", 414, 453], ["complex problems", "PROBLEM", 457, 473], ["no consistent", "UNCERTAINTY", 36, 49], ["definition", "OBSERVATION", 50, 60], ["joint", "ANATOMY", 137, 142]]], ["Although there is an inevitable blurring of boundaries, co-production differs from participatory research, which often seeks to disrupt the traditional power relationships and distinction between researcher and the researched (Higginbottom and Liamputtong, 2017).", [["an inevitable blurring of boundaries", "PROBLEM", 18, 54], ["inevitable", "OBSERVATION_MODIFIER", 21, 31], ["blurring", "OBSERVATION", 32, 40], ["boundaries", "OBSERVATION_MODIFIER", 44, 54]]], ["Co-production focuses on a commitment to working together, recognising the equity of all forms of knowledge, and the social capital of the participants (Voorberg et al., 2015).", [["participants", "SPECIES", 139, 151]]], ["Participants in co-production recognise that although different parties may require different outcomes from the process, undertaking the journey together will result in a jointly owned product (Hickey, 2018).", [["Participants", "SPECIES", 0, 12]]], ["A recognised challenge is the paradigm shift that students must undertake to see themselves as co-producers rather than participants (Vargo and Lush, 2004) and acknowledge the capital they bring in terms of experience and perspective.Background ::: IntroductionDespite the importance that policy makers attach to co-production, a systematic review (Voorberg et al., 2015) identified a dearth of studies that addressed the outcomes and concluded that the process is primarily seen as a virtue in itself, with few external objectives given to legitimise the choice of process.", [["participants", "SPECIES", 120, 132]]], ["Ultimately, knowledge is scarce about how co-production works in practice, in what context it is best utilised, or whether it is a superior approach to alternatives (Oliver et al., 2019).Background ::: IntroductionThis study evaluates the feasibility and acceptability of the co-production process, in order to gain insight into the value and utility of the process of co-production to the stakeholders and project objectives.", [["This study", "TEST", 214, 224]]], ["The established co-production toolkit, Experience Based Co-design (EBCD), was used to guide the process (Point of Care Foundation, 2016).", [["co-production toolkit", "OBSERVATION", 16, 37]]], ["The toolkit consists of specified exercises and steps, which were implemented as described in Table 1.Data collection ::: MethodsThe mixed methods approach incorporated three data collection methods: questionnaire data collection, semi structured interviews and reflective field notes.Data collection ::: Methods", [["Methods", "TREATMENT", 122, 129], ["The mixed methods approach", "TREATMENT", 129, 155], ["questionnaire data collection", "TEST", 200, 229], ["Methods", "TREATMENT", 305, 312], ["mixed", "OBSERVATION_MODIFIER", 133, 138]]]], "PMC7473197": [["IntroductionIn a highly mobile, interdependent but interrelated world, infectious diseases spread sorapidly that they pose a serious global threat to public health [1].", [["infectious diseases", "DISEASE", 71, 90], ["infectious diseases", "PROBLEM", 71, 90], ["infectious", "OBSERVATION_MODIFIER", 71, 81]]], ["Rapid, convenient, and high-throughput testing is a key tocontrol the transmission of emerging infectious agents.", [["throughput testing", "TEST", 28, 46], ["emerging infectious agents", "TREATMENT", 86, 112], ["infectious", "OBSERVATION", 95, 105]]], ["Antibodies have been used inmicrobial immunoassay for more than 50 years [2].Their inherent ability to bind microbial preparations and their products makes them ideal tocapture molecules for immunoassay, such as ELISA, immunochromatographic bands, columnchromatography, and immunosensor development [3,4].", [["Antibodies", "TEST", 0, 10], ["bind microbial preparations", "TREATMENT", 103, 130], ["immunoassay", "TEST", 191, 202], ["ELISA", "TEST", 212, 217], ["immunochromatographic bands", "TEST", 219, 246], ["columnchromatography", "TEST", 248, 268]]], ["However, there is an increasingneed for affordable, rapid, sensitive, and high throughput methods in identifying new orre-emerging infectious agents or distinguishing resistant subclones.IntroductionNucleic acid aptamer is small single-stranded DNA (ssDNA) or RNA, identified and selectedfrom a synthetic oligonucleotide library with a length of 20\u201380 bases via systematicevolution of ligands by exponential enrichment (SELEX) or other modified SELEX strategies[5].", [["subclones", "ANATOMY", 177, 186], ["IntroductionNucleic acid", "CHEMICAL", 187, 211], ["subclones", "CELL", 177, 186], ["IntroductionNucleic acid", "SIMPLE_CHEMICAL", 187, 211], ["DNA", "CELLULAR_COMPONENT", 245, 248], ["ssDNA", "CELLULAR_COMPONENT", 250, 255], ["resistant subclones", "CELL_LINE", 167, 186], ["small single-stranded DNA", "DNA", 223, 248], ["ssDNA", "DNA", 250, 255], ["infectious agents", "TREATMENT", 131, 148], ["resistant subclones", "PROBLEM", 167, 186], ["IntroductionNucleic acid aptamer", "TEST", 187, 219], ["small single-stranded DNA (ssDNA)", "PROBLEM", 223, 256], ["RNA", "PROBLEM", 260, 263], ["a synthetic oligonucleotide library", "TREATMENT", 293, 328], ["systematicevolution of ligands", "TREATMENT", 362, 392], ["exponential enrichment (SELEX", "TREATMENT", 396, 425], ["other modified SELEX strategies", "TREATMENT", 430, 461], ["infectious", "OBSERVATION", 131, 141], ["resistant subclones", "OBSERVATION", 167, 186], ["small", "OBSERVATION_MODIFIER", 223, 228], ["stranded DNA", "OBSERVATION_MODIFIER", 236, 248]]], ["Aptamers have been considered to be\u201cartificial antibodies,\u201d and considerable attention has been given to nucleic acid aptamersbecause of their low production cost, easy chemical modification, high chemical stabilityand binding affinity, repeatability, and reusability.", [["nucleic acid", "SIMPLE_CHEMICAL", 105, 117], ["artificial antibodies", "TREATMENT", 36, 57], ["nucleic acid", "TEST", 105, 117], ["their low production cost", "PROBLEM", 137, 162], ["easy chemical modification", "TREATMENT", 164, 190]]], ["It may be folded into secondary andtertiary spatial structure with a combination of loops, stems, hairpins, pseudoknots, bumps,or G-quadruplexes.", [["loops, stems, hairpins, pseudoknots, bumps", "PROBLEM", 84, 126], ["G-quadruplexes", "PROBLEM", 130, 144], ["may be", "UNCERTAINTY", 3, 9], ["secondary", "OBSERVATION_MODIFIER", 22, 31], ["andtertiary", "OBSERVATION_MODIFIER", 32, 43], ["spatial structure", "OBSERVATION", 44, 61], ["loops", "OBSERVATION", 84, 89], ["stems", "OBSERVATION_MODIFIER", 91, 96], ["hairpins", "OBSERVATION_MODIFIER", 98, 106], ["bumps", "OBSERVATION_MODIFIER", 121, 126]]], ["This feature gives them high specificity and affinity to a variety oftargets, ranging from ions to molecules of various properties, sizes, and complexitiesthroughout a cell, including small molecules (such as amino acids, nucleotides,antibiotics), macromolecules (peptides, proteins, nucleic acids), or whole viruses,bacteria, and cells, etc. The advantages of aptamers in biological use are conciselyhighlighted in Table 1.", [["cell", "ANATOMY", 168, 172], ["cells", "ANATOMY", 331, 336], ["amino acids", "CHEMICAL", 209, 220], ["nucleic acids", "CHEMICAL", 284, 297], ["amino acids", "CHEMICAL", 209, 220], ["nucleotides", "CHEMICAL", 222, 233], ["cell", "CELL", 168, 172], ["amino acids", "AMINO_ACID", 209, 220], ["cells", "CELL", 331, 336], ["a variety oftargets", "PROBLEM", 57, 76], ["small molecules", "PROBLEM", 184, 199], ["amino acids", "TREATMENT", 209, 220], ["nucleotides", "TREATMENT", 222, 233], ["antibiotics", "TREATMENT", 234, 245], ["macromolecules (peptides, proteins, nucleic acids)", "PROBLEM", 248, 298], ["whole viruses", "PROBLEM", 303, 316], ["bacteria", "PROBLEM", 317, 325], ["cells", "PROBLEM", 331, 336], ["aptamers", "TREATMENT", 361, 369], ["sizes", "OBSERVATION_MODIFIER", 132, 137]]], ["Aptamers are equallyapplicable in many assays where antibodies are used, and they are even more flexible andamendable when real-time detection is needed or for on-site detection when a refrigerator isunavailable.", [["antibodies", "PROTEIN", 52, 62], ["Aptamers", "TREATMENT", 0, 8]]], ["Those advantages make it possible to be a detecting probe for infectiousagents.IntroductionBecause of the unique advantages in capable of diagnosis, aptamers have been used in thedesign of biosensors applicable in infectious diseases over the past 20 years.", [["infectious diseases", "DISEASE", 214, 233], ["infectiousagents", "PROBLEM", 62, 78], ["aptamers", "TREATMENT", 149, 157], ["biosensors", "TREATMENT", 189, 199], ["infectious", "OBSERVATION", 214, 224]]], ["Thetechnology of detecting infectious diseases based on aptamers has achieved tremendousprogress and is becoming a promising detection strategy in recent 10 years.", [["infectious diseases", "DISEASE", 27, 46], ["infectious diseases", "PROBLEM", 27, 46], ["infectious", "OBSERVATION", 27, 37]]], ["Since its firstapplication in 1990 [6], SELEX has undergone manymodifications.", [["manymodifications", "TREATMENT", 60, 77]]], ["The novel modification makes the obtained aptamer more specific, theselection process more efficient, cost-effective, and greatly reduces time consumption[7].", [["The novel modification", "TREATMENT", 0, 22]]], ["Specific aptamers for infectiousmicroorganisms in the event of new epidemic outbreaks can be quickly obtained throughefficient SELEX technology, such as the recent specific aptamers of SARS-CoV-2 have beenobtained rapidly [8].", [["SARS", "DISEASE", 185, 189], ["SARS-CoV-2", "ORGANISM", 185, 195], ["Specific aptamers", "TEST", 0, 17], ["infectiousmicroorganisms", "PROBLEM", 22, 46], ["new epidemic outbreaks", "PROBLEM", 63, 85], ["SARS", "PROBLEM", 185, 189], ["CoV", "TEST", 190, 193], ["new", "OBSERVATION_MODIFIER", 63, 66]]], ["Once the specific aptamersof pathogenic microorganisms or their toxic molecules are identified, a variety of detectionschemes can be designed based on the aptamers, including chemiluminescent, electrochemicalor fluorescent detection according to the different detection signals [9\u201312].", [["the specific aptamersof pathogenic microorganisms", "PROBLEM", 5, 54], ["their toxic molecules", "PROBLEM", 58, 79], ["chemiluminescent", "TEST", 175, 191], ["electrochemicalor fluorescent detection", "TEST", 193, 232], ["toxic molecules", "OBSERVATION", 64, 79]]], ["In order to improvethe sensitivity of aptamer-based detection, several research teams tried to develop signalamplification strategies.", [["aptamer", "TEST", 38, 45], ["signalamplification strategies", "TREATMENT", 103, 133]]], ["Three methods, catalytic molecule, cyclic enzymatic, androlling-circle amplification (RCA) are used to amplify signals for better detection and abreakthrough has been made in the sensitivity of aptamer-based infectious agents detection[13\u201315].", [["catalytic molecule", "PROTEIN", 15, 33], ["cyclic enzymatic", "TREATMENT", 35, 51], ["androlling-circle amplification (RCA", "TREATMENT", 53, 89], ["aptamer", "TEST", 194, 201], ["infectious", "OBSERVATION", 208, 218]]], ["Through theacquisition of specific aptamers of pathogenic microorganisms and the establishment ofsensitive and stable aptamer-based detection methods, it is possible to diagnose infectiousagents conveniently, quickly, and effectively in any environment.IntroductionThis review intends to provide an update in the use of aptamer-based technologies indetection of infectious agents, and to demonstrate the flexibility and applicability ofthese technologies in precise detection of many categories of microbial agents, such aspathogenic bacteria, viruses, parasites or their products in a solid or liquid phase (Figure 1).", [["pathogenic microorganisms", "PROBLEM", 47, 72], ["aptamer", "TREATMENT", 320, 327], ["infectious agents", "TREATMENT", 362, 379], ["microbial agents", "TREATMENT", 498, 514], ["such aspathogenic bacteria", "PROBLEM", 516, 542], ["viruses", "PROBLEM", 544, 551], ["parasites", "PROBLEM", 553, 562], ["stable", "OBSERVATION_MODIFIER", 111, 117], ["infectious", "OBSERVATION", 362, 372]]], ["In-depth technical overviews regardingemerging aptamer-based biosensors and cutting-edging technologies for the detection ofproteins from various pathogens are available [16,17].", [["cutting-edging technologies", "TREATMENT", 76, 103], ["the detection ofproteins", "TEST", 108, 132], ["various pathogens", "PROBLEM", 138, 155]]], ["Representative aptamer-basedmethods for pathogenic targets from recent literature are briefly discussed in the text andthe remaining is mentioned in Tables 2\u20133.", [["Representative aptamer", "TEST", 0, 22], ["pathogenic targets", "PROBLEM", 40, 58]]]], "9bf21a37cb5f90fba25522d4764bd549cef8a2ad": [["O n February 24, 2020, the first infected person with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was diagnosed in Switzerland.", [["acute respiratory syndrome coronavirus", "DISEASE", 61, 99], ["person", "SPECIES", 42, 48], ["severe acute respiratory syndrome coronavirus", "SPECIES", 54, 99], ["SARS-CoV-2", "SPECIES", 103, 113], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 54, 99], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["respiratory syndrome", "OBSERVATION", 67, 87]]], ["On March 9, 2020, the first patient requiring mechanical ventilation was admitted to the intensive care division at Geneva University Hospitals, the largest healthcare complex in Switzerland.", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["mechanical ventilation", "TREATMENT", 46, 68], ["largest", "OBSERVATION_MODIFIER", 149, 156]]], ["The complex serves a population of 506,000 inhabitants, with a 30-bed medical and surgical ICU and a full technical plateau (1) .", [["complex", "OBSERVATION_MODIFIER", 4, 11]]]]}